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Abstract 
Introduction 
Cisplatin has been widely used to treat solid tumours and much success has come 
from the use of this drug in the treatment of head and neck, ovarian, testicular, cervical 
and small-cell lung cancers. However, the success of cisplatin treatment is limited due 
to its dose-limiting toxicity and its resulting side-effects, such as nephro- and 
ototoxicity. The devastating side-effects induced by cisplatin treatment provided the 
platform for this study whereby the aim was to lower the concentration of cisplatin 
while maintaining its cancer-specific cytotoxic action. Equally concerning is, cisplatin 
resistance which is becoming increasingly common, and this radically limits the clinical 
efficacy and utility of the drug. Adjuvant therapy has thus become necessary in an 
attempt to possibly curb or lessen the extent of cisplatin resistance. Due to the large 
body of evidence implicating the importance of autophagy in cancer, the prospect of 
targeting this mechanism has generally been accepted. Various chemotherapy agents 
induce autophagy in cancer cells; however the effect of cisplatin on autophagic 
induction has not been very well explored. We thus hypothesise that the manipulation 
of the autophagic pathway will sensitise cancer cells to a low concentration of cisplatin 
treatment. Furthermore, due to the functional interaction between Bcl-2 and Beclin-1 
and its role in the regulation of autophagy, ratio analysis of Beclin-1 to Bcl-2 as means 
of detecting the role of autophagy within the cell under homeostatic and 
treatment/stress conditions has been conducted. Additionally, Bcl-2 has a prominent 
role in the malignant cell and it’s over-expression has been found to confer resistance 
in a variety of cancerous cell lines. We therefore hypothesise that the silencing of Bcl-
2 prior to cisplatin treatment will sensitise cervical cancer cells to apoptosis and 
increase the Beclin-1/Bcl-2 ratio in favour of apoptosis. 
Materials and Methods 
Three human cervical cell lines were used: a non-cancerous ectocervical epithelial cell 
line (Ect1/E6E7) and two cancerous cervical cell lines (HeLa and CaSki). In order to 
determine a concentration of cisplatin that was non-toxic to the non-cancerous 
Ect1/E6E7 cell line, a dose-response was performed.  
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With the use of an autophagy inhibitor (bafilomycin A1) and an autophagy inducer 
(rapamycin), autophagic flux capacities were assessed in each cell line through the 
Western blotting technique. In order to assess whether the chosen concentration of 
cisplatin induced autophagy, flow cytometry with the use of a Lysotracker™ dye was 
utilised, as well as analysis of autophagy protein levels (LC-3 II, Beclin-1 and p62). 
Autophagy modulation was achieved through two methods: pharmacological 
modulation with use of two recognised agents, namely bafilomycin A1 and rapamycin, 
and biological manipulation with the use of ATG5 and mTOR mRNA silencing. The 
effects of different treatment regimes on cell death was assessed with the use of 
PARP and caspase-3 cleavage through Western blotting, caspase-3/-7 activity 
(Caspase-Glo®), PI inclusion, LDH release and MTT reductive capacity. Additionally 
the effects of these treatment regimes on cell-cycle progression were also analysed. 
Beclin-1 and Bcl-2 expression was determined through Western blotting and 
immunocytochemistry before and after treatment with cisplatin in HeLa and CaSki 
cells. To assess the reliance of the cervical cancer cells on Bcl-2 after cisplatin 
treatment, Bcl-2 knock-down was achieved through RNA interference, where after the 
Beclin-1/Bcl-2 ratio was assessed as well as apoptosis with the use of cleaved PARP 
analysis (Western blotting) and Caspase-Glo©. 
For the ex vivo analysis, biopsies were collected from patients undergoing routine 
colposcopy screenings and hysterectomies at Tygerberg Hospital, Tygerberg, Western 
Cape. A total of 10 normal, 29 low-grade squamous intraepithelial lesions (LSIL), 33 
high-grade squamous intraepithelial lesions (HSIL) and 13 carcinoma biopsies were 
collected for analysis, where after the expression profiles of two autophagy markers 
(mTOR and LC-3 II), as well as one anti-apoptotic marker (Bcl-2) were assessed. 
Protein levels were analysed through Western blot and confirmed through 
immunohistochemistry. 
Results 
Dose-response curves revealed that 15 µM of cisplatin did not induce cell death in the 
normal cervical epithelial cell line (Ect1/E6E7) and was therefore utilised through-out 
the remainder of the study. It was additionally determined that the CaSki cells were 
more resistant to cisplatin treatment when compared to the HeLa and Ect1/E6E7 cells. 
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Autophagic flux analysis revealed that, although all three cell lines were cervix derived, 
their autophagic flux capacities differed. 
It was observed that the chosen concentration of cisplatin was able to induce 
autophagy in all three cell lines, with the HeLa cells demonstrating a particularly 
pronounced response. Autophagy modulation in conjunction with cisplatin treatment 
revealed the following: Autophagy inhibition with bafilomycin A1 lead to significant 
increases in caspase-3 and PARP cleavage and LDH release in both cervical cancer 
cell lines. The inhibition of autophagy through silencing of ATG5 induced caspase-3 
cleavage and agrees with results obtained from pharmacological inhibition of 
autophagy with bafilomycin A1. 
In addition to autophagic induction, a low concentration of cisplatin induced the up-
regulation of Bcl-2, which when silenced significantly improved cisplatin-induced 
apoptosis in both cervical cancer cell lines.  
Analysis of the expression profiles of mTOR and LC-3 in normal, pre-malignant (LSIL 
and HSIL) and cancerous cervical tissue revealed that autophagy is significantly up-
regulated in HSILs and carcinoma of the cervix. Additionally, Bcl-2 expression is 
significantly increased in cervical carcinoma tissue, which agrees with results from 
other studies. 
Conclusion 
Autophagic flux capacities between the three cell lines investigated, derived from the 
same organ, differ significantly. This should be taken into consideration when 
autophagic modulation is being used as an adjuvant treatment. With regard to 
chemotherapy treatment in cervical cells, a low-concentration of cisplatin significantly 
induces autophagy in malignant and non-malignant cervix-derived cell lines where it 
serves a pro-survival mechanism. Inhibition of autophagy with bafilomycin A1 and 
ATG5 siRNA confirmed this survival effect in both cancerous cell lines where 
apoptosis was significantly increased. Interestingly, rapamycin pre-treatment together 
with cisplatin did not induce significant levels of apoptosis in HeLa cells where 
autophagy induction may have provided additional protection from the cytotoxic effects 
of cisplatin. Therefore the inhibition of autophagy through pharmacological and 
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biological inhibition improves the cytotoxicity of a low concentration of cisplatin and 
provides a promising new avenue for the future treatment of cervical cancer. 
Bcl-2 up-regulation in response to cisplatin treatment also serves as a protective 
mechanism by which cervical cancer cells survive. The extent of apoptotic cell death 
observed after biological inhibition of Bcl-2 reiterates the fact that this response may 
be exploited in order to favour the use of lower concentrations of cisplatin. Analysis of 
clinical specimens emphasised the value of the in vitro work: Cervical cancer biopsies 
had increased expression of both LC-3 II and Bcl-2, indicating autophagy induction 
and apoptosis inhibition, respectively.  
Thus two novel methods of improving cisplatin cytotoxicity have been demonstrated in 
the following study. Treatment regimens may administer more frequently and 
prolonged due to the minimal side-effects that accompanies low-dose cisplatin 
treatment.   
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Uittreksel 
Inleiding 
Sisplatien word algemeen gebruik vir die behandeling van soliede gewasse. Baie 
sukses is reeds deur die gebruik van díe middel behaal in die behandeling van kop en 
nek, ovariale, terstikulêre, servikale en klein-sel kankers. Die sukses van Sisplatien-
behandeling word wel ingeperk deur die dosis-beperkende toksisiteit en die gevolglike 
newe-effekte soos nefrotoksisiteit. Hierdie verwoestende newe-effekte wat deur 
sisplatien behandelings geïnduseer word, het as die platform vir hierdie studie gedien. 
Die doel was om die sisplatien konsentrasies te verlaag, maar terselfdertyd die 
kankerspesifieke sitotoksisiteit te behou. Nog ŉ punt van kommer is dat sisplatien-
weerstandigheid aan die toeneem is, wat die kliniese effektiwiteit en gebruik van 
hierdie middel geweldig beperk. Byvoegmiddels het dus noodsaaklik geraak in die 
poging om die sisplatien-weerstandigheid te verhoed. As gevolg van verskeie bewyse 
wat die belangrikheid van outofagie in kanker impliseer, is die vooruitsig om hierdie 
meganisme te teiken, algemeen aanvaar. Verskeie chemoterapeutiese middels 
induseer outofagie in kanker selle, hoewel die effek van Sisplatien op outofagiese 
induksie nog nie goed ondersoek is nie. Ons hipotese is dus dat die manipulasie van 
die outofagiese pad die kankerselle sensitiseer tot ŉ lae konsentrasie van sisplatien. 
Verder, as gevolg van die funksionele interaksie tussen Bcl-2 en Beclin-1, en hul rol in 
die regulering van outofagie, is verhouding-analises van Beclin-1 tot Bcl-2 uitgevoer 
met die doel om die rol van outofagie in die sel onder homeostatiese en 
behandeling/stres kondisies te bepaal. Verder is Bcl-2 bekend daarvoor om ŉ 
prominente rol te speel in kwaadaardige selle, en die ooruitdrukking daarvan is gevind 
om weerstandigheid aan te help in ŉ verskeidenheid van kankeragtige sellyne. Ons 
hipotetiseer dus dat geenonderdrukking van Bcl-2 voor die behandeling met sisplatien 
die servikale kanker selle sal sensitiseer tot apoptose en ŉ verhoging in die 
verhouding van Beclin-1/Bcl-2 veroorsaak, wat in die guns van apoptose is. 
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Materiale en Metodes 
Drie menslike servikale sellyne was gebruik: ŉ nie-kankeragtige servikale epiteel 
sellyn (Ect/E6E7) en twee kankeragtige servikale sellyne (HeLa en CaSki). Om ŉ 
konsentrasie van sisplatien te bepaal wat nie-toksies tot die nie-kankeragtige 
Ect1/E6E7 sellyn is, was ŉ dosisrespons uitgevoer. Met die gebruik van ŉ outofagiese 
inhibeerder (bafilomycin A1) en ŉ outofagiese induseerder (rapamycin), is die 
outofagiese-fluks kapasiteite van elke sellyn deur die Western Blotting tegniek 
geassesseer. Om te bepaal of die gekose konsentrasie van sisplatien outofagie 
induseer, is vloeisitometrie met ŉ Lysotracker™ kleurstof gebruik, sowel as analises 
op outofagie proteïenvlakke (LC-3 II, Beclin-1 en p62). Outofagie modulering is behaal 
deur twee metodes: farmakologiese modulering met twee erkende middels, naamlik 
bafilomycin A1 en rapamycin, en biologiese manipulasie met die gebruik van ATG5 en 
mTOR geenonderdrukking. Die effekte van die verskillende behandeling skedules op 
seldood was geassesseer deur gebruik te maak van PARP en kaspase-3 splitsing 
deur Western Blotting, kaspase-3/-7 aktiwiteit deur Caspase-Glo ®, PI-insluiting, LDH 
vrystelling en MTT reduserende kapasiteit. Verder is die effekte van hierdie 
behandeling skedules op selsiklus progressie ook geanaliseer. 
Beclin-1 en Bcl-2 uitdrukking was ook bepaal deur Western Blotting en 
immunohistochemie voor en na behandeling met sisplatien in HeLa en CaSki selle. 
Om die afhanklikheid van die servikale kankerselle op Bcl-2 na sisplatien 
behandelings te toets, is Bcl-2 onderdruk deur RNA-inmenging, waarna Beclin-1/Bcl-2 
verhouding geassesseer is, sowel as opoptose deur die gebruik van gesplitste PARP 
analises (Western Blotting) en Caspase-Glo©. 
Vir die ex vivo analises is biopsies vanaf pasiënte wat roetine kolposkopie en 
histerektomies ondergaan, verkry (Tygerberg Hospitaal, Tygerberg, Westelike 
Provinsie). ŉ Totaal van 10 normale, 29 lae-graad plaveisel intraepiteel letsels (LSIL), 
33 hoe-graad plaveisel intraepiteel letsels (HSIL) en 13 karsinoom biopsies is verkry 
vir analises. Die uitdrukkingsprofiel van twee outofagiese merkers (mTOR en LC-3 II), 
asook een merker vir apoptose (Bcl-2), was geassesseer. Proteïen vlakke was ook 
deur Western Blotting geanaliseer en deur immunohistochemie bevestig. 
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Resultate 
Dosisrespons kurwes het getoon dat 15 µM sisplatien nie seldood in die normale 
sellyn (Ect1/E6E7) geïnduseer het nie, en was daarom gebruik deur die res van 
hierdie studie. Verder is daar ook gevind dat CaSki selle meer weerstandig tot 
sisplatien behandelings is wanneer vergelyk word met die HeLa en Ect1/E6E7 selle. 
Outofagiese-fluks analises het getoon dat, alhoewel al drie sellyne vanaf die serviks 
afkomstig is, daar verskille is in hul outofagiese-fluks kapasiteit. 
Daar is ook waargeneem dat die gekose konsentrasie van sisplatien in staat was om 
outofagie te induseer in al drie sellyne, met HeLa selle wat die mees merkbare 
respons getoon het. Modulering van outofagie in samewerking met sisplatien 
behandelings het die volgende onthul: inhibisie van outofagie deur bafilomycin A1 het 
gelei tot ŉ beduidende verhoging in kaspase-3, PARP splitsing en LDH vrylating in 
beide servikale kankersellyne. Geenonderdrukking van ATG5 induseer kaspase-3 
splitsing en stem ooreen met resultate wat verkry is deur farmakologiese inhibisie van 
outofagie met bafilomycin A1. 
Bykomend tot outofagiese indusering, het ŉ lae konsentrasie sisplatien die 
opregulering van Bcl-2 geïnduseer. Wanneer Bcl-2 geenonderdrukking in hierdie 
scenario toegepas was, het dit ŉ beduidende verbetering in sisplatien-geïnduseerde 
apoptose in beide servikale kankersellyne getoon. 
Analises van die uitdrukkingsprofiel van mTOR en LC-3 in normale, pre-maligne (LSIL 
en HSIL) en kankeragtige servikale weefsel, het getoon dat outofagie beduidend 
opgereguleer is in HSILs en servikale karsinome. Verder is Bcl-2 uitdrukking ook 
gevind om beduidend verhoog te wees in servikale karsinoomweefsel, wat 
ooreenstem met resultate verkry in ander studies. 
Gevolgtrekking 
Outofagiese-fluks kapasiteite tussen die drie sellyne, afkomstig van dieselfde orgaan, 
toon beduidende verskille. Hierdie bevinding moet in ag geneem word wanneer 
outofagiese-modulering as ŉ bevorderingsbehandeling gebruik word. Met betrekking 
tot chemoterapie behandeling in servikale selle; ŉ lae konsentrasie van sisplatien 
veroorsaak ŉ beduidende indusering van outofagie in kwaadaardige en nie-
kwaadaardige serviks-afkomstige sellyne, en dien as ŉ oorlewingsmeganisme. 
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Inhibisie van outofagie met bafilomycin A1 en ATG5 siRNA het hierdie beskermings 
effek bevestig, aangesien apoptose beduidend verhoog was in beide kankersellyne. 
Interessant genoeg het rapamycin pre-behandeling tesame met sisplatien nie 
beduidende vlakke van apoptose in HeLa selle geïnduseer nie. Outofagie induksie 
mag dalk addisionele beskerming teen die sitotoksiese effekte van sisplatien gebied 
het. Daarom het die inhibisie van outofagie deur farmakologiese en biologiese 
inhibering die sitotoksisiteit van ŉ lae konsentrasie sisplatien bevorder, wat ŉ 
belowende bevinding is vir die toekomstige behandeling van servikale kanker. 
Bcl-2 opregulering as gevolg van sisplatien behandelings dien ook as beskermings 
meganisme waarby servikale kankerselle oorleef. Die mate van apoptotiese seldood 
wat waargeneem word na biologiese inhibering van Bcl-2, wys weer op die feit dat 
hierdie respons uitgebuit kan word vir die gebruik van laer konsentrasies van 
sisplatien. Analises van die kliniese monsters het ook die waarde van die in vitro werk 
versterk: Servikale kanker biopsies het verhoogde uitdrukking van beide LC-3 II en 
Bcl-2 getoon, wat aandui dat outofagie geïnduseer en apoptose geïnhibeer word. 
Daar is dus twee nuwe metodes vir die verbetering van sisplatien-toksisiteit in hierdie 
studie gedemonstreer. Behandeling regimes kan meer gereeld en vir langer tydperke 
toegepas word, aangesien die newe-effekte van lae-dosis sisplatien behandelings 
minimaal is. 
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1  
Overview 
 
1.1. Problem Statement and Motivation 
Cervical cancer is the second most frequently diagnosed cancer in women worldwide 
despite effective screening programmes (Garcia et al., 2007, Jemal et al., 2008). 
Currently, cisplatin is used as cytotoxic agent for the management of this particular 
disease (Monk et al., 2005), however the severity of the side-effects of cisplatin 
treatment limits the use of this drug, particularly at high doses. The patient is often 
left with long-term damage which further decreases the quality of life (Redeker et al., 
2000, Carlson et al., 2001).  
Cancer cells are also becoming increasingly resistant to cisplatin treatment. A 
mechanism which is used by cancer cells to induce chemo-resistance is to increase 
autophagic activity in the cell (Chen et al., 2010, Notte et al., 2011). Autophagy, a 
process that functions as an intracellular quality control mechanism, has attracted 
much interest in the field of cancer research. Normally, basal autophagy is 
responsible for protein turnover and the elimination of damaged organelles and 
cytoplasmic components to maintain homeostasis in the cell (Maiuri et al., 2007). 
Under pathological conditions however, autophagy is considered to serve as a pro-
survival mechanism, but inappropriate activation of autophagy can also result in cell 
death (Yang et al., 2008). Autophagy is up-regulated under conditions such as 
nutrient depletion, hypoxia and chemotherapy (Tsuchihara et al., 2008, Morselli et al., 
2009, Brech et al., 2009).  
Therefore the motivation for this study was to explore new avenues of chemotherapy 
and adjuvant treatment that would favour the use of lower concentrations of cisplatin, 
thereby limiting the side-effects that are commonly observed in normal tissue. 
Furthermore, mechanisms to reduce chemo-resistance through the manipulation of 
autophagy will also be investigated.  
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1.2 Hypothesis 
It is thus hypothesised that modulation of the autophagic pathway will increase the 
cytotoxicity of cisplatin in cervical cancer cells, thus making the cancer cells more 
responsive to treatment and less chemo-resistant, thereby sensitising cervical cancer 
cells to cell death. 
1.3 General Aims 
An in vitro cervical cancer model made use of three cervix derived human cell lines: a 
normal non-cancerous ectocervical cell line (Ect1/E6E7), an adenocarcinoma cell line 
(HeLa) and a metastatic squamous cell carcinoma cell line (CaSki). Chapter 4 
addresses four important pre-requisites/aims for this study: Firstly, to determine a 
concentration of cisplatin that is non-toxic to the normal, non-cancerous cervical cell 
line (Ect1/E6E7, Chapter 4.1), secondly to determine whether autophagic flux 
capacities could provide insight into the aggressive nature i.e. resistance, of the two 
cervical cancer cell lines (Chapter 4.2), thirdly to determine whether the three cell 
lines (from the same tissue) respond in a similar or different manner to autophagic 
stimulation, and lastly, to determine the value of autophagic flux as a pre-evaluation 
which will serve as a predictive tool in selecting a suitable autophagic modulator. 
Autophagic modulation may be achieved by the inhibition of autophagy with the use 
of bafilomycin A1, or its induction with the use of rapamycin before treatment with 
cisplatin.  
There is very little information concerning cisplatin-induced autophagy as a focus 
point in the literature, particularly in malignant and non-malignant cervical cell lines. 
Therefore this is a relevant and worthwhile avenue to explore since it may shed light 
not only on the intracellular effects of cisplatin, but whether non-cytotoxic doses may 
be a future possibility in the treatment of cervical cancers. Therefore Chapter 5 aims 
to characterise the effects of the non-toxic concentration of cisplatin on autophagy, 
i.e. assess whether autophagy is up-regulated in response to this particular 
concentration of cisplatin and secondly to assess whether the cervical cell lines 
respond in a similar manner to treatment with cisplatin. 
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Literature suggests that cells utilise autophagy as a mechanism of surviving 
unfavourable conditions induced by anticancer drugs (Tiwari et al., 2008), therefore 
Chapter 6 aims to evaluate autophagic modulation as a pre-treatment to cisplatin 
with the use of two pharmacological agents (bafilomycin A1 and rapamycin) and two 
biological agents (ATG5 siRNA and mTOR siRNA). This will determine the reliance of 
both cancer cell lines on autophagy as a mechanism of resistance, and therefore the 
extent of cell death that is induced following autophagy induction or inhibition in 
combination with cisplatin treatment. This may then demonstrate the efficacy of 
autophagic flux pre-evaluation. 
Cisplatin resistance is increasingly common, and has limited the efficacy and use of 
this drug in the clinic. Apart from autophagy, Bcl-2 up-regulation has been implicated 
in this resistance to cisplatin in a variety of non-cervical cancer cell lines (Miyashita 
and Reed, 1993, Dole et al., 1994, Miyake et al., 1998, Zangemeister-Wittke et al., 
1998, Park et al., 2001, Oltersdorf et al., 2005, Cho et al., 2006, Michaud et al., 
2009). Additionally, the functional interaction between Beclin-1 and Bcl-2 on 
autophagy and apoptosis respectively is highlighted as an important point of 
convergence between the two pathways (Pattingre et al., 2005, Maiuri et al., 2007), 
therefore the ratio of Beclin-1 to Bcl-2 is recommended as a means of assessing the 
role of autophagy under conditions of apoptosis (Pattingre and Levine, 2006a). 
Chapter 7 therefore aims to i) assess Bcl-2 expression under control and cisplatin 
treatment conditions, ii) assess the ratio of Beclin-1 to Bcl-2 under control and 
treatment conditions, iii) re-assess the Beclin-1/Bcl-2 ratio after silencing Bcl-2, and 
finally iv) to evaluate the extent of cell death (if any) with the use of Bcl-2 silencing as 
a pre-treatment to cisplatin therapy.  
In order to determine the significance of the in vitro results, it was necessary to 
evaluate clinical specimens for autophagic (LC-3 II and mTOR) and apoptotic 
markers (Bcl-2). Due to the fact that cervical cancer development begins with a well-
defined pre-malignant phase (Ambros and Kurman, 1990) that is characterised by 
low- and high-grade squamous intraepithelial lesion (LSIL and HSIL) development, 
Chapter 8 focused on evaluating the expression profile of two autophagy markers 
(mTOR and LC-3) and an apoptotic marker (Bcl-2) during each phase.  
Before a study of this nature can be attempted, a thorough knowledge and insight 
into the aetiology and pathology of cervical cancer is required. In addition, autophagy 
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and apoptosis as well as the interaction between these two pathways need to be 
outlined for the purpose of this study. The current understanding and knowledge of 
these aspects will now be addressed in the literature discussion (Chapter 2). 
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2 
Literature Review 
2.1. Cervical Cancer 
2.1.1. Incidence 
The fight against cervical cancer thus far is a promising one; from the introduction 
of the Papanicolaou (Pap) test and liquid-based cytology, to the more recent 
development and release of the human papilloma virus (HPV) vaccine which is 
currently in use as a primary preventative measure for cancer of the cervix. 
Unfortunately, the disproportionate burden of cervical cancer in developing countries 
is due to the lack of screening, and as a result, 80% of all new cases in the world will 
occur in these under developed regions (Garcia et al., 2007). In South Africa alone, 
16.48 million women are at risk of developing this disease (WHO/ICO, 2009). If 
introduction of a wide-spread immunization programme was introduced, it could 
lower the incidence of cervical cancer by up to 70% and greatly reduce the costs of 
cervical cancer screening (Woodman et al., 2007). It is however unlikely that 
secondary prevention through screening programmes would be scaled down or 
completely withdrawn for a number of reasons: older women that are not covered by 
the vaccination programme will still be at risk; protection by the vaccines are not 
absolute and the longevity is still uncertain up to this point with protection lasting a 
minimum 5 years (Villa et al., 2006, Harper et al., 2006). Equally important to note is 
that vaccines will only protect against HPV types that are targeted by the vaccine and 
the possibility of genotype replacement cannot be excluded. 
Screening and vaccine programmes should ideally be integrated, as each alone will 
not reach all women. Effective strategies are needed to reach vulnerable populations 
where screening is needed most, and ensure that it is cost-effective (specifically for 
low-income districts) and that promotion of these programmes are community based 
and culturally sensitive. Thus the burden of cervical cancer is a long way from being 
resolved and the need for new and improved therapeutic strategies exists. 
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2.1.2. Epidemiology and Aetiology of Cervical Cancer 
As early as 1842, it was determined by the Italian physician, Rigoni-Stern, that the 
development of cervical cancer was related to sexual contacts (Rigoni-Stern, 1842). 
Through the analysis of death certificates of women in Verona, Italy, during the 
period 1760-1839, he noted a high frequency of cervical cancer in prostitutes, 
widows and married women, but noticed its extreme rarity in virgins and nuns.  
This notion rapidly set the wheels in motion to the discovery of the causal factor of 
cervical cancer, and by the 1970s, studies on the possible role of HPV in cancer 
induction was initiated. In 1982, a model was proposed whereby the high rates of 
cervical cancer in Latin American women could be attributed to a large number of 
sexual partners among males. This sexual behaviour pattern was paralleled by 
monogamy or few sexual partners among females (Skegg et al., 1982). Through this 
study, as well as others (Buckley et al., 1981, Brinton et al., 1989) it was determined 
that men operate as HPV vectors in the epidemiological chain and that HPV types 
related to cervical cancer are a wide-spread sexually transmitted disease. The 
massive growth of epidemiological and molecular data from then onward confirmed 
the carcinogenesis of HPV, and in 1991 it was officially concluded by the 
International Agency for Research on Cancer (IARC) that the association between 
HPV infection and cervical cancer is beyond reasonable doubt and that HPV is the 
aetiological factor in cervical cancer development (Bosch et al., 1992). 
Over 100 HPV types have been identified, of these, 40 infect the genital tract (de 
Villiers et al., 2004). 15 high-risk or oncogenic types have been confirmed, of which 
HPV 16 followed by HPV 18, are the types found most commonly in squamous cell 
carcinomas (Clifford et al., 2003, Muñoz, 2003). HPV 18 is the type most strongly 
associated with adenocarcinomas of the cervix and is almost always integrated into 
the host genome in women with high-grade cervical intraepithelial neoplasia and 
invasive disease (Woodman et al., 2007). Although the incidence of squamous cell 
carcinoma has begun to decline in developed countries, adenocarcinoma of the 
cervix is now on the rise (Wang et al., 2004, Bray, 2005). 
HPV types which infect the genital area can be divided into four groups depending on 
their oncogenic activity: high-risk types (HPV -16, -18, -31, -33, -35, -39, -45, -51, -
52, 56, -58, and -59), probable high-risk types (HPV -26, -53, -66, -68, -73, 82), low-
risk types (HPV -6, -11, -13, -40, -42, -43, -44, -54, -61, -70, -72, -81, and -89), and 
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types of undetermined risk (HPV -30, -32, -34, -62, -67, -69, -71, -74, -83, -84, -85, -
86, -87, -90 and -91) (Muñoz et al., 2006). Because of the differing abilities of these 
HPV types to induce cellular oncogenic changes, it is becoming increasingly 
important in a clinical setting to implement HPV typing. This is a way of identifying 
patients who are at risk of developing cervical lesions and cancer, and as a result, 
patients can be managed and treated accordingly. 
2.1.3. HPV Pathogenesis at the Cytological and Molecular Level 
Genital HPV infections are transmitted by mucosa-to-mucosa or skin-to-skin contact 
(Burchell et al., 2006) where the virus enters presumably via microwounds in the 
epithelium. These openings allow the virus to reach the basal layer of cells (Fig. 2.1.), 
which consist of stem cells and undifferentiated cells that are continuously dividing 
(Longworth and Laimins, 2004). It is these basal undifferentiated cells that provide an 
ideal environment for copying viral DNA. The survival and thus successful 
reproduction of the HPV virus is highly dependent on the keratinocyte’s differentiation 
program. Upon infection, a viral cascade is activated where the early genes are 
expressed (E1,E2 and E4-E7) (Table 1.). These are responsible for transcribing all 
Figure 2.1. HPV-mediated progression to cervical cancer. The target of HPV is the basal 
cells where they are thought to enter via mico-abrasions in the cervix. Initial infection induces 
the expression of the early genes and the viral DNA replicates from episomal DNA (red nuclei). 
Progression into the upper layer causes the viral genome to replicate further, expressing the late 
genes which are responsible for encapsulating the viral genomes to form progeny virions in the 
nucleus. The shed virus then initiates new infections. Microinvasive and invasive carcinoma is 
associated with integration of the HPV genome into host chromosomes (green nuclei). Adapted 
and modified (Woodman et al., 2007) 
Squamous intraepithelial lesion 
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viral proteins, except for those involved in capsid formation. 
The HPV E6 protein has been the subject of great interest over the past few years 
with regards to its role in cervical cancer and its effect on the tumour suppressor 
protein p53. The E6 protein in high-risk HPVs are oncogenic, and this is mainly due 
to the fact that it binds with a higher affinity to p53 when compared to the E6 protein 
found in the low-risk types (Sotlar et al., 2004). p53, often referred to as the 
‘Guardian of the genome’, plays a major role in DNA damage repair. Its expression is 
transiently increased, where it indirectly causes cell cycle arrest at the G1 phase 
through its ability to control cell cycle progression. The E6 protein functions to either 
bind to and stimulate p53 degradation through a selective ubiquitin-dependant 
proteolytic pathway (Werness et al., 1990, Scheffner et al., 1990), or simply to bind to 
and inactivate p53. Ubiquitination and subsequent degradation of p53 decreases its 
half-life from several hours to less than 20 minutes in keratinocytes (Hubbert et al., 
1992). The E6-mediated interference with p53 prevents the cell from undergoing 
apoptosis, thus resulting in genetic instability (chromosomal duplications and 
centrosomal abnormalities) and an increased risk of malignant conversion.  
The E7 viral product functions to bind to and interfere with the retinoblastoma (Rb) 
family of tumour suppressor proteins, as well as other proteins involved in cell cycle 
control. It reduces the ability of the Rb proteins to effectively manage the transition of 
the cycle through the G1/S phase (Steenbergen et al., 2005). As the HPV-infected 
basal cells divide, the copied viral genomes become separated into daughter cells, of 
which one begins to move toward the mid-zone where it nears differentiation. 
Uninfected cells will leave the cell cycle after progressing away from the basal layer 
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and lose their nuclei; this lack of nuclei at the suprabasal regions is characteristic of 
normal uninfected epithelia. In infected epithelia however, the keratinocytes remain 
active in the cell cycle and retain their nuclei (Longworth and Laimins, 2004). At this 
point, highly differentiated, infected cells re-enter the S-phase and activate the 
expression of viral components necessary for replication (Longworth and Laimins, 
2004).  
In the studies outlined above, it suggests that the functioning of E6 and E7 by the 
inactivation/degradation of p53 and Rb, respectively, is responsible for the oncogenic 
potential of HPV. However, malignant conversion is undesirable for the virus as well 
as the host because of the viral genome being integrated into the host genome, 
causing its disruption. Integrated HPV genomes almost always occur in women 
showing severe dysplasia or invasive disease where episomal forms are rarely 
detected (Woodman et al., 2007). This notion of integration being unfavourable to 
viral replication is established through the fact that cervical cancer cells do not 
produce viral particles. It therefore seems unlikely that the function of E6 and E7 in 
the viral life cycle is to contribute to oncogenic conversion (Vousden, 1993). A more 
probable hypothesis is that these proteins serve to generate a favourable cellular 
environment for replication. As mentioned previously, the viral life cycle is closely 
linked to the differentiation program of the keratinocyte and is highly dependent on 
the host replication machinery. It is thus important to continuously induce DNA 
replication in the host cell. The normal function of E6 and E7 may therefore be to 
prevent blocks in cell cycle progression and encourage production of DNA synthesis 
in keratinocytes. 
The Bethesda system for reporting cervical or vaginal cytological diagnoses was 
introduced in order to establish uniform terminology and standardise diagnostic 
reports. An additional aspect was that it introduced a standardised approach for 
determining whether an individual specimen was adequate for evaluation in cytology 
smears stained by the Papanicolaou technique. For the forthcoming cytopathological 
discussion, the most recent 2001 Bethesda system (Apgar et al., 2003) will be used 
on a referral basis. 
The cytological features of non-invasive HPV associated cervical lesions of the low-
grade form are easily recognisable in cytological specimens. These features are 
indicative of productive viral infection and include: perinuclear halos, irregular nuclear 
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outlines, nuclear enlargement, nuclear hyperchromasia and multinucleation. 
Squamous epithelial cells exhibiting these characteristics are referred to as 
koilocytes and when these characteristics are evident in a cytological specimen, it is 
referred to as a low-grade squamous intraepithelial lesion (LSIL) (Apgar et al., 2003). 
Regression of HPV infection through the actions of the immune system occurs within 
2 years of infection in approximately 90% of women (Wright, 2006), however these 
immune responses are poorly understood. 
High-grade HPV-associated lesions exhibiting neoplasia are referred to as high-
grade intraepithelial lesions (HSIL). These high-grade lesions may develop rather 
fast (within 2 years following normal cytology). HPV-induced cytological effects are 
present, but are usually less prominent than when compared to LSILs, most likely 
due to the fact that the viral genomes have been integrated and replication has come 
to a stop (mentioned previously). The immature basal cells have a minimal amount of 
cytoplasm and thus a high nucleus to cytoplasm ratio. Nuclear crowding, loss of 
normal cellular polarity and pleomorphisms are common features (Wright, 2006). 
Abnormal mitotic figures (aneuploidy) are characteristic of HSILs and their presence 
indicates that the lesion is neoplastic. If the viral infection has not been cleared by 
this stage cells begin to exhibit an expression pattern that is indicative of HPV-
induced transformation. It is this step that sets the cell in motion toward gaining an 
immortal phenotype and subsequent invasive growth properties. 
E6 and E7 expression play a major role in inducing transformation of the keratinocyte 
as a result of the deregulation of transcription seen in these oncogenes. Disruption of 
the viral genome as a result of integration into the host genome is the causal factor 
for the up-regulation of these genes seen in high-grade lesions and cervical cancer 
(Woodman et al., 2007, Steenbergen et al., 2005). Viral integration occurs 
downstream of the early genes, E6 and E7, frequently in the E1 or E2 region. This 
interference results in the loss of negative-feedback control by the viral regulatory E2 
protein, which ultimately leads to complete silencing of p53 and Rb.  
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2.1.4. HPV Pathogenesis at the Histological Level 
Cervical cancer is characterised by a well-defined pre-malignant phase which can be 
suspected upon cytological examination and confirmed through histological 
examination of cervical tissue. It was Richart (Richart, 1974) who introduced the 
concept that all types of precursor lesions to squamous cell carcinomas of the cervix 
represented a single disease process. The generic term used to describe this 
process was termed ‘cervical intraepithelial neoplasia’ (CIN). 
 
The pre-malignant changes are classified histologically on the basis of progressive 
atypia of epithelial cells: CIN1 (mild dysplasia) to CIN2 (moderate dysplasia) to CIN3 
(severe dysplasia/carcinoma in situ) (Fig. 2.2.), and became widely adopted for the 
use in histopathology and cytopathology. The WHO classification system (Wells et 
al., 2003) is referred to from hereon in when discussing histopathological features of 
the pre-malignant/malignant cervix. Histological changes are seen in CIN1 where the 
architecture of the squamous epithelium becomes altered. A common feature is the 
thickening of the epithelium (acanthotic) as well as the formation of papillary 
projections with central fibrovascular cores. It is the proportion of the thickness of the 
epithelium showing mature and differentiated cells that is used for grading CIN and is 
dependent on the differentiation, maturation and stratification of the keratinocytes. In 
CIN1, undifferentiated cells are confined to the lower third of the epithelium where 
Koilocytosis CIN I CIN II CIN III 
Invasive 
cancer 
Low grade 
SIL 
High grade 
SIL 
Invasive 
cancer 
 
Figure 2.2. Terminology of precursor lesions of squamous cell carcinoma of the cervix. HPV 
infection induces cellular changes of the keratinocytes over time, consequently contributing to 
dysplasia and finally invasive cancer. CIN – Cervical intraepithelial lesions (terminology used to 
describe cytological changes), SIL – Squamous intraepithelial lesions (terminology used when 
describing histological changes of the cervix).  
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good maturation of basaloid cells is seen. Mitotic figures are present, but are not very 
numerous. CIN2 is characterised by the appearance of mitotic figures in the lower 
half of the epithelium and dysplastic cellular changes which are more marked that 
those in CIN1. In CIN3, mitotic figures are seen through the full thickness of the 
epithelium, as well as the loss of cellular polarity. As a result, differentiation and 
stratification may be totally absent. 
It is important to realise however, that certain lesions do not represent pre-cancer, 
and this is highly important for diagnostic specificity. For example, CIN1 is an 
insensitive histopathological sign of HPV infection, and is not pre-cancer. This was 
seen in studies done on histologically confirmed cases of CIN1 where it was shown 
that such lesions in fact represent a lower risk of progression to carcinoma than do 
the interpretations of LSILs (Cox et al., 2003). If a diagnosis indicates CIN1, this does 
not predict a significantly higher risk of CIN3 than does a negative biopsy (Cox et al., 
2003). CIN3 on the other hand is suggestive of HPV-induced transformation and is a 
scientifically valid surrogate for long- term cancer risk as it can be estimated in 
clinical trials and prospective studies. In a comprehensive review on the natural 
history of CIN, it was found that only 32% of CIN3 lesions will regress when 
compared to 57% and 43% chance of regression of CIN1 and CIN2 lesions, 
respectively (Ostor, 1993). In the same study it was found that 56% of CIN3 lesions 
will persist if untreated, compared to 32% and 35% persistence of CIN1 and CIN2 
lesions, respectively. 
2.1.5. Invasive cancer: HPV involvement 
The multi-step process toward the development of invasive cancer begins with 
persistence of high-risk HPV types in an individual where CIN lesions become 
progressively worse. The deregulation of E6 and E7 protein expression then occurs 
where the fine tuning of cell cycle control is altered, leading to genetic instability 
(mentioned previously). At this point, viral integration is often seen in conjunction with 
the evasion of the infection from the host immune system (Steenbergen et al., 2005). 
CIN2 is the result of these multi-factorial events and takes about 2-3 years to 
manifest.  
It then takes a further 10-12 years for the lesion to gain an invasive phenotype 
(Koutsky et al., 1992). Within this time period, further cellular changes occur, such as 
genetic alterations involving oncogenes and tumour suppressor genes. The E6/E7 
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induced genetic instability causes tumour suppressor genes to become inactivated 
and oncogenes to become active. The inactivation of tumour suppressor genes 
causes immortalisation of the cell, as well as telomerase activation. Mortality stage 
barriers are bypassed with increased telomerase activation as it functions to maintain 
telomere length during cell division (Steenbergen et al., 2005). In a study conducted 
by Snijders et al, it was found that telomerase activity was found in 96% of squamous 
cell carcinomas and 40% of CIN3 lesions, with no detectable telomerase activity 
seen in normal cervices, CIN1 and CIN2 (Snijders et al., 1998). The final step is 
reached when the cell evolves from an immortal to an overt malignant and invasive 
phenotype. 
Staging of cervical carcinomas is established using the FIGO (International 
Federation of Gynaecologists and Obstetricians) system. Invasive cancer cannot be 
visualised through gross inspection of the lesion, instead, diagnosis is based on 
histological examination of cervical tissue, preferably a cone, which must include the 
entire lesion. Invasion is characterised by the protrusion of malignant cells through 
the basement membrane, causing the margin of the invading nests to have a 
‘ragged’ appearance. This irregularity in contour is the most reliable criterion in the 
diagnosis of invasive carcinoma. The extent to which the cells project into the stroma 
is a demonstration of the varying severities of invasion, where stage I is indicative of 
invasion confined strictly to the cervix, stage II is carcinoma that extends beyond the 
cervix and into the upper two-thirds of the vagina, but not as far as the pelvic wall. 
Stage III is characterised as carcinoma extending into the pelvic sidewall and lower 
third of the vagina, as well as hydronephrosis or a non-functioning kidney. Stage IV is 
carcinoma that has involved the mucosa of the bladder and/or rectum. 
 
2.2. Cisplatin: The Platinum Drug 
It has been almost 40 years since the clinical development of the neutral, square 
planar, coordination complex cis-diaminedichloroplatinum(II) (cisplatin). Cisplatin has 
been considered the most effective anticancer drug against cervical cancer in 
neoadjuvant and salvage treatment, with its success owing to the formation cytotoxic 
interstrand and intrastrand DNA cross-links. Cisplatin treatment is mainly 
administered to patients in the early stages of carcinoma (stages I to IIA), as well as 
patients with locally advanced or bulky cervical cancer. It can also be administered in 
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conjunction with radiation therapy followed by radical hysterectomy. It was previously 
unknown how the cellular uptake of platinum based complexes was regulated, but 
fairly recently, three copper transporters (CTR1, ATP7A and ATP7B) were found to 
be responsible (Lin et al., 2002, Kruh, 2003, Safaei et al., 2004a). Once cisplatin 
enters the cell, the drug undergoes strong hydration to form positively charged active 
species that interact with cellular nucleophiles (Andrews and Howell, 1990). There 
are many organelles and molecules with nucleophilic sites besides DNA, such as 
RNA, proteins, cytoskeletal microfilaments and membrane phospholipids that 
cisplatin also reacts with, therefore, despite the fact that it is generally accepted that 
genomic DNA is the critical pharmacological target of cisplatin, it is possible that it is 
not the causal factor of cisplatin-induced cytotoxicity.  
It has been postulated that the cytotoxicity of the DNA adducts is translated into a 
programmed form of cell death, namely apoptosis (discussed in Section 2.4.) 
(Eastman, 1999). The advantage of apoptotic cell death, over necrotic cell death is 
the absence of an inflammatory response. Thus, apoptotic cell death is a favourable 
option when inducing cell death of cancer cells.  
2.2.1. Cisplatin Resistance 
Despite the broad clinical applications of cisplatin, resistance of cancer cells to the 
drug is becoming increasingly common and often culminates in chemotherapeutic 
failure. It has been suggested that this resistance may be attributed to a disruption in 
the normal apoptotic response. As a result of DNA damage incurred after cisplatin 
treatment, differential expression of various pro- and anti-apoptotic proteins has been 
observed. As mentioned earlier, p53 plays a major role in inducing apoptosis, the 
effects of which are seen by HPV-induced disruption of this protein resulting in major 
cellular and histological changes. In cisplatin resistant cells (HeLa/CDDP), it was 
demonstrated that even through the overexpression of p53 by transduction of a wild-
type p53 gene, apoptosis could not be induced (Minagawa et al., 1999), indicating 
that HeLa/CDDP cells were resistant to p53-mediated cisplatin-induced apoptosis. 
On the other hand, in normal cisplatin-sensitive cells, overexpression of the same 
wild-type gene increased the susceptibility to cisplatin-induced apoptosis. Thus, 
cisplatin-resistant cells have managed to suppress this pathway to an extent through 
the down-regulation of specific upstream initiator proteins and/or downstream effector 
proteins.  
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Resistance has also been attributed to a decreased influx of cisplatin into the cells. 
As mentioned earlier, CTR1, a membrane protein found to transport cisplatin into the 
cell, has altered expression levels in resistant cells. A study done on cisplatin 
resistant cervical cancer and ovarian cancer cells showed an almost 2-fold decrease 
in CTR1 expression when compared to the respective sensitive cell lines (Zisowsky 
et al., 2007). It is clear from the above discussion that these, as well as other factors 
are responsible for cisplatin resistance, whether they work in conjunction resulting in 
a cumulative effect, or work alone. 
Another factor in rendering the cervical cancer cell resistant to cisplatin, is that which 
initiated the development of the cancer initially: HPV. Not surprisingly, the HPV 
oncogenic viruses have several mechanisms of suppressing apoptosis in order to 
survive. It was observed that HPV-positive cells were resistant to the anti-proliferative 
effects of cisplatin when compared to the viability of the HPV-negative cell line which 
was reduced by 51% over a 24h time period (Padilla et al., 2001). 
2.2.2. Cisplatin: An in vitro perspective 
Studies which focus on analysing the effects of chemotherapeutic drugs primarily use 
a concentration that inhibits 50% of cell growth (IC50), a value that is obtained 
through analysing a dose response curve. Concentrations of cisplatin that have 
recently been used on various cell lines are specified in Table 2. When compared to 
the dose selected in this study (15 µM / 4.5 μg/ml for 24 h), the indicated doses are 
relatively high, and since the action of cisplatin is time-dependant, this too has 
significant effects on cytotoxicity. The strength of this approach is highlighted by the 
fact that this chosen concentration is up to 66 times less concentrated than the 
studies using cisplatin represented in Table 2. As mentioned previously, the efficacy 
of cisplatin treatment is underpinned by the toxic side effects which are often 
observed, thus there is a need for effective treatment options which utilise lower 
doses of cisplatin that are able to provide similar tumour-selective cell death with less 
cellular toxicity. 
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Furthermore, many studies fail to evaluate the effect of chemotherapy (particularly 
cisplatin) treatment in vitro on non-malignant cells, and this has created a gap in the 
literature. 
 
2.3. Autophagy 
Autophagy has been described as the first defence mechanism in response to a 
variety of cellular stressors (Moreau et al., 2010). Autophagy, a word derived from 
Greek meaning ‘to eat one’s self’, embraces several different processes: 
microautophagy, macroautophagy and chaperone-mediated autophagy (Mizushima et 
al., 2008), all of which have a central function to degrade cellular proteins through the 
use of lysosomal machinery. Microautophagy involves the direct engulfment of 
cytoplasm at the surface of the degradative organelle by invagination, septation or 
protrusion resulting in direct sequestration of organelles by lysosomes. Chaperone-
mediated autophagy is a process whereby unfolded proteins that contain a particular 
pentapeptide motif are chaperoned by the heat shock cognate (hsc) protein 70 to the 
lysosome for its subsequent degradation. Macroautophagy, hereafter referred to as 
autophagy, occurs at basal levels where it functions as a cytoplasmic ‘quality control’ 
process whereby long-lived/damaged organelles are eliminated (Mizushima et al., 
2008). The role of autophagy in maintaining homeostasis extends further than 
sustaining a healthy cellular environment through organelle degradation; it is activated 
in response to nutrient depletion (Lum et al., 2005), it plays a role in cellular processes 
such as cellular development and differentiation (Levine and Kilonsky, 2004), and has 
been shown to play a protective role in the development of diseases such as cancer 
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(Levine and Kilonsky, 2004). Recently, it was proposed to serve as a mechanism by 
which tumour cells survive metabolically unfavourable conditions, such as hypoxia 
(Tsuchihara et al., 2008). 
 
2.3.1 Autophagy: The Mechanism 
Autophagy is process that is controlled by the autophagy-related genes (ATG) 
originally found in yeast (Klionsky et al., 2003). An upstream component is 
responsible for the regulation and activation of these genes (Fig.2.3.). It 
Figure 2.3. The process of autophagy. TORC1/mTOR, a rapamycin sensitive complex, is controlled 
upstream by PI3-K/Akt growth signalling complex where it negatively rates autophagy. Upon inhibition 
of TORC1/mTOR, Beclin-1 complexed with Vps34 and other essential proteins functions to sort 
vesicles and aid in membrane trafficking which initiates autophagosome formation (inhibited by 
silencing ATG5). Bcl-2, a Beclin-1 interacting protein, is able to bind to Beclin-1 and inhibit its pro-
autophagic activity. Expansion of the phagophore and sequestration of organelles by p62 coincides 
with conversion of LC-3 I to LC-3 II, after which it is recruited to the forming the autophagosome and 
becomes membrane-bound. Completion and maturation of the autophagosome is signified by the 
fusion of the autophagosome with a lysosome to form an autophagolysosome. Lysosomal hydrolases 
then degrades the cellular components, including LC-3 II and p62. The macromolecular components 
are then made available to the cell’s metabolism for other uses. 
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encompasses three main proteins: Phosphoinositide 3-kinase (PI3-k), Akt, and the 
mammalian target of rapamycin (mTOR) (Levine and Deretic, 2007). The class III 
PI3-k (Vps34) induce autophagy through binding with Atg 6 (Beclin-1) where it 
becomes localised in the trans-golgi network (the region where autophagosome 
formation is thought to take place). Here, Beclin-1 functions to sort specific 
autophagosomal components (Kihara et al., 2001). Vesical biogenesis is thought to 
occur de novo as the double-membraned vesicles do not appear to be budding off 
from pre-existing organelles. It is generally accepted that the source of the 
autophagosomal membrane is the endoplasmic reticulum (ER) and is supported by 
the fact that ER function and machinery are necessary for autophagy (Ishihara et al., 
2001).  
Shaping of the autophagosome is controlled by two pathways: the Atg12-Atg5 
pathway and the microtubule-associated protein 1 light chain 3 (LC3/Atg8)-
phosphatidylethanolamine (PE) pathway (Ohsumi, 2001)(Fig.2.4.). The Atg12 
pathway begins with irreversible bond formation between Atg12 and Atg5. A 
conjugate is then formed with the additional binding of Atg7 and Atg10. The binding 
of Atg7 causes the activation of Atg12 which is then able to transfer and bind to 
Atg10 through a thioester bond.  Finally, Atg12 binds covalently to Atg5 to form the 
final conjugate (Atg12-Atg5). This conjugate then binds non-covalently to Atg16 
forming the Atg12-Atg5-Atg16 complex (Mizushima et al., 1999). It becomes 
membrane-bound and is a pre-requisite for the recruitment of LC3-II, the product of 
the second conjugated pathway.  
The second pathway involved in autophagosome formation begins with the cleavage 
of LC3 to LC3-I by Atg4. Upon activation by Atg7, LC3-I is transferred to Atg3 where 
it eventually becomes conjugated to PE through an amide bond. The resulting LC3-II 
then becomes membrane-bound where it is able to function as a membrane protein 
(Yorimitsu and Kilonsky, 2005). It has thus been utilised as a marker for detecting 
autophagosomes. The pre-autophagosomal structure (PAS) is formed as a result. 
Expansion/elongation occurs through the supply of lipids; possibly in the form of lipid 
bilayers present in transport vesicles. At this point, the exact source of lipids is still 
unknown. It is thought that lipid delivery is as a result of the cycling of Atg9 from the 
mitochondria serving as the donor to the autophagosome serving as the acceptor 
membrane (Reggiori et al., 2005). Upon autophagosome completion, ATG proteins 
comprising of the vesicle-forming machinery dissociate through a process known as 
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uncoating. Only after uncoating, the autophagosome is able to fuse with a lysosome, 
indicating that coating may prevent premature fusion of the autophagosome and 
lysosome (this step may be inhibited by bafilomycin A1). 
Fusion of the outer membrane of the autophagosome with the lysosomal membrane 
occurs with the assistance of specific fusion machinery. After the outer membrane 
has fused (forming the autophagolysosome), the inner membrane then enters the 
lysosome where it is now termed the autophagic body. Lytic enzymes then proceed 
to degrade the outer membrane, allowing for the cytoplasmic components to be 
released and subsequently degraded. The final stage of autophagy occurs when the 
degraded products are recycled and reused for synthesis of other proteins that are 
Figure 2.4. The molecular mechanism of autophagy. The process of autophagosome formation 
involves two ubiquitin-like conjugation pathways. A. The Atg5-Atg12 pathway which is responsible for 
driving the expansion of the membrane and dissociates just before, or immediately following 
completion. B. Atg8/LC-3 – PE pathway that results in covalent bond formation between ATG 8 and 
phosphatidylethanolamine (PE). This formation is essential for the sequestration and formation of 
vesicles in the autophagic pathway where it becomes degraded along with the cytoplasmic cargo. 
Adapted and modified (Yorimitsu and Klionsky, 2005). 
A. 
B. 
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needed or that are in short supply at that stage (Yorimitsu and Kilonsky, 2005). 
2.3.2 Autophagic Flux 
The capacity of a cell to induce autophagy is dependent on tissue type, which 
suggests that the reliance of cells on autophagy in different organ systems is 
dependent on their metabolic demand (Mizushima et al., 2004). This begs the 
question of whether all cancer cells have the same basal autophagic levels, or 
whether it differs among cell types. Also, do these cells have a similar or different 
capacity to induce autophagy, i.e. under certain conditions where autophagic flux is 
analysed, how much of the autophagic machinery is up-regulated when stimulated to 
its maximum? This may therefore represent an important indicator of aggressiveness 
and resistance. Autophagic flux can be described not only as the increased synthesis 
of LC-3, but completion of the process. 
An accepted method for determining flux through the autophagic pathway is by 
analysing the turn-over of LC-3 II by Western blotting in the presence and absence of 
lysosomal degradation (Klionsky and Deter, 2008, Klionsky et al., 2012). If this 
pathway is blocked downstream where the fusion of autophagosomes with 
lysosomes is inhibited, thus preventing the recycling of the autophagosome, and 
induced upstream, autophagosomes (and therefore LC-3 II) will accumulate. 
bafilomycin A1 is a commonly used inhibitor of vacuolar formation and thus 
autophagy, and rapamycin, an inhibitor of mTOR, is a well- known autophagic 
inducer, both of which have been used in this study.  
2.3.3. Dysregulation of Autophagy in Cancer 
In the context of cancer, autophagy has been observed to exhibit both tumour-
suppressive and tumour promoting functions under varying conditions. It may 
function as a temporary survival mechanism under various conditions of stress 
(Moreau et al., 2010), or cell death may ensue if this cellular stress leads to 
excessive or continuous autophagy (Liang and Jung, 2010). It is likely that it plays 
both roles, depending on the stage of cancer progression, the cell type, surrounding 
environment, amino acid levels, oxygen availability, viral invasion, etc. The 
engagement of autophagy by cancer cells is often observed during the late stages of 
tumour progression when it becomes up-regulated as a means of surviving 
unfavourable nutrient/oxygen conditions. Interestingly, literature suggests that both 
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the induction and the inhibition of autophagy in combination with chemotherapy 
treatment induces cell death. 
a. Pro-Tumour Functions of Autophagy 
It has been observed that autophagy is up-regulated under conditions such as 
nutrient depletion, hypoxia as well as chemotherapy (Tsuchihara et al., 2008, Morselli 
et al., 2009, Brech et al., 2009) and it has subsequently been proposed that 
autophagy promotes survival of cancerous cells under metabolic stress. Central to 
this metabolic stress is a lack of a steady supply of oxygen and substrates, a 
phenomenon commonly observed in primary, untreated tumours. These tumours do 
not have an established blood supply that is able to meet the high nutritional 
demands of aberrantly proliferating cells due to the requirement of amino acids and 
oxygen outweighing their respective availability supplied by the normal vasculature. 
Even after establishment of functionally and structurally adequate tumour vessels, 
the disorganised proliferation of these cells usually destroys the network of nutrient 
and oxygen supplying vessels, yet these cells are able to survive. During metabolic 
stress such as this, autophagy becomes up-regulated as a means of catabolising 
various unused/long-lived organelles as a source of metabolic substrates. By 
mitigating this metabolic stress, the integrity of the genome is preserved which will 
then confer resistance to anti-cancer therapy (Tsuchihara et al., 2008, Morselli et al., 
2009). 
The necessity for autophagy in cancer cells is observed in the following studies: In 
tamoxifen-resistant breast cancer cells, Beclin-1, ATG5 and ATG7 were eliminated 
through RNA interference, after which the cells were exposed to tamoxifen. This 
resulted in enhanced tamoxifen induced apoptosis (Qadir et al., 2008), which 
suggests that autophagy would normally assist in cell survival under these 
conditions. Likewise, the silencing of ATG proteins through siRNA sensitised cancer 
cells to radio- and chemotherapy (Tiwari et al., 2008). In cells that have detached 
from the extracellular matrix in order to metastasise, it was observed that autophagy 
was up-regulated (Lock and Debnath, 2008); presumably utilised as a way of 
surviving in the blood stream and in other organs where blood supply is limited. In 
cells defective in undergoing apoptosis (a common characteristic of cancer cells), 
autophagy is used to survive metabolic stress induced by radio- or chemotherapy 
(Kondo et al., 2005).  
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These examples substantiate the idea that cells utilise autophagy as a mechanism of 
surviving unfavourable conditions induced by anticancer drugs. Additional studies are 
required whereby autophagy is inhibited under conditions that induce its up-
regulation, particularly with anti-cancer drugs, in order to elucidate at which point this 
inhibition becomes effective. 
b. Anti-Tumour Functions of Autophagy 
The first indication that autophagy may have a tumour suppressing effect emerged 
when it was observed that some cancer cells have a down-regulated autophagic 
response (Gunn et al., 1977, Kisen et al., 1993). A possible explanation for this may 
be that the up-regulation of the PI3-Kinase pathway is often observed in cancer cells 
(LoPiccolo et al., 2008, Jiang and Liu, 2008) which in turn results in the activation of 
the mammalian target of rapamycin (mTOR), a potent inhibitor of autophagy. This 
reveals an interesting point: autophagy- inducing molecules are under the control of 
tumour suppressor proteins such as phosphotensin-homologue deleted on 
chromosome ten (PTEN) and tuberous sclerosis (TSC) (Inoki et al., 2004).These are 
both tumour suppressors which function to suppress mTOR, a molecule which is a 
key regulator of cancer cell proliferation. Suppression of mTOR induces autophagy, 
whereas molecules which induce mTOR, such as the class I PI3-K and Akt, that are 
often up-regulated in various cancers (LoPiccolo et al., 2008, Jiang and Liu, 2008) , 
lead to the suppression of autophagy. Additional evidence to support these findings 
is the fact that autophagy genes themselves may operate as tumour suppressors 
(Liang and Jung, 2010). Although this suggests an anti-tumour function for 
autophagy, these molecules have roles in pathways that govern both life and death 
decisions, and thus reiterates the dynamics not only autophagy, but the cross-talk 
between this process and apoptosis. 
Since autophagy has also been described as a ‘quality control’ process, it is not 
surprising that its down-regulation may prevent adequate maintenance of a healthy 
cellular environment, and may result in the accumulation of oncogenic events in the 
cell. In autophagy-defective cells, accelerated DNA damage was observed (Abedin et 
al., 2007, Katayama et al., 2007) as well as chromosomal instability followed by 
increased tumour susceptibility (Mathew et al., 2007). The exact mechanism for 
chromosomal instability is not known, however the accumulation of damaged 
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mitochondria and peroxisomes may play a role, as they are sources of excess 
reactive oxygen species (ROS), which induce genotoxic stress.  
mTOR has been a central point of interest in terms of its regulation of autophagic 
function. Rapamycin, isolated from the microorganism Streptomyces hygroscopicus, 
functions to mechanistically inhibit mTOR (Vezina et al., 1975). Much success has 
come from the use of this inhibitor in cancer research (Vignot et al., 2005), and 
evidence suggests that the induction of autophagy has promising anti-tumour effects 
(Lefranc et al., 2007). For example, CaSki cells were observed to be increasingly 
sensitive to paclitaxel after the addition of rapamycin (Faried et al., 2006). Beclin-1 
overexpression in the same cell line as well as various gastric cancer cell lines 
(MKN1, MKN28, MKN45, NUGC-3, AZ512 and TMK1) resulted in the sensitisation of 
these cells to undergo apoptotic cell death in the presence of cisplatin and other anti-
cancer drugs (Furuya et al., 2005, Sun et al., 2010).  
With regard to cisplatin treatment, overexpression of the Beclin-1 gene in CaSki and 
other cancer cells increases the chemosensitivity to cisplatin (Sun et al., 2010), and 
the combination of Beclin-1 over-expression together with anti-cancer drug 
administration is superior to that of anti-cancer treatment alone. Similarly, the 
induction of autophagy through the biological inhibition of mTOR using siRNAs 
restores cisplatin chemosensitivity in various lung cancer cell lines (Wangpaichitr et 
al., 2008).   
Although these results contradict previous results related to cisplatin treatment, this 
differential response to the anti-cancer drug may be attributed to the following 
circumstances: firstly, the basal level of autophagy in the cell and its capacity to 
induce an autophagic response, secondly to what extent the cell relies/utilises 
autophagy in the presence of cisplatin, and lastly the dose and duration of cisplatin 
that is administered. 
2.3.4. Cisplatin-Induced Autophagy 
There is very little information concerning cisplatin-induced autophagy as a focus 
point in the literature, particularly in malignant and non-malignant cervical cell lines. 
Therefore this is a relevant and worthwhile avenue to explore since it may shed light 
not only on the intracellular effects of cisplatin, but whether non-cytotoxic doses may 
be a future possibility in the treatment of cervical cancers. More importantly, if 
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cisplatin does in fact induce autophagy, would it be possible to exploit this finding as 
a means of forcing the cell toward cell death?  
Additionally, many studies fail to evaluate the effect of chemotherapy (particularly 
cisplatin) treatment in vitro on non-malignant cells and this should be addressed in 
the literature. There have been no studies to our knowledge that have assessed the 
effects of cisplatin and autophagy in the non-malignant Ect1/E6E7 cells, thus this will 
be assessed for the first time in this study. With that in mind however, a large amount 
of work has focused on the effects of cisplatin on cell death and autophagy in renal 
tubule epithelial cells, since cisplatin preferentially accumulates in this area, resulting 
in nephrotoxicity. It has been reported that cisplatin induces autophagy in renal 
epithelial cells in vitro and in vivo (Kaushal et al., 2008, Yang et al., 2008, Inoue et 
al., 2010) where it serves as a protective mechanism for the survival of these cells 
against apoptosis, which was determined through inhibiting autophagy with 3-MA and 
bafilomycin A1 (Periyasamy-Thandavan et al., 2008). Low-dose cisplatin (1 – 20 µM) 
was also observed to induce hepatic autophagy in vitro and in vivo where it plays a 
protective role against ischemia/reperfusion injury (Cardinal et al., 2009). The above 
results suggest that cisplatin may have an effect in activating the autophagic 
machinery in non-malignant cell types. 
The effect of a low concentration of cisplatin in inducing autophagy is equally largely 
unknown, however a few studies have reported the following: Lui and colleagues 
reported an up-regulation of autophagy in oesophageal squamous carcinoma cells in 
response to cisplatin treatment (1.5 mg) through the analysis of LC-3 II and Beclin-1 
(Liu et al., 2011). A similar response was observed in human U251 glioma, rat C6 
glioma and mouse L929 fibrosarcoma cell lines in a dose and time-dependant 
fashion (Harhaji-Trajkovic et al., 2009), as well as in A549/DDP and A549 cells (Ren 
et al., 2010). This study by Ren and colleagues proposed that the cisplatin resistance 
observed in the lung carcinoma cells (A549/DDP) is attributed to the increased levels 
of autophagy when compared to the sensitive lung carcinoma cell line. These data 
suggest the potential importance of the role of autophagy in cisplatin treatment and 
therefore needs to be a point of focus in future studies. 
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2.4. Apoptosis 
In instances of severe cellular stress, whether induced in the microenvironment or 
intracellularly, the organism is able to initiate cell death through apoptosis and avoid 
potentially life-threatening consequences. The term ‘apoptosis’ (Greek: apo- from, 
ptosis- falling) was coined in 1972 by Kerr, Wyllie and Currie to delineate the 
molecular events which lead to the distinct morphological cellular characteristics of 
cell death in living tissues (Kerr et al., 1972). Such characteristics include cellular 
shrinkage, membrane blebbing, chromatin condensation, and eventually 
fragmentation into apoptotic bodies. The fact that apoptosis is a gene-directed 
program has profound implications in our understanding of tissue homeostasis, as it 
implies that cell numbers can be regulated by factors that influence cell survival, 
proliferation, development (Zakeri and Lockshin, 2005, Zakeri and Lockshin, 2002) 
and aging (Lockshin and Zakeri, 1990). It is a multitude of interconnected pathways 
where the pattern of apoptotic death events manifest in a timely, ordered fashion. As 
a result, this process is often termed programmed cell death (PCD). PCD is essential 
in the removal of cells during development and degenerative disorders, as well as in 
cells that have been exposed to toxic compounds. Apoptosis occurs rapidly, leaving 
little trace, and as a consequence, the death of the cell is systemically unnoticed as 
no inflammatory response is initiated. In the last decade, the mechanisms of various 
signal transduction pathways that lead to PCD have been clarified, and with this 
information, apoptotic cascades have been described as intrinsic or extrinsic, 
caspase-dependent or -independent, p53-dependent or -independent and 
mitochondrial derived or death receptor governed.  
a. Intrinsic Induction of Apoptosis 
Intrinsically, apoptosis occurs as a result of a disturbance in the intracellular 
homeostasis (Fig.2.5.). Mitochondria play a critical role in the induction and execution 
of cell death in this pathway, and as a result it is often termed the ‘mitochondrial 
death pathway’. It is initiated in response to intracellular death signals, such as DNA 
damage, growth factor withdrawal, oxidative stress or oncogene activation.  
The decision of a cell’s fate is dependent on the expression levels of the Bcl-2 family 
of intracellular proteins at any given time. The members of this family have been 
shown to both induce and inhibit the apoptotic process. They are characterised by 
the presence or absence of Bcl-2 homology (BH) domains, of which four have been 
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described: BH1, BH2, BH3, and BH4. The anti-apoptotic proteins, Bcl-2 and Bcl-XL, 
both consist of all four BH domains, and function to antagonise pro-apoptotic protein 
function upstream of mitochondrially-mediated apoptosis. Two sub-families of pro-
apoptotic proteins exist: the bax family (Bax, Bok, and Bak), which are comprised of 
the BH domains 1, 2, and 3, and the BH3 only family of proteins (Bid, Bim, Bik, Bad, 
Bmf, Hrk, Noxa, and PUMA). Both families of pro-apoptotic proteins are essential for 
the completion of apoptosis, and in some instances they work together in order to 
ensure it. A successful example of this is seen when Bid is cleaved by caspase-8 into 
the active tBid, which in turn induces Bax/Bak- dependent permeabilisation of the 
outer mitochondrial membrane and the subsequent release of cytochrome-c during 
Fas mediated apoptosis (Li et al., 1998). This relationship is established by the 
finding that apoptosis cannot be induced in the absence of Bak and Bax (Zong et al., 
2001). There is still much to be learnt about the regulation of this family of proteins, 
Figure 2.5. The Intrinsic Apoptotic Pathway. An apoptotic signal in the form of cytotoxic stress, 
DNA damage, etc. induces the translocation of Bax to the mitochondrial membrane which then 
facilitates the opening of the mitochondrial permeability transition pore (mPTP), leading to decrease in 
mitochondrial membrane potential (ΔΨm). Bcl-2, an anti-apoptotic protein is able to prevent this 
opening by interaction with Bax. Cytochrome-c is then released where it complexes with Apaf-1 and 
pro-caspase-9 to form an apoptosome. This facilitates cleavage of pro-caspase-9 into caspase-9 
which then induces cleavage of the effector pro-caspase-3. Caspase-3 then cleaves PARP which 
prevents it from repairing DNA strand breaks and apoptosis is induced. 
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both between and within sub-families at the level of transcriptional control, protein 
translocation, and protein-protein interactions. 
Apoptotic signals change the function of the Bcl-2 proteins leading to a change in 
mitochondrial integrity. One of these proteins is Bax, which is a pro-apoptotic protein 
whose expression is increased in response to death inducing stimuli. Bax moves 
from the cytosol and embeds itself into the mitochondrial membrane together with 
Bak, another pro-apoptotic protein. Here it is thought to cause the opening of the 
mitochondrial permeability transition pore (PTP), leading to a decrease in 
mitochondrial membrane potential and subsequent release of cytochrome-c. Bax and 
Bak are proven to be essential in mitochondrially mediated apoptosis since 
mitochondria deficient in either of them fail to release cytochrome-c (Wel et al., 
2001). Cytochrome-c plays a crucial role in the electron transport chain and is found 
embedded in between the inner and outer membrane of the mitochondria. This 
supported the belief that the release of cytochrome-c is a crucial step in the 
execution of apoptosis. After its release, it binds to an adaptor protein known as 
Apaf-1 (apoptotic protease-activating factor-1), which, in the presence of ATP, 
induces self-oligomerisation. Once assembled, Apaf-1 recruits pro-caspase-9 and 
causes its auto-activation through a proximity-induced action. Procaspase-9 thus 
becomes the initiator caspase-9 that in turn activates the downstream effector 
caspase cascade. 
Caspases. Cysteinyl aspartate-specific proteases (caspases) operate as a team to 
initiate and execute an orderly, irreversible and self-amplifying cascade that induces 
cell death (Cohen, 1997). Initially, caspases are synthesised as pro-caspases that 
are composed of a highly homologous protease domain, as well as an NH2 terminal 
pro-domain. The critical protease domain contains two sub-units of approximately 10 
and 20 kDa that form a heterodimer following its proteolytic processing. Two 
heterodimers then associate to form a tetramer which is the active form of the 
caspase (Walker et al., 1994). The NH2 terminal pro-domain varies in length 
depending on the functional activity of the caspase. For example, initiator and 
inflammatory caspases possess long pro-domains that are more than 100 amino 
acids in length compared to the effector caspases which are characterised by pro-
domains that are less than 30 amino acids long. Each long pro-domain host motifs 
that are essential for caspase activity, such as death effector domains (DEDs) in 
caspase-8 and -10, or caspase recruitment domains (CARD) in caspases -1, -2, -4, -
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5, -9, -11, -12, -13, and -14. Both caspase-9 which serves as an initiator caspase 
during intrinsically induced apoptosis and caspase-8 which operates as an initiator 
caspase during extrinsically induced apoptosis, are able to cleave and activate 
effector caspases (-3, -6 and -7), thus rendering caspase-3, -6 and-7 the ultimate 
morphological and biochemical hallmarks of apoptosis, regardless of the apoptotic 
inducer. 
PARP. Another hallmark of apoptotic cell death is the cleavage of poly (ADP- ribose) 
polymerase (PARP)(Berger and Petzold, 1985). Under normal circumstances, PARP 
catalyzes the poly (ADP- ribosyl)ation of many nuclear proteins, with NAD as a 
substrate (Hamid Boulares et al., 1999). It becomes activated when bound to DNA 
ends or strand breaks (DNA damage) and is needed during the repair of DNA 
damage. During cell death through apoptosis, caspase-3 is primarily responsible for 
the cleavage of PARP (Tewari et al., 1995, Nicholson et al., 1995), which inactivates 
the enzyme by destroying its ability to respond to DNA strand breaks within the cell, 
resulting in death. It has been suggested that the cleavage of PARP occurs as a 
means of preventing the depletion of energy (NAD and ATP) which is needed for late 
stage apoptosis (Berger and Petzold, 1985). As a result of PARP inactivation, DNA is 
fragmented into 200 base pair repeats that can be visualised on an agarose gel. 
b. Apoptosis in Cancer 
Early findings that indicate that apoptosis may have an effect on the development of 
a malignant phenotype goes back to the early 1970s where kinetic studies on tumour 
growth were conducted (Kerr et al., 1972). Tumour growth rates were less than 5% of 
that predicted by proliferation measurements alone, implying that cell loss from 
tumours may be substantial and that this ‘cell-loss factor’ may have a major impact 
on tumour growth or regression (Kerr et al., 1972, Wyllie et al., 1980). These 
observations, as well as subsequent studies on cytotoxic agents and tumour 
regression suggested not only that apoptosis contributed to cell loss in malignant 
tumours, but also that tumour progression may be promoted if apoptosis is disrupted.  
Role in Tumourigenesis. One of the characteristics of tumour cells is their ability to 
evade apoptosis to allow them to survive and proliferate under stressful conditions, 
such as environments which lack nutrients and oxygen. In order to identify the role of 
apoptosis in tumour formation, it is important firstly, to identify apoptotic ‘triggers’ that 
a non-malignant cell encounters under various conditions, and secondly to determine 
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how these ‘triggers’ will provide insight into the driving forces of tumour evolution. In 
the skin, cells that are exposed excessively to UV rays undergo apoptosis 
presumably to remove cells that are extensively damaged (Ziegler et al., 1994). But 
loss of p53 in these damaged cells allows for their survival and subsequent 
transformation into malignant, tumourigenic cells (Ziegler et al., 1994). It is thus 
observed that a link between DNA damage, p53 signalling and apoptosis induction 
exists. Similarly, in patients treated with cisplatin, a common side-effect of 
nephrotoxicity is observed. Non-malignant renal tubular cells are especially sensitive 
to cisplatin treatment and it has been found that DNA damage (cross-links brought 
about by cisplatin treatment) in these cells induces apoptosis (Zhan et al., 1999) and 
that acute renal failure is associated with this treatment (Zhou et al., 1999).   
Loss of p53 function in tumours is a common clinical phenomenon. Briefly, upon 
receiving the signal, cytoplasmic p53 undergoes (multi)mono-ubiquitination and 
rapidly translocates to the mitochondrial membrane where it interacts with members 
of the Bcl-2 family of proteins to cause permeabilisation of the outer membrane 
(Vaseva and Moll, 2008). This is accomplished through the interaction and 
subsequent neutralisation of the anti-apoptotic proteins Bcl-XL and Bcl-2 which 
results in robust mitochondrial outer membrane permeabilisation and apoptosis 
(Mihara et al., 2003). If p53 becomes mutated (a common characteristic of many 
cancers) or degraded (as a result of infection with high risk-HPV), this down-stream 
cascade of events cannot occur, resulting in the malignant cell failing to die.  
The Bcl-2 protein is another molecule that is altered in tumours. Its levels of 
expression have been used as a predictor of prognosis in ovarian cancer through the 
finding that late stage tumours had a higher expression of Bcl-2, which the authors 
suggest is the reason for the cells impaired ability to undergo apoptosis (Mano et al., 
1999). Conversely, if Bcl-2 is found to be phosphorylated after treatment with a DNA 
damaging drug such as cisplatin, it is an indication that cell death through apoptosis 
is likely to follow, and that the drug is thus effective (Pratesi et al., 2000). Taken 
together, increased anti-apoptotic functioning of Bcl-2 plays a major role in tumour 
evolution (Adams and Cory, 2007). 
2.5. The Beclin-1 Bcl-2 Interactome 
The interaction between Beclin-1 and Bcl-2 proteins is an important point of 
convergence between the apoptotic and autophagic pathways. The initial discovery 
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of this complex was observed in a yeast two-hybrid screen where Beclin-1 was found 
to interact with Bcl-2 (Liang et al., 1999), and the significance of this was highlighted 
when Bcl-2 was down-regulated in HL60 cells resulting which resulted in cell death 
through autophagy (Saeki et al., 2000). At this point, little was known about the 
functional significance of this interaction, until work published by Pattingre and 
colleagues (Pattingre et al., 2005) suggested that Bcl-2 exerts an anti-autophagic 
function by binding to and inhibiting Beclin-1. Subsequently, the functional and 
spacial interaction between Beclin-1 and the anti-apoptotic proteins, Bcl-2 and Bcl-XL 
was elucidated (Maiuri et al., 2007). 
Under conditions of homeostasis, the Beclin-1-Bcl-2 interaction ensures that 
autophagy is precisely regulated, and its activity is maintained particularly during 
nutrient depletion. Bcl-2/Bcl-XL firstly binds to and interferes with the pro-apoptotic 
proteins Bax and Bak at the mitochondrial membrane, thereby preventing apoptosis, 
and secondly it interacts with Beclin-1 to prevent excessive autophagy and possibly 
cell death (Pattingre et al., 2005). The importance of this interaction is underlined by 
the fact that Beclin-1 is a tumour suppressor protein and that inhibition of its function 
by Bcl-2 contributes to the oncogenic potential of Bcl-2 (Pattingre and Levine, 
2006b). In an early study, the oncogenicity of Bcl-2 was observed in cervical 
carcinoma in situ samples as well as in invasive cervical carcinomas where it was 
determined that 81% and 62% of cases respectively were positive for Bcl-2 
expression (Tjalma et al., 1998). In a study by Won and colleagues, tissue samples 
of invasive breast cancer were analysed for the presence of Bcl-2 and Beclin-1, and 
it was observed that Bcl-2 expression correlated with histological grade, distant 
metastasis and mitotic count, amongst other parameters (Won et al., 2010). Also, this 
expression was inversely correlated with the expression of Beclin-1, which the 
authors suggest is due to its inhibition by Bcl-2. In another study by Wang and 
colleagues (Wang et al., 2011), cervical squamous carcinoma tissue was analysed 
for the expression of Beclin-1. Although Bcl-2 expression was not analysed, a 
common trend was seen where Beclin-1 expression decreased significantly in 
malignant cervical cancer tissue when compared to those of normal or cervical 
intraepithelial neoplasia tissue.  
The above evidence suggests that Bcl-2 not only has oncogenic potential, but also 
that its expression often occurs in the absence of Beclin-1 in a malignant cell. This 
association is likely to be more complex, nevertheless, it may bare the possibility that 
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potential for therapeutic treatment strategies exist. Bcl-2 antagonists have been 
applied clinically, and preliminary results seem promising (Leber et al., 2010).   
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3 
Materials and Methods 
3.1. Cell culture lines 
HeLa and CaSki cells were purchased from Highveld Biological (South Africa) and 
grown in Dulbecco’s Modified Eagles Medium (DMEM) supplemented with 10% 
foetal bovine serum (FBS) (Gibco. Ltd) and 1% penicillin/streptomycin (P/S) (Sigma-
Aldrich). Ect1/E6E7 cells (a kind gift from Dr. Donita Africander, Stellenbosch 
University, South Africa) were grown in Keratinocyte Serum-Free Medium (KSFM) 
supplemented with 4 mM CaCl2, 0.1 ng/ml epidermal growth factor, 50 µg/ml bovine 
pituitary extract (Gibco. Ltd) and 1% P/S (Sigma-Aldrich). All cells were grown at 
37°C and 5% CO2 under humidified conditions. HeLa and CaSki cells were passaged 
upon reaching 70-80% confluency, and Ect1/E6E7 cells were passaged at a 
confluency of 60%. 
3.2. Cisplatin preparation and treatment 
Cisplatin (Sigma-Aldrich) was prepared before each treatment period by dissolving 
the powder in 0.9% NaCl solution to obtain a 0.001 M stock solution. It was then 
added to sub-confluent cells to reach final working concentrations of 5, 10, 15, 30, 
60, 80,100 and 160 µM and incubated for a period of 24 h. 
3.3. Autophagy modulators 
Cells were treated at a confluency of 80 – 90% with 10 nM bafilomycin A1, 50 μM 
rapamycin or both (autophagic flux determination). In the case of dual treatment, 
cells were first treated with 10 nM bafilomycin A1 and left for a period of 24 h, where 
after 50 μM of rapamycin was added and left for a further 24 h. When acting as an 
adjuvant treatment, autophagic modulators were added to cells 24 h prior to cisplatin 
treatment.  
3.4. MTT assay  
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay is 
based on the principle of the reduction of MTT into blue formazan pigments by viable 
mitochondria in healthy cells and is therefore used to evaluate cytotoxicity 
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(Mosmann, 1983). HeLa and CaSki cells were both seeded in 24-well plates at a 
density of 3 x 104 cells/well and were allowed 24 h to adhere. Ect1/E6E7 cells were 
seeded in 24-well plates at a density of 5 x 104 cells/well and allowed 48 h to adhere. 
After the treatment period, 0.01 g/ml MTT was added to each well where after cells 
were incubated for 2 h at 37˚C in an atmosphere of 5% CO2. HCl-isopropanol-Triton 
solution (1% HCl in isopropanol, 0.1% Triton X-100 in a 50:1 ration) was then added 
to each well and gently agitated for 5 min. Addition of this solution causes lysis of the 
cell membrane and the release of blue formazan pigments. The optical density (OD) 
was determined on a plate reader (EL-800, Micro-Tek instruments) at a wavelength 
of 540 nm and the values expressed as a percentage of the control. 
3.5. Chromatin condensation analysis 
Chromatin condensation (pyknosis) is a classical morphological characteristic of 
apoptosis (Kerr et al., 1972) and is one of the observable ultra-structural changes 
upon induction of this type of cell death (Kerr et al., 1972). The DNA intercalating 
flourochrome, Hoechst 33342 (1:200 dilution) was used to visualise this 
morphological nuclear change and was examined using a Nikon eclipse E 400 
microscope. Cells were grown on coverslips in 6-well plates at a density of 2,5 x 105 
cells/well for HeLa and CaSki cells, and 3,0 x 105 cells/well for the Ect1/E6E7 cells. 
They were then treated with varying concentrations of cisplatin and were incubated 
for a period of 24 h. Cells with condensed nuclear chromatin were counted and 
quantified as a percentage of the total number of cells.  
3.6. Lysotracker™ (flow cytometry) 
Cells were grown in T25 flasks at a seeding density of 700 000 cells/flask. After the 
treatment period, 2 ml Tryple-Xpress trypsin (Gibco) was added to each flask for 3-4 
min until all cells had detached from the bottom of the flask. The cell suspension was 
then added to labelled 15 ml Falcon tubes (BD Biosciences) and centrifuged at 400 g 
for 3 min. The pellet was washed once with 0.1 M PBS where after Lysotracker™ 
(Invitrogen™, USA) was freshly prepared before use (1:10 000) and added to a final 
volume of 500 µl. Falcon tubes were then incubated at room temperature (RT) for 10 
min and analysed. At least 10 000 cells were collected and analysed with a 488 nm 
laser at an emission of 610LP, 616/23BP. 
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3.7. Caspase Glo® Assay 
The Caspase-Glo® Assay (Promega) is a luminescent assay that measures the 
activities of caspase-3 and -7, which are members of the cysteine aspartic acid-
specific protease family that play vital roles in the execution of apoptosis. The 
principle of the assay is based on a caspase -3/7 luminogenic substrate which in the 
presence of cleaved caspase-3/7, enables a light reaction that is detectable at 490 
nm EX and 510-570 nm EM. Cells were seeded at a density of 10 000 cells/well in a 
96-well plate. After the treatment period, the Caspase-Glo® buffer was added to the 
Caspase-Glo® substrate (as per manufacturer’s instructions) and mixed to produce a 
working Caspase-Glo® reagent. This working solution was then added in equal 
volumes to cells containing medium (i.e. 100 µl medium and 100 µl Caspase-Glo® 
reagent). The liquid was mixed gently by pipetting and incubated at RT for 45 min 
where it was subsequently analysed using the GloMax luminometer (Glomax, 
Promega). 
3.8. Lactate Dehydrogenase Assay 
This Cytotoxicity Detection KitPLUS (Roche) is a colorimetric assay that measures 
lactate dehydrogenase (LDH) activity. LDH is a cytoplasmic enzyme that is readily 
released into the cell culture supernatant upon disruption of the plasma membrane. 
The principle of the assay is based on an enzymatic reaction: LDH catalyses the 
conversion of lactate to pyruvate with the simultaneous reduction of NAD+ to NADH + 
H+. A catalyst (diaphorase) then transfers the H and H+ to the tetrazolium salt INT 
which is then reduced to formazan. Cells were grown in 96-well plates at a seeding 
density of 5000 cells/well in a final volume of 100 µl growth media and allowed 24 h 
to adhere. A background control was included to determine the LDH activity 
contained in the culture medium (blank) as well as a low control (LDH activity 
released from untreated cells) and a high control (maximum releasable LDH activity 
of the cells); these were performed on a separate plate in triplicate. After the 
treatment period, 5 µl ‘Lysis Solution’ was added to the high control wells and 
incubated for 10 min at 37 °C on a cell shaker. 100 µl “Reaction Mixture’ was added 
to each well (including the high control, low control and background control) using a 
multi-pipette and then incubated at room temperature for 15 min and protected from 
light. Next, 50 µl ‘Stop Solution’ was added and the plates were allowed to shake for 
10 s. An ELISA plate reader (EL-800, Micro-Tek instruments) was used to measure 
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the absorbance at 490 nm with a reference wavelength of 600 nm. The percentage of 
LDH release was determined as follows: LDH release (%) = (exp. value – low control) 
/ (high control – low control) x 100. 
3.9. Propidium Iodide (PI – Flow Cytometry) 
Cells were grown in T25 flasks at a seeding density of 700 000 cells/flask. After the 
treatment period, 2 ml Tryple-Xpress trypsin (Gibco) was added to each flask for 3-4 
min until all cells had detached. The cell suspension was then added to 15 ml Falcon 
tubes (BD Biosciences) and centrifuged at 6000 g for 3 min. The supernatant was 
removed and the pellet washed with 0.1 M PBS. The cells were centrifuged again at 
the same specifications and the supernatant was removed as before. PI (Sigma-
Aldrich) was added to the unfixed cells to obtain a final concentration of 1 mg/ml, 
incubated for 10 min and analysed on the flow cytometer (BD FACSAria I). A 
minimum of 10 000 events were collected and analysed using a 488 nm laser and 
610LP, 616/23BP emission filters. PI inclusion signified loss in membrane integrity 
and cell death. Values were represented as a percentage of the control. 
3.10. Western Blotting 
Cell were lysed with RIPA buffer (50 mM Tris-HCl pH 7.4, 10 ml of 10% NP-40, 2.5 
ml of 10% Na-deoxycholate, 1 ml of 100 mM EDTA pH 7.4, 1 mM 
phenylmethylsulfonyl fluoride (PMSF), 1 mg/ml leupeptin, 5 mg/ml SBT1, 1 M 
benzamidine, 0.1 mM sodium orthovandate, 50 mM sodium fluoride and 1 ml Triton 
X-100). The lysate protein content was determined using the Bradford technique 
(Bradford, 1976). Mini-PROTEAN® TGX™ (BIO RAD, USA) gradient gels were used 
(4-15%), which allowed for low as well as high molecular weight proteins to be 
probed for on the same membrane post-transfer (after stripping and re-probing).Cell 
lysates were diluted in Laemmli sample buffer and boiled for 5 min. 20 μg of protein 
was loaded and separated by electrophoresis. Proteins were then transferred to a 
PVDF membrane at 15 V and 0.05 A. Separated proteins were routinely stripped and 
re-probed with anti-actin antibody to ensure equal loading. Non-specific binding sites 
on the membranes were blocked with 5 g milk powder (fat-free) in 100 ml Tris- 
buffered saline-0.1% Tween 20 (TBS-T) and then incubated with primary antibodies 
(1:1000 dilution): Cleaved caspase-3, cleaved PARP, LC-3, p62, mTOR. ATG5, Bcl-
2, Beclin-1 and β-actin (Beverly, MA, USA). Membranes were subsequently washed 
with large volumes of TBS-T (3 x 5 min) and the immobilized antibody was then 
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incubated with a horseradish peroxidase labelled secondary antibody (1:20 000 
dilution) for 1 h. After washing again with TBS-T (3 x 5 min), membranes were 
covered with ECL™ detection reagents and quickly exposed to an autoradiography 
film (Hyperfilm ECL, RPN 2103) to detect light emission through a non-radioactive 
method. Films were densitometrically analysed (UN-SCAN-IT, Silkscience). All blots 
were scanned at a resolution of 150 dpi and the exact outline of each band was 
demarcated using this programme which takes into account all aspects of density 
and distribution. These analyses were performed under conditions where 
autoradiographic detection was in the linear response range. 
3.11. RNA interference 
mTOR and control/scrambled siRNA were purchased from Cell Signaling 
Technologies (Beverly, MA, USA) and supplied as a 10 µM stock solution. ATG5 
siRNA was purchased from Invitrogen (USA) and supplied as a 20 pmol stock. The 
relevant proteins were silenced through reverse transfection. In brief, mTOR and 
control siRNAs were each diluted in 100 µl of serum-free, antibiotic-free 
DMEM/KSFM to a final concentration of 10 nM. ATG5 siRNA was diluted in 100 µl 
serum-free, antibiotic-free DMEM/KSFM to a final concentration of 20 nmol. This 
mixture was added to a well in a 24-well plate and mixed gently. 3 µl of FuGENE6 
(Roche) was then added to this mixture and subsequently incubated for 20 min at 
room temperature (RT). During this time,cells were split from T75 flasks in antibiotic-
free DMEM/KSFM and counted. 30 000 cells were then re-suspended in 300 µl 
antibiotic free media and added to the wells containing the siRNA-FuGENE6 mixture. 
The plate was gently rocked to allow adequate mixing of reagents and cells. Cells 
were then incubated for 48 h before continuing with treatments and analyses. 
Silencing was confirmed through Western blotting to detect changes in total amount 
of the targeted proteins. 
3.12. Cell Cycle Analysis (flow cytometry) 
Cell cycle analysis was performed by using the CycleTEST™ PLUS DNA Reagent kit 
(Becton Dickinson, CA, USA).  CaSki and HeLa cells were seeded at a density of 
250 000 cells per T25 flask and the Ect1/E6E7 cells at a density of 350 000 cells per 
T25 flask. Plating was performed 48 h before treatment. After the treatment period, 
cells were trypsinized and the cell suspension was centrifuged at 400 x g for 5 min at 
room temperature. The pellet was washed with 0.1 M PBS where after the cell 
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suspension was dentrifuged at the above specifications. 250 µl of trypsin buffer was 
added to each tube and allowed to incubate at room temperature for 10 min. 
Subsequently, 200 µl of RNase buffer and trypsin inhibitor was added to each tube 
and allowed to react for a further 10 min. Finally, 200 µl of ice cold PI stain was 
added to each tube and placed in the dark for an additional 10 min before analysis. 
At least 10 000 list-mode data events were acquired for each sample. A bandpass 
filter of 585/42 was utilised to detect light emitted between 564 and 606 nm. Results 
were obtained by using the CycleTEST™ PLUS DNA Reagent kit and ModFit LT 
software (Verity software house, Inc., ME, USA) on BD FACSAria I.  
3.13.  Immunocytochemistry 
HeLa and CaSki cells were grown on coverslips in six-well plates (250 000 
cells/well). After the treatment period, the medium was removed and cells were 
washed once with PBS. Cells were fixed with ice-cold methanol and acetone (1:1) 
and left to incubate at RT for 10 min. The fixative mixture was then removed and 
coverslips were allowed to air-dry for a further 10 min where after they were rinsed 
twice with PBS. Non-specific binding was prevented by incubating cells with 10% 
donkey serum for 1 h at RT. After this time period, the donkey serum was blotted off 
and Beclin-1 and Bcl-2 primary antibodies diluted in 1% bovine serum albumin (BSA, 
1:50) was added to cells and allowed to incubate overnight at 4°C. Cells were then 
rinsed three times with PBS and allowed to incubate with the appropriate secondary 
antibody for 1 hr at RT. 10 min before the completion of incubation, Hoechst dye 
(1:200) was additionally added and kept in contact with cells for the remainder of the 
incubation period. Next, cells were rinsed and the coverslips were mounted on glass 
slides with DAKO fluorescent mounting medium (DAKO Inc., CA, USA). Slides were 
kept at -20°C until analysis. 
3.14. Patients and specimen collection 
Biopsies were collected from patients undergoing routine colposcopy screenings and 
hysterectomies at Tygerberg Hospital, Tygerberg, Western Cape (ethical reference 
number: N09/02/045). Samples were rinsed with PBS, placed in a cryovial and stored 
directly in liquid nitrogen until further use. A total of 10 normal, 29 LSIL, 33 HSIL and 
13 carcinoma biopsies were collected for analysis. 
3.15. Immunohistochemistry 
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Biopsies were embedded and sectioned at the pathology department at Tygerberg 
Hospital where 6 sections of each biopsy was prepared specifically for the purposes 
of this study. Prior to staining, tissue sections were deparaffinised in xylene and 
rehydrated in a graded series of ethanol. Epitope retrieval was acquired through 
trypsinisation for 1 h at 37°C. Blocking was done with donkey serum (1:50 dilution) 
for 1 h and blotted off. Primary antibodies recognising mTOR, Bcl-2 and LC-3B (Cell 
Signaling, USA) were diluted in 1% BSA (1:50 dilution) added to sections, and 
incubated overnight at 4 °C. Excess antibody was removed through rinsing 3 times 
with PBS where after a secondary antibody conjugated to a fluorophore was added 
(1:200 dilution) and incubated in the dark for 1 h at RT. Sections were washed 3 
times with PBS and incubated with Hoechst 33342 dye (1:200 dilution) for 5 min at 
RT. After a final rinse with PBS, DAKO fluorescent mounting medium (DAKO Inc., 
CA, USA) was added and a coverslip placed carefully on each section for 
visualisation. 
3.16. Statistical analysis 
All values are represented as the mean ± standard error of the mean (SEM). A one-
way or two-way analysis of variance (ANOVA) test was used where appropriate. A 
Bonferonni post hoc analysis was then employed to test for significance. The minimal 
level of significance was accepted as p < 0.05. 
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4 
4.1. Dose-Response Curves and In Vitro Establishment of a Non-Toxic Dose 
of Cisplatin. 
 
4.1.1. Introduction and Aims 
In South Africa, 16.48 million women are at risk of developing cervical cancer 
(WHO/ICO, 2009). Every year, 6742 women are diagnosed with cervical cancer, and 
of these, 3681 die from the disease (WHO/ICO, 2009). Women suffering from this 
disease have an overall decrease in quality of life (QOL), and on average, women 
who have cervical cancer have a decrease in life expectancy of 26 years (Herzog 
and Wright, 2007). Additionally, the administration of chemotherapy to cancer 
patients is more often than not a traumatic and painful experience and the side-
effects that are commonly experienced during the treatment phase typically lead to a 
further decrease in QOL scores (Redeker et al., 2000). This is observed particularly 
in patients undergoing high-dose chemotherapeutic regimes (Carlson et al., 2001). 
Here, an in vitro model was employed where a dose response using various 
concentrations of cisplatin was conducted, and its effects on cell death were 
analysed. The aims were to determine the concentration of cisplatin that did not 
significantly induce apoptosis in a non-cancerous Ect1/E6E7 cervical cell line. This 
dose response was conducted on two cervical cancer cell lines, namely CaSki, and 
HeLa cells, as a means of evaluating the response of these metabolically different 
cells and to compare their sensitivity to cisplatin treatment. 
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4.1.2. Results 
All cell lines exhibit a dose-dependent decrease in cell viability, and increase in 
apoptosis in response to increasing concentrations of cisplatin. 
Figure 4.1. Cisplatin dose-response performed on Ect1/E6E7 cells for a period of 24 h. A. The 
MTT assay was employed in order to assess the effects of increasing doses of cisplatin on cell 
viability over a 24 hour time period. * p < 0.05, ***  p < 0.001 vs. control, # p < 0.05 and $ p < 0.001 
vs. 30 μM cisplatin, @ p < 0.001 vs. 15 μM cisplatin (n = 4). B. Chromatin condensation analysis 
using Hoechst 33342 dye was used to analyse the percentage of cells undergoing apoptosis in 
response to increasing concentrations of cisplatin over a 24 h time period. *** p < 0.001 vs. control, # 
p < 0.001 vs. 15 μM and $ p < 0.01 vs. 15 μM. 
A. 
B. 
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In order to establish a concentration of cisplatin that was not cytotoxic to non-
cancerous, cervical epithelial cells (Ect1/E6E7), a dose-response was conducted 
where two methods were employed: one to assess overall cell viability (mitochondrial 
functioning) (Fig. 4.1.A) and one to assess apoptotic cell death (Fig.4.1.B). When 
compared to the control, Ect1/E6E7 cells did not show a significant reduction in their 
ability to reduce MTT to formazan when treated with 5, 10 or 15 µM of cisplatin 
(Fig.4.1.A). However, when treated with 30 µM of cisplatin, the reductive capacity 
decreased significantly (65.15 ± 0.98% vs. control, p < 0.05). Additionally, Ect1/E6E7 
cells treated with 60, 80, 100 and 160 μM of cisplatin significantly decreased 
mitochondrial reductive capacity when compared to cells treated with 30 μM of 
cisplatin (60 µM: 47.35 ± 5.62% vs. 30 µM: 65.15 ± 0.98% p < 0.05;80 µM 34.13 ± 
11.83% vs. 30 µM, p < 0.001; 100 µM: 48.20 ± 4.928% vs. 30 µM, p < 0.05; 160 µM: 
27.55 ± 9.84% vs. 65.15 ± 0.98% p < 0.001). Furthermore, no significant differences 
between concentrations were observed in MTT reductive capacities of Ect1/E6E7 
cells treated with 60, 80, 100 and 160 µM of cisplatin. 
Condensed chromatin (pyknosis) was the next parameter assessed by means of 
Hoechst 33342 staining (Fig.4.1.B). Only cells treated with concentrations of 30 μM 
cisplatin and above exhibited a significant increase in cells with nuclear 
condensation, an indicator of apoptosis, when compared to the control (30 µM: 61.83 
± 8.50%; 60 µM: 68.00 ± 9.37%; 80 µM: 48.33 ± 10.83%; 100 µM: 72.03 ± 5.35%; 
160 µM: 89.10 ± 4.00% vs. control p < 0.001). 
15 μM of cisplatin was therefore chosen as the concentration to be utilised through-
out the study as it did not induce significant changes in viability of the non-cancerous 
cells (Fig.4.1.A and B). All concentrations above 15 μM induced a significant 
decrease in mitochondrial MTT reductive capacity over a 24 h time period when 
compared to cells treated with 15 µM of cisplatin (30 µM: 65.15 ± 0.98%; 60 μM: 
47.35 ± 5.62%; 80 μM: 34.13 ± 11.83%; 100 μM: 48.20 ± 4.93%; 160 μM: 27.55 ± 
9.84% vs. 15 µM: 92.20 ± 3.84% p < 0.001). Similar results were observed in the 
fluorescent staining of DNA with Hoechst 33342: all concentrations of cisplatin 
induced significant increases in total percentage of nuclear condensation when 
compared to cells treated with 15 μM (30 μM: 61.83 ± 8.50%; 60 μM: 68.00 ± 9.37%; 
100 μM: 72.03 ± 5.35%; 160 μM: 89.10 ± 4.00% vs. 15 µM: 12.63 ± 1.94% p < 0.001 
and 80 μM: 48.33 ± 10.83% vs. 15 µM, p < 0.01).  
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Figure 4.2. Cisplatin dose-response performed on HeLa cells for a period of 24 h. A. The 
MTT assay was employed in order to assess the effects of increasing doses of cisplatin on cell 
viability over a 24 hour time period. *** p < 0.001 vs. control, # p < 0.001 vs. 30 μM cisplatin, @ 
p < 0.001 vs. 15 μM (n = 4). B. Chromatin condensation using Hoechst 33342 dye was used to 
analyse the percentage of cells undergoing apoptosis in response to increasing concentrations 
of cisplatin over a 24 h time-point. *** p < 0.001 vs. control (n = 3). 
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When compared to the control, HeLa cells did not show a significant reduction in their 
ability to reduce MTT to formazan when treated with 5, 10 or 15 µM of cisplatin 
(Fig.4.2.A). However, when treated with 30 µM of cisplatin, the reductive capacity 
decreased significantly (61.8 ± 4.32% vs. control, p < 0.001). Additionally, HeLa cells 
treated with 60, 80, 100 and 160 μM of cisplatin further decreased the ability of the 
cells to reduce MTT to formazan when compared to cells treated with 30 μM of 
cisplatin (60 µM: 20.25 ± 8.49%; 80 µM: 22.03 ± 4.88%; 100 µM: 19.80 ± 3.58%; 160 
µM: 18.90 ± 2.74% vs. 30 µM: 61.8 ± 4.32% p < 0.001). However, doses of 60 µM 
cisplatin and more did not induce any additional significant decreases in MTT 
reductive capacity. 
Cisplatin treatment resulted in a dose-dependent increase in chromatin condensation 
in HeLa cells over a 24 h time period (Fig. 4.2.B). A significant increase pyknosis was 
observed when HeLa cells were treated with 30, 60, 80, 100 and 160 µM of cisplatin 
when compared to the control (30 µM: 87.33 ± 1.41%; 60 µM: 81.70 ± 5.93%; 80 µM: 
86.07 ± 2.39%; 100 µM: 92.13 ± 2.66%; 160 µM: 100 ± 0.00% vs. control p < 0.001). 
No significant increase in pyknosis was observed when HeLa cells were treated with 
doses of 30 µM cisplatin and more. 
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Figure 4.3. Cisplatin dose-response performed on CaSki cells for a period of 24 h. A. The 
MTT assay was employed in order to assess the effects of increasing doses of cisplatin on cell 
viability over a 24 hour time period. *** p < 0.001 vs. control, # p < 0.001 and vs. 15 μM cisplatin 
(n = 4). B. Chromatin condensation using Hoechst 33342 as an indication of apoptosis in 
response to increasing concentrations of cisplatin over a 24 h time period. *** p < 0.001 vs. 
control and # p < 0.01 vs. 60 μM (n = 3). 
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In response to an increasing concentration of cisplatin, the reductive capacity of 
CaSki cells was significantly reduced when treated with 60, 80, 100 and 160 µM of 
cisplatin (60 µM: 65.88 ± 4.33%; 80 µM: 55.35 ± 4.33%; 100 µM: 51.35 ± 4.30%; 160 
µM: 51.75 ± 6.08% vs. control p < 0.001) in comparison to the control and no 
significant decrease in reductive capacity was observed when cells were treated with 
5, 10, 15 or 30 µM of cisplatin over a 24 h time period (Fig.4.3.A). Concentrations of 
60 µM cisplatin and higher did not induce any additional significant decrease in 
reductive capacity of CaSki cells. 
Results obtained in the assessment of chromatin condensation (Fig. 4.3.B) were in 
agreement with the MTT analysis: Significant changes were observed only in CaSki 
cells treated with 60, 80, 100 and 160 µM of cisplatin for a 24 h time period (60 µM: 
33.97 ± 2.19%; 80 µM: 49.77 ± 4.42%; 100 µM: 47.87 ± 3.20%; 160 µM: 39.95 ± 
0.70% vs. control p < 0.001). Cells treated with 80 and 100 µM of cisplatin induced 
further significant increases in the percentage of apoptotic cells when compared to 
cells treated with 60 µM (p<0.01). No significant increases in chromatin condensation 
were observed when cells were treated with 5, 10, 15 or 30 µM of cisplatin over a 24 
h time period.  
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Figure 4.4. Cisplatin dose-response performed on HeLa, CaSki and Ect1/E6E7 cells. A.The MTT 
assay was employed in order to assess each cell line’s ability to reduce MTT to formazan when 
treated with increasing doses of cisplatin over a 24 hour time period. *** p < 0.001 vs. HeLa # p < 
0.001 vs. HeLa, $ p < 0.05, @ p < 0.001, ϕ p < 0.01 vs. CaSki. B. Chromatin condensation detected 
by Hoechst 33342 dye was used to analyse the percentage of cells undergoing apoptosis in response 
to increasing concentrations of cisplatin over a 24 h time period. *** p < 0.001, # p < 0.001, ϕ p < 0.05  
vs. HeLa, α p < 0.001, σ p < 0.01 vs. CaSki.   
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Next, differences between the three cell lines with regards to their responses to 
cisplatin treatment, was assessed by measuring cell viability and apoptotic 
parameters. 
In Fig.4.4.A, no significant differences were observed between the three cell line’s 
capacity to reduce MTT when treated with 5, 10, or 15 µM of cisplatin. However, the 
reductive capacity of the CaSki cells was significantly higher than that of the HeLa 
cells when treated with 30, 60, 80, 100 and 160 µM of cisplatin (30 µM: 88.13 ± 
2.10%; 60 µM: 65.88 ± 4.33%; 80 µM: 55.35 ± 4.33%; 100 µM: 51.35 ± 4.30%; 160 
µM: 51.75 ± 6.08% vs. HeLa p < 0.001). CaSki cells were also more efficient in 
reducing MTT than when compared to the Ect1/E6E7 cells (60 µM: 47.35 ± 5.62% p 
< 0.05 vs. CaSki; 80 µM: 29.78 ± 8.26% p < 0.001 vs. CaSki; 160 µM: 27.55 ± 
9.84%; p < 0.01 vs. CaSki). These results indicate that CaSki cells were least 
affected by cisplatin treatment at higher doses over a 24 h time period and were able 
to maintain close to 50% viability. On the other hand HeLa cells lost about 80% of 
their ability to reduce MTT and were greatly affected by cisplatin treatment.  
Figure 4.4.B depicts a comparison between all three cell lines and the percent of 
pyknosis when treated with increasing concentrations of cisplatin for a period of 24 h. 
These results mirror those observed in Figure 4.4.A: no significant differences were 
observed between the three cell lines with regard to the percentage of pyknosis 
present when treated with 5, 10, or 15 µM of cisplatin. Similarly, CaSki cells exhibited 
the least amount of pyknosis and thus apoptotic cell death when compared to HeLa 
cells (30 µM: 12.13 ± 1.93%; 60 µM: 33.97 ± 2.19%; 80 µM: 49.77 ± 4.42%; 100 µM: 
47.87 ± 3.20%; 160 µM: 39.95 ± 0.70% vs. HeLa p < 0.001), and Ect1/E6E7 cells (30 
µM: 61.83 ± 8.50%; 60 µM: 68.00 ± 9.37%; 160 µM: 89.10 ± 4.00% vs. CaSki p < 
0.001; 100 µM: 72.03 ± 5.35% p < 0.01). These results strengthen those observed in 
Fig.4.4.B suggesting that CaSki cells are indeed more resistant to undergoing cell 
death than both HeLa and Ect1/E6E7 cells when treated with increasing doses of 
cisplatin for 24 h. 
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4.1.3. Discussion 
Although cisplatin is considered the most effective anti-cancer drug for treatment in 
both neoadjuvant and salvage treatment of cervical cancer (Benedetti Panici et al., 
2001, 2003), its success is hindered by the dose-limiting factors commonly observed 
during and after treatment, such as nephrotoxicity, ototoxicity, neurotoxicity and 
gastrointestinal toxicity (Vermorken et al., 1983, Safirstein et al., 1986, Blakley et al., 
1994, Cardinaal et al., 2000, Sergi et al., 2003). Furthermore, patients with cervical 
cancer experience a decrease in QOL (Herzog and Wright, 2007) which is 
exacerbated further by chemotherapy treatment (Monk et al., 2005). 
The necessity for a lower dose of cisplatin exhibiting similar anti-cancer effects to that 
of the higher doses would therefore be ideal. For this purpose, it was necessary first 
and foremost to conduct a dose-response as a means of determining a non-toxic 
concentration of cisplatin, as well as to evaluate each cell’s response to cisplatin 
treatment. The aims were firstly to determine a dose of cisplatin that is non-toxic to 
non-cancerous ectocervical cells (Ect1/E6E7); secondly to conduct this analysis on 
two cervical cancer cell lines (HeLa and CaSki) in order to assess their propensity to 
undergo cell death, and finally to compare the dose-responses to one another as a 
means of determining their sensitivity/resistance to cisplatin in comparison to one 
another. 
The result of the MTT assay indicates that MTT reductive capacity, and therefore cell 
viability, decreases as the concentration of cisplatin increases, which infers that the 
effects of cisplatin treatment is dose dependent (Fig.4.1.A). This agrees with other in 
vitro studies (Choi et al., 2004, Kuwahara et al., 2000, Cheng et al., 2010, Funaoka 
et al., 1996) conducted on HeLa, CaSki and other cell lines. Moreover, the results 
suggest that concentrations of 60 µM and more do not result in any additional 
significant decreases in MTT reductive capacity, suggesting no added benefit as the 
dose increases further. This observation agrees with Stewart and colleagues who 
proposed that dose-response curves flatten at higher doses (Stewart et al., 2007). 
The results examining chromatin condensation agree with those observed in the MTT 
assay: a dose-dependent effect whereby increasing concentrations of cisplatin 
induce an increase in pyknosis (Fig. 4.1.B). 
Based on the results, it was concluded that 15 μM of cisplatin would be selected as 
the working concentration for all subsequent experimental studies, as both the MTT 
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and chromatin condensation assays revealed no significant changes when compared 
to the control (Fig.4.1.A and B). 
The results obtained in the HeLa cells show a similar response to the Ect1/E6E7 
cells (Fig. 4.2. A. and B.), however HeLa cells display a more pronounced decrease 
in MTT reductive capacity and increase in apoptosis induction, indicating an 
increased sensitivity to concentrations of 30 μM and higher. The fact that the non-
cancerous cells exhibit this ‘tolerance’ to cisplatin treatment may be due to the 
differences in cell cycle activity and rate of proliferation. 
When dose-response analysis was performed on the CaSki cells, tolerance to 
cisplatin treatment was observed (Fig. 4.3.A. and B.). The previously described 
response to increasing concentrations of cisplatin was observed (as seen with the 
other two cell lines), however to a much lesser extent. Significant effects on MTT 
reductive capacity and apoptosis induction were only observed following treatment 
with 60 μM and more, with a loss in MTT reductive capacity and increase in apoptotic 
induction by about 44% and 35% respectively (Fig. 4.3.A. and B.). In other words, 
CaSki cells were able to tolerate double the concentration that the Ect1/E6E7 and 
HeLa cells were able to with not even a 50% loss in their overall viability. As with the 
previous two dose-response graphs, a plateau was reached in MTT reductive 
capacity at higher doses, indicating that concentrations of 60 μM and more offered no 
significant added benefit in increasing cell death. However, this was not the case 
when analysing the extent of apoptosis through chromatin condensation, a slightly 
different picture emerged: significant increases in the percentage of total cells with 
condensed chromatin were evident in CaSki cells treated with cisplatin up until 80 
μM, where after a gradual trend toward a decrease in apoptotic cells was observed. 
Undetected necrosis may be ascribed to the observed result. The CaSki cells appear 
to tolerate increasing concentrations of cisplatin to better extent than the other two 
cell lines.  
Figures 4.4.A. and B. are presented such that HeLa, CaSki and Ect1/E6E7 dose-
responses are plotted on the same axis. When both parameters were analysed, the 
CaSki cell’s ability to reduce MTT was significantly improved when compared to the 
HeLa and Ect1/E6E7 cells. This was mirrored in Figure 4.4.B where CaSki cells 
displayed a lesser propensity to undergo apoptosis than both HeLa and Ect1/E6E7 
cells. This data suggests that CaSki cells are more resistant to the intracellular 
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effects of cisplatin treatment than the HeLa cells, which agrees with a study 
conducted by Funaoka and colleagues (Funaoka et al., 1996). 
It has been hypothesised that the shape of the dose-response curve will provide 
insight into possible resistance mechanisms both in vitro and in vivo (Stewart et al., 
1996). It has been postulated that if resistance is seen at lower doses, this is due to 
excess of a resistance factor (i.e. active resistance) that may be overwhelmed by the 
administration of high concentrations of chemotherapy drugs. Active resistance 
factors have been described as being those that high-dose chemotherapy and 
resistance modulating agents interfere with that would under normal circumstances 
improve therapeutic efficacy, i.e. DNA repair mechanisms, drug efflux, glutathione, 
etc. It has therefore been proposed that the presence of an active resistance factor is 
characterised by a shoulder on the log response vs. dose curve with the eventual 
saturation of the resistance factor. 
Conversely, passive resistance in this setting has been described as the 
ineffectiveness of high doses and resistance modulating agents in inducing additional 
increases in cell death due to defective apoptosis for example, and generally arises 
from gene deletion/down-regulation/mutation or decreased drug affinity for a target. 
This may be characterised by a relatively flat log response vs. dose curve (Stewart et 
al., 1996, Stewart et al., 2007, Stewart, 2007).  
Figure 4.5. Log response vs. dose curve of Ect1/E6E7, HeLa and CaSki cells. Both Ect1/E6E7 
and CaSki cells display similar composite curves which indicate a passive resistance mechanism 
against cisplatin treatment according to Stewart and colleagues (Stewart et al., 1996, Thompson, 
2008) . The HeLa cells composite curve is characterised by a shoulder at low doses of cisplatin, 
indicating induction of an active resistance factor, and a terminal plateau indicating a form of 
passive resistance (Stewart et al., 1996) 
Ect1/E6E7 HeLa CaSki 
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The log response vs. dose curve of the Ect1/E6E7, HeLa and CaSki cell lines were 
plotted and analysed, with each plot representing the log of each mean. Our results 
indicate that the CaSki cell’s response to cisplatin is governed by a passive 
resistance mechanism as the log response vs. dose curve is relatively flat. Given the 
fact that CaSki cells are positive for HPV DNA, a virus with oncoproteins which are 
known to degrade and inactivate proteins essential for cell cycle control, it may 
indicate such passive resistance as described by Stewart and colleagues (Stewart et 
al., 1996).  
The composite curve of the HeLa cells on the other hand takes on a sigmoid shape, 
which might be an indication of active resistance toward cisplatin treatment at low 
doses and passive resistance at higher doses which is depicted by the terminal 
plateau. The active resistance factor that the HeLa cells are engaging in order to 
tolerate the low doses of cisplatin could be the up-regulation of autophagy. Literature 
suggests that in response to chemotherapeutic agents autophagy is in fact increased 
as a protective mechanism (deBruin and Medema, 2008) and may contribute to 
resistance (Chen et al., 2010). Since there is very little information supported by the 
literature that suggests that cisplatin prompts autophagic induction, this will be 
addressed in subsequent chapters.  
The log response versus dose curve of the Ect1/E6E7 cells is relatively flat and is 
similar to the CaSki composite curve which may suggest a passive resistance 
mechanism against cisplatin treatment. However one might anticipate a slight 
shoulder on the composite curve. Forthcoming chapters will provide insight into 
possible factors that may confer this passive resistance. 
A number of conclusions may be drawn from the above study: Firstly, 15 μM of 
cisplatin was selected as the final dose due to its non-toxic effects on a non-
cancerous cervical cell line. This low dose of cisplatin also did not induce cytotoxic 
effects in the cancer cells, therefore, a major aim of this study will be to increase the 
cytotoxic effect of cisplatin on cancer cells with the aid of adjuvant therapy. Secondly, 
we confirmed that cisplatin has a dose-dependent effect on all three cell lines and 
that it induces apoptosis and decreases viability. Thirdly we have demonstrated that 
CaSki cells have an increased tolerance to cisplatin treatment and that this response 
is likely to be cell type dependent. Lastly through plotting the log response versus 
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dose we provided data of value for resistance mechanisms engaged by the cell in 
response to treatment. 
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4.2. Characterisation of Autophagic Flux in Three Different Cervical Cell Lines. 
4.2.1. Introduction and Aims 
The mechanism by which autophagy may be up-regulated could partly be due to 
metabolic reprogramming from oxidative phosphorylation to aerobic glycolysis, 
commonly termed the ‘Warburg effect’ (Warburg, 1925). This provides the cancer 
cells with the unique ability to increase the efficiency of its energy production to 
compensate for increased growth rates that favour anabolic metabolism. Metabolic 
reprogramming is therefore imperative in order for cancer cell survival under 
anaerobic conditions where autophagy plays a major role in tumour survival (Lozy 
and Karantza, 2012). With the above in mind, determination of autophagic flux in the 
different cell lines is thus imperative.  
Autophagic flux determination may then possibly allow us to answer questions that 
arose from Chapter 4.1., such as the reasons behind the differential tolerance to 
cisplatin treatment observed between the three cell lines. Additionally, we may be 
able to predict, depending on how reliant the cell is on autophagy, whether the 
inhibition or induction of autophagy may drive the cell toward death. The aim of this 
chapter is therefore i) to establish the capacity of each cell line to induce an 
autophagic response and determine whether the three cell lines respond in a similar 
or different manner, ii) to determine the value of autophagic flux as a pre-evaluation 
which will serve as a predictive tool in selecting a suitable autophagic modulator. 
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4.2.2. Results 
All Three Cell Lines Exhibit Differential Flux through the Autophagic Pathway.  
 
Autophagic flux was analysed in Ect1/E6E7, HeLa and CaSki cells whereby each cell 
line was either not treated, treated with rapamycin alone, bafilomycin A1 alone or 
Rapamycin and bafilomycin A1 together (Fig. 4.6.). Flux capacity of each cell line is 
indicated by the group treated with both autophagic modulators (Rapa. + Baf.). 
Densitometry indicates that LC-3 II expression is significantly increased in Ect1/E6E7 
cells when compared to the control (1.23 ± 0.11 vs. control, * p < 0.05 and ** p < 
0.01). No significant differences in LC 3 II expression (flux) was observed in both 
HeLa and CaSki cells. 
 
 
 
 
Figure 4.6. Representative blot and corresponding densitometry of autophagic pathway 
flux in Ect1/E6E7, HeLa and CaSki cells. All three cell lines were either treated with:  rapamycin 
(Rapa.), bafilomycin A1 (Baf.), or both (R + B) and analysed for  the expression of  LC-3 II. * p < 
0.05 and ** p < 0.01 vs. control Ect1/E6E7, n = 3. 
C     Rapa. Baf.  R+B C     Rapa. Baf.  R+B C     Rapa. Baf.  R+B 
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4.2.3. Discussion 
The importance of autophagy in whole body metabolism is an interesting concept: 
under normal homeostatic conditions, it functions as an anti-tumour mechanism 
whereby it prevents genomic instability and other oncogenic events from taking place 
(Abedin et al., 2007, Katayama et al., 2007), essentially maintaining the integrity of 
many organs. On the other hand, under conditions of starvation, autophagy is 
induced in order to supply substrates for energy metabolism. The capacity of a cell to 
induce autophagy is dependent on tissue type, which suggests that the reliance of 
cells on autophagy in different organ systems is dependent on their metabolic 
demands (Mizushima et al., 2004). An example of this is observed in the liver where 
protein turn-over rates are especially high; consequently, the demand on autophagy 
is similarly great, particularly under starvation conditions. Conversely, under 
starvation conditions in the brain, autophagy is not induced, even after 48 hours of 
food with-drawl in mice (Mizushima et al., 2004). It is possible that this could be due 
to fuels such as glucose and ketone bodies being supplied by other organs for 
utilization by the brain. The diversity of autophagic induction between tissues is 
further emphasised by the fact that it is constitutively activated in thymic epithelial 
cells under nutrient-rich conditions and functions to degrade cytosolic antigens to be 
expressed on major histocompatibility (MHC II) class II proteins for recognition and 
selection by lymphocytes (Mizushima et al., 2004). Therefore, the basal levels of 
autophagy and the propensity of the cell to up-regulate autophagy does indeed 
appear to be dependent on tissue type and whether the particular organ itself has a 
high metabolic demand. 
On the subject of metabolic demand, it is now clear that once cells within a particular 
tissue become malignant, their metabolism alters and allows them not only to favour 
anabolic reactions to support cell growth, but also to induce autophagy as a means of 
surviving harsh, unfavourable conditions. This fact gave rise to the notion that it 
functions as mechanism of resistance against the death-inducing effects of various 
anti-cancer drugs (Chen et al., 2010, Notte et al., 2011). The reliance of cancer cells 
on autophagy may also differ between cancer types and may contribute to the 
aggressiveness of the particular cancer. With the above in mind, the aim of this 
chapter was to assess each of the cell line’s capacity to induce autophagy through 
analysing the presence of LC3 II by Western blot in the presence of rapamycin and 
bafilomycin A1. HeLa, CaSki and Ect1/E6E7 cells are isolated from the cervix: CaSki 
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and Ect1/E6E7 cells are both squamous cells originating from the ectocervix, with 
former having a malignant phenotype, and HeLa cells (also malignant) originate from 
a glandular cell type in the endocervix. Thus, an additional aim was to assess 
whether cells from the same organ have differential flux through the autophagic 
pathway, and in this way it is hoped that it may provide information on the particular 
organ/tissue in question with regards to the reliance of the malignant cell on 
autophagy and/or metabolic demands of the of tissue. 
Studies have identified CaSki cells to possess a more resistant phenotype than most 
cervical cancer cell lines, including HeLa cells (Funaoka, Shindoh et al. 1996; Padilla 
2006, Padilla 2002). Although speculative, it may be the ability of these cells to 
induce autophagy that aids them in developing this resistant phenotype. We thus 
examined the autophagic flux capacities of each cell line to possibly move toward 
proving this hypothesis. In Figure 4.6., LC-3 II expression was assessed using 
Western blotting under various conditions (corresponding densitometry below blots). 
Autophagic flux was determined by inducing autophagy upstream by using 
rapamycin, and inhibiting the fusion of autophagosomes with lysosomes downstream 
with bafilomycin A1, thus preventing the recycling of LC-3 II (as measured by 
Western blot). This results in the accumulation of autophagosomes in the cytoplasm 
which is indicative of the flux through the pathway. Only the non-cancerous 
Ect1/E6E7 cells induce significant increases in LC-3 II. Although not statistically 
significant, visual observation of the Western blot suggests that flux through the 
autophagic pathway is somewhat less in the CaSki cells than when compared to its 
non-carcinogenic counterpart, which agrees with other studies (Gunn et al., 1977, 
Kisen et al., 1993, Kirkegaard et al., 2004). A similar observation (although more 
pronounced), was seen in HeLa cells which originate from glandular cells in the 
endocervix: a weak capacity to induce autophagy upon stimulation with the 
autophagic modulators was exhibited by these cells. This data strengthens previous 
findings that autophagic induction is cell type dependent. We have further 
demonstrated that there are also differences in the same cell type between normal 
and transformed cells. 
In the previous chapter it was demonstrated that CaSki cells had the highest 
tolerance to treatment with cisplatin, and the HeLa cells had the lowest tolerance. 
From the data obtained in this chapter it could be speculated that in response to 
cisplatin treatment, HeLa cells could not increase flux through the pathway at a 
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sufficient enough rate to act as a protective mechanism, and at higher doses 
underwent subsequent cell death. On the other hand, the CaSki cells displayed the 
highest tolerance to cisplatin treatment, and combined with the above data it is 
suggested that its ability to induce increased flux through the autophagic pathway 
may have functioned as a protective mechanism to prevent cell death induction. 
However, no literature (to our knowledge) which assessed autophagic flux in these 
cell lines is available to compare our results with. Therefore in conclusion, each cell 
line displays differential flux through the autophagic pathway and this may provide 
insight to the aggressiveness of the particular cell type and that this differential flux is 
in fact cell type dependent. 
It can thus be concluded that these three cell lines have a differential ability to induce 
autophagy and that they are differentially resistant to cisplatin treatment. The major 
aim of this study is therefore, with the aid of adjuvant therapy through the 
manipulation of autophagy, to sensitise the cervical cancer cells to cisplatin 
treatment. This aim will be addressed in the following two chapters.  
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5 
The Effect of a Non-Toxic Concentration of Cispatin in Inducing Autophagy in 
Three Cervical Cell Lines. 
5.1. Introduction and Aims 
Cisplatin-induced autophagy is not sufficiently addressed within the literature, 
particularly in cervical cancer cell lines. This is therefore a relevant and worthwhile 
avenue to explore since it may not only provide information on the intracellular effects 
of cisplatin, but whether non-cytotoxic doses may be a future possibility in the 
treatment of cervical cancers. Additionally, it is possible that the autophagic response 
that is induced by cisplatin treatment may be exploited in order to improve cisplatin-
induced apoptosis. 
With the above in mind, the aims of this chapter are to determine whether cisplatin 
induces autophagy at the chosen dose of 15 µM in Ect1/E6E7, HeLa and CaSki cells, 
and whether this response differs between these three cervical cell lines. 
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5.2. Results 
5.2.1. Comparison of three cervical cell lines to cisplatin induced autophagy 
with the use of Lysotracker™. 
 
 
Methods for monitoring autophagy include the use of dyes such as Lysotracker™, 
and although it’s a reliable approach, results should be strengthened with the use of 
other acceptable techniques. The responses of all three cell lines to cisplatin 
treatment were compared to one another to assess whether lysosomal biosynthesis 
differed significantly. All cell lines exhibit increased lysosomal compartmentalisation 
in comparison to the control (Ect1/E6E7: 12.36 ± 0.45, HeLa: 17.41 ± 1.52, CaSki: 
11.12 ± 0.46 vs. control, *** p < 0.001). HeLa cells exhibit significantly higher mean 
lysosomal acidity in response to cisplatin treatment when compared to the Ect1/E6E7 
and CaSki cells (12.36 ± 0.45 vs. HeLa,# p < 0.05 and 11.12 ± 0.462 vs. HeLa, $ p < 
0.001). 
Figure 5.1. Comparison of changes in mean lysosomal compartmentalisation (flouresence) 
between Ect1/E6E7, HeLa and CaSki cells (flow cytometry). *** p < 0.001 vs. control, # p < 0.05 
vs. Ect1/E6E7 and $ p < 0.001 vs. HeLa, n = 3-7. 
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5.2.2. The effect of cisplatin treatment on p62, Beclin-1 and LC-3 II in three 
cervical cell lines. 
 
Changes in endogenous p62, Beclin-1 and LC 3 II protein levels were detected by 
using the Western blotting technique. Significant changes in protein levels were 
observed with LC-3 II and p62 (0.38 ± 0.11 and 0.62 ± 0.115 vs. control, *p < 0.05).  
Figure 5.2.A. Cisplatin (15 μM, 24 h) induces autophagy in Ect1/E6E7 cells. Western blots 
(left) and corresponding densitometry data (right) depict changes in p62, Beclin-1 and LC-3 II 
protein expression in response to treatment with 15 μM cisplatin for a 24 h time period (AU – 
arbitrary units) . * p < 0.01 vs. control, n > 4. 
Control   Cisplatin 
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Treatment of HeLa cells with 15 µM cisplatin for a 24 h time period induced a 
significant decrease in p62 protein levels when compared to the control (0.53 ± 0.15 
vs. control, *** p < 0.001).  
 
Control   Cisplatin 
Figure 5.2.B. Cisplatin (15 μM, 24 h) induces autophagy in HeLa cells. Western blots (left) and 
corresponding densitometry data (right) depict changes in p62, Beclin-1 and LC-3 II protein expression 
in response to treatment with 15 μM cisplatin for a 24 h time period (AU – arbitrary units) . *** p < 0.01 
vs. control, n > 4. 
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CaSki cells treated with 15 µM cisplatin for a 24 h time period induced a significant 
decrease in p62 protein levels when compared to the control(0.80 ± 0.06 vs. control, 
** p < 0.01).  
 
 
5.3. Discussion 
Figure 5.2.C. Cisplatin (15 μM, 24 h) induces autophagy in CaSki cells. Western blots (left) and 
corresponding densitometry data (right) depict changes in p62, Beclin-1 and LC 3 II protein 
expression in response to treatment with 15 μM cisplatin for a 24 h time period (AU – arbitrary units) . 
** p < 0.01 vs. control, n > 4. 
Control      Cisplatin 
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The side-effects and long-term damage induced by cisplatin chemotherapy limits its 
clinical efficacy, therefore the challenge lies in achieving a similar level of cancer cell 
death with the use of a lower, non-toxic dose of cisplatin with the aid of adjuvant 
therapy .It was first necessary to characterise the effects of this lower dose (15 μM) 
in the three cell types with regards to autophagy in order to determine whether this 
response may be exploited. 
It was observed that the Ect1/E6E7, HeLa and CaSki cells did not exhibit any 
significant deviations in cell viability or apoptotic cell death when treated with 
concentrations of cisplatin up to 15 µM (Chapter 4.1.). It was hypothesised that a 
mechanism of resistance was initiated by the cervical cells that permitted a large 
degree of tolerance to cisplatin exposure for the 24 h time period. The possibility that 
this was indeed resistance being observed was strengthened by work conducted by 
Stewart and colleagues who suggest that the various shapes displayed by the log vs. 
dose response curve may be indicative of the presence of active or passive 
resistance factors (Stewart et al., 1996). It was previously mentioned in Chapter 4.1. 
that the HeLa cells are relying predominantly on an active mechanism of resistance, 
of which autophagy was selected as a possible candidate. The CaSki and Ect1/E6E7 
cell’s log vs. dose response curve suggest more of a passive resistance mechanism 
at play. This chapter therefore aimed firstly to determine whether cisplatin at the 
chosen concentration induces autophagy, and secondly whether this response was 
similar or differs between cell lines by comparing them to one another. 
Toward the completion of the autophagic process, it is required that the 
autophagosome fuses with a lysosome in order to degrade the endocytosed and 
autphagocytosed organelles/proteins (Kroemer and Jaattela, 2005), therefore, an 
increase in lysosomal production is synchronised with the induction of autophagy, 
and it is this characteristic that can be utilised to assess the extent of autophagy that 
is induced by the cell.  
5.3.1. Differential induction of autophagy in three cervical cell lines. 
Since the responses to cisplatin treatment and autophagic flux capacities differed 
between all 3 cell lines (Chapter 4.1. and 4.2.), it was necessary to determine 
whether the levels of cisplatin-induced autophagy were similar or different between 
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cell lines i.e. did the cells respond in a similar fashion with regard to autophagy 
induction when exposed to 15 µM cisplatin for 24 h.  
Lysotracker™ is a weakly basic dye that concentrates in acidic cellular organelles 
such as lysosomes and has been commonly used to evaluate their biosynthesis in 
the context of autophagy (Hu et al., 2012, Viola et al., 2012, Kaminskyy et al., 2012). 
It was utilised in this study to assess the effects of low-dose cisplatin in inducing 
autophagy in three cervical cell lines (Fig. 5.1). The Ect1/E6E7, HeLa and CaSki cells 
all exhibited significant increases in intracellular acidity as measured by the flow 
cytometer when treated with 15 µM cisplatin for 24 h. Additionally, it is clear that both 
the Ect1/E6E7 and CaSki cells induce a similar level of autophagy when exposed to 
the chosen dose of cisplatin. On the other hand, the results additionally indicate that 
the HeLa cells had significantly higher mean lysosomal acidity/flourescence in the 
presence of cisplatin when compared to both the Ect1/E6E7 and CaSki cells (Fig. 
5.1.) which suggests autophagy up-regulation. This implies that the HeLa cells have 
differential sensitivity to cisplatin and the ability to up-regulate autophagy. It may be 
likely as no cell death was observed when the HeLa cells were treated with 15 µM 
cisplatin for 24 h. If it is recalled from the log vs. dose response curve, it was 
deduced (according to the hypothesis put forward by Stewart and colleagues 
(Stewart et al., 1996), that an active resistance mechanism is utilised by the cells at 
these lower doses of cisplatin. We can now partially confirm this hypothesis; however 
the expression of various autophagic proteins would need to be evaluated to confirm 
this finding. Also, manipulation of this pathway with inhibitors/inducers of autophagy 
with cisplatin treatment will reveal how necessary this mechanism is in order for 
HeLa cell survival.  
This suggests that autophagy is most likely induced in response to cisplatin 
treatment, nevertheless, confirmation is required through the detection of the up-
regulation of LC-3 II protein through Western blotting. Lui and colleagues used a 
similar lysosomal stain, known as MDC as a method for the detection of autophagy in 
response to cisplatin treatment in oesophageal cancer cells, which they later 
confirmed through immunoblotting with LC-3 II (Liu et al., 2011). Lysosomal staining 
with the use of acridine orange was utilised as a method of autophagy detection in a 
wide variety of cancer cell types in response to cisplatin treatment (Harhaji-Trajkovic 
et al., 2009). For the purposes of this study, it is noteworthy to mention, that the 
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above studies use high doses of cisplatin treatment. Nevertheless, the commonality 
of this particular method for the detection of autophagy verifies its reliability.  
Interestingly the function of these lysosomes may not be exclusively for the use of 
autophagy. Lysosomes can also function as intermediary compartments to either 
store metals from influx pathways or distribute them to efflux systems (Eaton and 
Qian, 2002, Larsen et al., 2003). With the use of x-ray microanalysis and ion 
microscopy, it was observed that platinum was detectable in lysosomes of the kidney 
in guinea pigs treated with cisplatin (Saito and Aran, 1994). Similarly, fluorescein-
tagged cisplatin was detected not only in the nucleus, but in cytoplasmic vesicles and 
lysosomes of cisplatin resistant- and ovarian cancer cells (Molenaar et al., 2000, 
Safaei et al., 2005a). Studies then confirmed that cisplatin resistance is attributed to 
abnormal protein trafficking and secretion (Chauhan et al., 2003, Safaei et al., 2005a) 
and that cisplatin-resistant cell types are associated with less lysosomes when 
compared to their sensitive counterparts (Safaei et al., 2004b). If Chapter 4.1 is 
recalled, it was established that the HeLa cells are more sensitive to cisplatin 
treatment in comparison to the CaSki cells (Fig. 4.4.), and taking into account this 
observation by Safaei and colleagues (Safaei et al., 2004), this may also be an 
explanation for the differential lysosomal induction induced by the three cervical cell 
lines. The question of whether the increased production of lysosomes is due to 
autophagy induction or a method of trafficking cisplatin toward efflux pathways will be 
addressed in the next chapter. 
The use of Lysotracker™ as a measure of autophagic activity is generally reliable; 
however protein expression analysis of the various markers of autophagy is required 
in order to confirm these findings. Three proteins were evaluated for the up-
regulation of autophagy: p62, Beclin-1 and LC 3 II.  
5.3.2. Cisplatin stimulates an increase in the molecules responsible for 
autophagic induction and execution. 
The results demonstrated in this study show significant decreases in p62 protein 
levels were observed in all three cervical cell lines (Figure 5.2. A, B and C) in 
response to cisplatin treatment. P62 is a functionally diverse protein that is implicated 
in obesity (Rodriguez et al., 2006) and cancer (Mathew et al., 2009). It is also present 
in cytoplasmic inclusions of protein aggregation diseases (Zatloukal et al., 2002). Its 
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functional significance in autophagy has not gone unnoticed: not only does it recruit 
LC3 to the autophagosomal membrane, but Pankiv and colleagues also proposed 
that it binds directly to LC-3 to facilitate degradation of proteins under various 
conditions where itself becomes degraded (Pankiv et al., 2007). Therefore total 
cellular levels of p62 correlate inversely with autophagic activity, as well as with other 
parameters commonly utilised for the analysis of autophagy (Mizushima et al., 2010). 
The role of p62 in cancer cell survival was emphasised when it was linked to tumour 
transformation and progression in vivo (Duran et al., 2008), where after its 
importance for cancer cell survival under hypoxic conditions was also established 
(Jaakkola and Pursiheimo, 2009). A recent study revealed that cisplatin resistant 
ovarian carcinoma cells express higher levels of p62 than their sensitive 
counterparts, and this is attributed to the fact that endoplasmic reticulum stress is 
minimised by the binding of p62 to ubiquitinated proteins for degradation by 
autophagy (Yu et al., 2011a). With regards to cisplatin treatment on endogenous p62 
levels, it was observed in one study that p62 protein expression decreased gradually 
over time as autophagy is induced in hepatoma cells (Xu et al., 2012a).  
An equally important marker of autophagy is Beclin-1; it forms part of an upstream 
complex that is responsible for the initiation of autophagy, and is negatively regulated 
by mTOR. It plays a tumour-suppressive role in cancer and its expression promotes 
autophagic cell death in tumours (Liang et al., 1999, Cao and Klionsky, 2007). No 
significant increase in Beclin-1 protein expression was observed in response to 
cisplatin treatment in all three cervical cell lines. This is in contrast to other studies:  It 
was determined that autophagy activation in response to cisplatin treatment is 
regulated by Beclin-1 and an up-regulation of this protein is observed in vitro in 
breast cancer cells, cervical cancer cells (Hou et al., 2010b, Xu et al., 2012c) as well 
as other cells (Harhaji-Trajkovic et al., 2009). Beclin-1 up-regulation was also 
observed in vivo in liver tissue of mice treated with cisplatin (Cardinal et al., 2009). 
Additionally, Beclin-1 over expression enhances cisplatin-induced apoptosis in 
gastric cancer cells. It may be argued here that the concentration of cisplatin utilised 
in the above mentioned studies are higher (> 20 μM) than the concentration used in 
this study (15 μM), and may therefore stimulate autophagy to a much greater extent, 
leading to a significant increase in Beclin-1 expression.  
Finally, LC-3 II protein expression was assessed and quantified in all three cell lines 
in response to cisplatin treatment (Fig. 5.2.A, B and C). Significant increases in LC-3 
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II expression was only observed in the non-cancerous Ect1/E6E7 cells. The lack of a 
significant increase in both cancer cell lines may be due to the continuous recycling 
of LC-3 II (Kabeya et al., 2000). Upon stimulation of autophagy, LC-3 is cleaved to 
form LC 3 I, which then becomes conjugated to phosphatidylinositol (PE) resulting in 
a membrane-bound LC-3 II protein (Yorimitsu and Kilonsky, 2005). During the later 
stages of autophagy, LC-3 II may become degraded or recycled back to cytosolic LC-
3 I (Kabeya et al., 2000), therefore even though autophagy may be induced, protein 
levels of LC-3 II may appear lower than expected. Therefore although LC-3 II is a 
promising marker of autophagosomal presence, and thus autophagy, it is necessary 
to evaluate other markers for confirmation.  
After the assessment of lysosomal biosynthesis as well as proteins involved in 
autophagy initiation and completion in all three cervical cell lines, it may be 
concluded that 15 μM of cisplatin treatment for a 24 hour time period sufficiently 
induces autophagy. Additionally, lysosomal biosynthesis between the cell lines 
appear to differ, i.e. HeLa cells induce synthesis of a significantly larger amount of 
lysosomes in response to cisplatin than when compared with the other two cell lines, 
indicating that they may be more dependent on autophagy to tolerate cisplatin 
treatment. In order to assess whether autophagy may be imperative for the survival 
of the cervical cancer cells at this low-dose treatment, the autophagic pathway will 
have to be induced and inhibited in conjunction with cisplatin treatment. 
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6 
The Effect of Autophagic Modulation in Sensitising Cervical Cancer Cells to 
Cisplatin Treatment. 
6.1. Introduction and Aims 
Studies have shown that the modulation of autophagic activity can sensitise cancer 
cells to chemotherapeutic agents (Zhuang et al., 2009) as well as augment 
chemotherapy-induced apoptosis (Notte et al., 2011). However, the effect of 
autophagic modulation as a pre-treatment strategy in conjunction with a low-
concentration of cisplatin on cell death induction remains to be elucidated. The 
importance of the cell cycle and its role as an indication for sensitivity in combination 
chemotherapy has been realised (Shah and Schwartz, 2001). Cell-cycle mediated 
drug resistance occurs when treatment with one agent impacts the cell-cycle such 
that the subsequent chemotherapy agent administered immediately afterward is less 
effective (Shah and Schwartz, 2001).  
 
The aims of this chapter are therefore to i) determine whether the induction or 
inhibition of autophagy proves to be more efficient in increasing cisplatin-induced 
apoptosis in two cancerous cell lines (HeLa and CaSki)., ii) conduct cell cycle 
analysis to determine whether the chemotherapy agents of choice act on cell cycle 
progression. 
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6.2. Results 
6.2.1. Pharmacological induction of autophagy in combination with cisplatin 
treatment: Effects on autophagy and apoptosis. 
a. The effect of rapamycin (induction of autophagy) and cisplatin on 
autophagy in Ect1/E6E7 cells. 
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Figure 6.2.1. The effect of rapamycin and cisplatin on autophagic induction in Ect1/E6E7 cells. A. 
mTOR activation, * p< 0.05 vs. Control, n = 3. B. p62 degradation, * p < 0.05, ** p < 0.01 vs. Control and # p< 
0.05 vs. rapamycin, n = 3. C. LC-3 II protein levels, * p < 0.05 vs. Control, n = 3. Corresponding densitometry 
below each representative Western blot. D. Fluorescence intensity: Lysosomal acidic compartment, ** p < 
0.01 vs. Control, n = 4. Statistical analysis: ANOVA and Bonferroni correction. All results expressed as mean ± 
SEM. Cont.-control, Cispl.-cisplatin, Rapa.- rapamycin, R+C.- Rapamycin + cisplatin, AU- Arbitrary units. 
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The effect of rapamycin and cisplatin treatment on mTOR, p62 and LC-3 II protein 
expression in Ect1/E6E7 cells was analysed using the Western blotting technique 
and flow cytometry. Cisplatin, rapamycin as well as rapamycin + cisplatin (R+C) all 
significantly reduced mTOR protein expression in Ect1/E6E7 cells in comparison to 
the control (cisplatin: 0.80 ± 0.04; rapamycin: 0.66 ± 0.02; R+C: 0.60 ± 0.07 vs. 
control, * p < 0.05, Fig. 6.2.1. A). A significant decrease in p62 protein expression 
levels in Ect1/E6E7 cells was observed after treatment with cisplatin (0.58 ± 0.11 vs. 
control, * p < 0.05) as well as with the combination of rapamycin and cisplatin (0.53 ± 
0.05 vs. control, ** p < 0.01 vs. rapamycin, # p< 0.05, Fig. 6.2.1. B). The analysis of 
LC-3 II protein levels in Ect1/E6E7 cells revealed a significant increase in the 
cisplatin, rapamycin and combination (R+C) treatment groups (cisplatin: 0.41 ± 0.08, 
rapamycin: 0.20 ± 0.01 and R+C: 0.32 ± 0.07 vs. control, * p < 0.05, Fig. 6.2.1.C). 
The lysosomal acidic compartment was analysed with the use of Lysotracker™, and 
fluorescence intensity subsequently quantified on the flow cytometer (Fig. 6.2.1. D). 
A significant increase in mean fluorescence intensity was observed in the 
combination group (1.44 ± 0.07 vs. control, * p <0.05).  
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b. The effect of rapamycin and cisplatin on autophagy and in HeLa cells. 
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Figure 6.2.2. The effect of rapamycin and cisplatin on autophagic induction in HeLa cells. A. mTOR 
activation, *** p < 0.001, ** p < 0.01 vs. Control, n = 3. B. p62 degradation, *** p < 0.001; * p < 0.05 vs. 
Control, n = 3. C. LC-3 II protein levels, n = 3. Corresponding densitometry below each representative 
Western blot. D. Lysosomal compartmentalisation, * p< 0.05 vs. control, n = 7. Statistical analysis: ANOVA 
and Bonferroni correction. All results expressed as mean ± SEM. Cont.-control, Cispl.-cisplatin, Rapa.- 
rapamycin, R+C.- Rapamycin + cisplatin, AU- Arbitrary units. 
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In Fig. 6.2.2. A, mTOR protein expression levels were significantly decreased in all 
treatment groups in HeLa cells (cisplatin: 0.26 ± 0.09 vs. control, ** p< 0.01; Rapa: 
0.10 ± 0.09 and  R+C: 0.13 ± 0.11 vs. control, *** p < 0.001). Similarly, p62 protein 
levels decreased significantly (Fig. 6.2.2. B, however only in the rapamycin and 
combination groups (0.56 ± 0.37 vs. control, * p < 0.05 and 0.11 ± 0.04 vs. control,*** 
p< 0.001). LC-3 II levels increased significantly in the cisplatin treated group (* p < 
0.05 vs. control, n = 4). Assessment of the lysosomal acidic compartment (mean 
fluorescence) revealed a significant increase in all treatment groups (cisplatin: 1.64 ± 
0.16; Rapa.: 1.28 ± 0.12 and R+C: 1.54 ± 0.17 vs. control, * p < 0.05, Fig. 6.2.2. D) 
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c. The effect of rapamycin and cisplatin on autophagy and in CaSki cells. 
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Figure 6.2.3. The effect of rapamycin and cisplatin on autophagic induction in CaSki cells. A. mTOR 
activation, * p < 0.05, ** p < 0.01 vs. Control, n = 3. B. p62 degradation, * p < 0.05; ** p < 0.01 vs. Control, # p < 
0.01 vs. cisplatin, n = 3. C. The combination group had significantly lower levels of LC-3 II protein when 
compared to CaSki cells treated with rapamycin alone, * p< 0.05 (n = 3, Representative blot). Corresponding 
densitometry below each representative Western blot. D. Lysosomal acidic compartmentalisation, n = 7. 
Statistical analysis: ANOVA and Bonferroni correction. All results expressed as mean ± SEM Cont.-control, 
Cispl.-cisplatin, Rapa.- rapamycin, R+C.- Rapamycin + cisplatin, AU- Arbitrary units. 
Stellenbosch University  http://scholar.sun.ac.za
77 
 
Intracellular mTOR protein levels were significantly lower in the rapamycin and 
combination groups in comparison to the control (0.32 ± 0.16 * p < 0.05 and 0.05 ± 
0.03 ** p < 0.01 vs. control, Fig. 6.2.3.A). CaSki cells treated with cisplatin, rapamycin 
and the combination of the two exhibited significantly lowered p62 protein levels 
(cisplatin: 0.79 ± 0.04** p < 0.01; rapa.: 0.31 ± 0.21 * p< 0.05; R+C: 0.07 ± 0.04 **p< 
0.01 vs. control and 0.07 ± 0.04 # p < 0.01 vs. cisplatin, Fig. 6.2.3.B). Analysis of LC-
3 II protein levels revealed that cisplatin induced a significant increase in LC-3 II 
signal (0.42 ± 0.45 vs. control, * p < 0.05) and the combination group significantly 
decreased levels of LC-3 II when compared to CaSki cells treated with rapamycin 
alone (0.09 ± 0.06 vs. rapamycin, * p < 0.05, Fig. 6.2.3. C). Assessment of the 
lysosomal acidic compartment by fluorescence intensity analysis did not reveal any 
significant changes in any of the treatment groups in the CaSki cells. 
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d. The effect of rapamycin and cisplatin on apoptosis in Ect1/E6E7 cells. 
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Figure 6.2.4. Effect on the induction of autophagy on apoptosis in Ect1/E6E7 cells. A. Cell viability (MTT 
reductive capacity), n = 5. B. Active caspase -3 and -7 activity * p< 0.05 vs. control and # p< 0.05 vs. cisplatin, n 
= 3. C. PARP cleavage, *** p< 0.001 vs. control, # p< 0.001 vs. cisplatin, and $ p< 0.001 vs. rapamycin, n = 3. 
D. LDH release, n = 5. E. Propidium iodide inclusion (flow cytometry), PI positive: quadrant A, PI negative: 
quadrant B, * p < 0.05 vs. control and # p < 0.05 vs. cisplatin, n = 3. Statistical analysis: ANOVA and Bonferroni 
correction. All results expressed as mean ± SEM Cont.-control, Cispl.-cisplatin, Rapa.- rapamycin, R+C.- 
Rapamycin + cisplatin, AU- Arbitrary units. 
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Ect1/E6E7 cells did not display any significant differences in viability upon cisplatin 
treatment (Fig. 6.2.4. A.), based on the MTT reductive capacity. Caspase -3 and -7 
activity was significantly reduced in the rapamycin and combination group when 
compared to the control and cisplatin treated cells (rapa.: 0.47 ± 0.17% and R+C: 
0.44 ± 0.17% vs. control * p < 0.05; Rapa. and R+C vs. cisplatin, # p < 0.05, Fig. 
6.2.4.B). Cleaved PARP protein levels in Ect1/E6E7 cells were observed to 
significantly increase in cells treated with the combination of rapamycin and cisplatin 
(14.49 ± 2.42 vs. control, *** p < 0.001, 14.49 ± 2.42 vs. cisplatin, # p< 0.001 and 
14.49 ± 2.42 vs. rapamycin, $ p< 0.001, Fig. 6.2.4. C.). No significant changes in 
LDH release was observed in any of the treatment groups (Fig. 6.2.4. D). The 
quantification of PI positive Ect1/E6E7 cells was achieved through flow cytometry. A 
significant increase in PI positive cells was observed in the rapamycin and 
combination groups (27.75 ± 3.60% and 23.18 ± 5.79% vs. control, * p < 0.05; 27.75 
± 3.60% and 23.18 ± 5.79% vs. cisplatin, # p < 0.05, Fig. 6.2.4. E).  
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e. The effect of rapamycin and cisplatin on apoptosis in HeLa cells.  
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Figure 6.2.5. Effect on the induction of autophagy on apoptosis in HeLa cells. A. Cell viability (MTT), * p< 
0.05 and ** p< 0.01 vs. control, # p < 0.05 vs. cisplatin, n = 7. B. Active caspase -3 and -7 activity, n = 3. C. 
PARP cleavage, representative blot, * p < 0.05 vs. control and # p < 0.05 vs. cisplatin, n = 4. D. LDH release, ** 
p < 0.01 vs. control and # p < 0.05 vs. cisplatin, n = 5. E.  Propidium iodide inclusion (flow cytometry), PI positive: 
quadrant A, PI negative: quadrant B * p < 0.05 vs. control, # p < 0.05 vs. cisplatin and $ p < 0.05 vs. rapamycin, 
n = 4. Statistical analysis: ANOVA and Bonferroni correction. All results expressed as mean ± SEM. Cont.-
control, Cispl.-cisplatin, Rapa.- rapamycin, R+C.- Rapamycin + cisplatin, AU- Arbitrary units. 
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HeLa cell viability was significantly reduced in the rapamycin and combination 
treatment groups (76.17 ± 6.45% * p < 0.05 and 73.42 ± 6.40% ** p < 0.01 vs. 
control, 73.42 ± 6.38% # p< 0.05 vs. cisplatin, Fig. 6.2.5. A.). Significant cleavage of 
PARP was observed in the combination treated group (0.45 ± 0.15 * p < 0.05 vs. 
control and # p < 0.05 vs. cisplatin, Fig.6.2.5.C). HeLa cells treated with the 
combination of rapamycin and cisplatin exhibited a significant increase in the 
percentage of LDH released (43.33 ± 11.18% ** p < 0.01 vs. control and 43.33 ± 
11.18% # p < 0.05 vs. cisplatin, Fig. 6.2.5. D). A significant increase in the 
percentage of PI positive cells was observed in the combination group (9.83 ± 0.90% 
vs. control, * p < 0.05; 9.83 ± 0.90% vs. cisplatin, # p < 0.05 and 9.83 ± 0.90% vs. 
rapamycin $ p < 0.05).   
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f. The effect of rapamycin and cisplatin on apoptosis in CaSki cells.  
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Figure 6.2.6. Effect on the induction of autophagy on apoptosis in CaSki cells. A. Cell viability (MTT), * p 
< 0.05 and *** p < 0.001 vs. control, # p< 0.05 vs. cisplatin, n = 7. B. Caspase -3 and -7 activity, * p < 0.05 vs. 
control, n = 3. C. PARP cleavage (representative blot), ** p< 0.01 vs. control and # p< 0.05 vs. cisplatin, n = 4. 
D. LDH, n = 4. E. Propidium iodide inclusion (flow cytometry), PI positive: quadrant A, PI negative: quadrant B, 
n = 4. Statistical analysis: ANOVA and Bonferroni correction. All results expressed as mean ± SEM. Cont.-
control, Cispl.-cisplatin, Rapa.- rapamycin, R+C.- Rapamycin + cisplatin, AU- Arbitrary units. 
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Cell viability (MTT) of CaSki cells treated with cisplatin, rapamycin and the 
combination of the two revealed a significant decrease in cell viability (80.37 ± 
4.04%; 74.76 ± 7.36% and 52.33 ± 7.65% vs. control * p < 0.05, *** p < 0.001, 
52.33 ± 7.65% vs. cisplatin, # p < 0.05, Fig. 6.2.6.A). Caspase -3/-7 activity of 
CaSki cells treated with rapamycin and rapamycin and cisplatin increased 
significantly in both groups when compared to the control (2.8 ± 0.65 and 1.52 ± 
0.13 vs. control, * p < 0.05, Fig. 6.2.6.B). PARP cleavage was significantly 
decreased in CaSki cells treated with rapamycin alone when compared to the 
control (0.26 ± 0.15 vs. control, ** p < 0.01) and the cisplatin group (0.26 ± 0.15 
vs. cisplatin, # p < 0.05, Fig. 6.2.6. C.  
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g. Analysis of cell cycle progression modulated by rapamycin and cisplatin 
treatment in Ect1/E6E7 cells. 
 
 
  
Figure 6.2.7. Modulation of cell cycle progression by rapamycin and cisplatin in Ect1/E6E7 cells. Cells were 
either treated with rapamycin (50 µM), cisplatin  (15 µM) or the combination of the two for 24 h. Cell cycle 
distribution pattern was assessed by flow cytometry, ** p < 0.01 vs. control G0/G1, # p < 0.01 vs. control S and $ p 
< 0.05 vs. control S; σ p < 0.05 vs. cisplatin S, n = 3. Statistical analysis: ANOVA and Bonferroni correction. All 
results expressed as mean ± SEM. Rapa. + cispl. = rapamycin + cisplatin. 
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The distribution of cells in different phases of the cell cycle phase after treatment with 
rapamycin, cisplatin, or the combination of the two is illustrated in Fig. 6.2.7. 
Induction of autophagy with rapamycin resulted in a significant decrease in the 
percentage of cells in the G1 phase in comparison to the control (23.70 ± 7.90% and 
21.91 ± 11.20% vs. control G1 ** p < 0.01), with a concomitant increase in the 
percentage of cells in the S phase when treated with rapamycin and the combination 
of rapamycin and cisplatin (70.42 ± 12.00% vs. control S, # p < 0.01 and 64.29 ± 
4.58% vs. control S, $ p < 0.05) and cisplatin treated Ect1/E6E7 cells (70.42 ± 
12.00% vs. cisplatin, σ p < 0.05). 
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h. Analysis of cell cycle progression modulated by rapamycin and cisplatin 
treatment in HeLa cells. 
Cell cycle analysis of HeLa cells reveals a significant decrease in the G1-phase after 
treatment with cisplatin (35.03 ± 8.76% vs. control G1, * p < 0.05) and S phase 
(63.14 ± 8.23% vs. control S, # p < 0.05, Fig. 6.2.8). 
  
Figure 6.2.8. Modulation of cell cycle progression by rapamycin and cisplatin in HeLa cells. 
Cells were either treated with rapamycin (50 µM) or cisplatin  (15 µM) or the combination of the two 
for 24 h. Cell cycle distribution assessed by flow cytometry,* p < 0.01 vs. control G0/G1, # p < 0.01 
vs. control, n = 3. Statistical analysis: ANOVA and Bonferroni correction.  All results expressed as 
mean ± SEM. Rapa. + cispl. = rapamycin + cisplatin. 
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i. Analysis of cell cycle progression modulated by rapamycin and cisplatin 
treatment in CaSki cells.  
 
 
** 
Figure 6.2.9. Modulation of cell cycle progression by rapamycin and cisplatin in CaSki. Cells were either 
treated with rapamycin (50 µM), cisplatin  (15 µM) or the combination of the two for 24 h. * p < 0.05 and ** p < 
0.01 vs. control S, $ p < 0.01 vs. control G2/M, n = 3. Statistical analysis: ANOVA and Bonferroni correction. All 
results expressed as mean ± SEM. Rapa. + cispl. = rapamycin + cisplatin. 
$ 
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CaSki cells did not undergo any prominent shifts in the various cell cycle phases, 
however treatment with cisplatin induced a significant decrease in the G2/M phase 
with a concomitant increase in the S phase in comparison to the control (0.16 ± 
0.16% and 40.66 ± 1.70% ** p < 0.01 vs. control S and $ p < 0.01 vs. control G2/M). 
The combination of rapamycin and cisplatin led to a significant increase in the S 
phase (43.29 ± 4.55% vs. control S, * p < 0.05 and, Fig. 6.2.9). 
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6.2.2. Biological induction of autophagy in combination with cisplatin 
treatment: Effects on autophagy and apoptosis. 
a. The response of mTOR silencing on autophagy in Ect1/E6E7 cells.  
 
Figure 6.2.10. mTOR silencing in Ect1/E6E7 cells and the effect on autophagy. A. Silencing of mTOR ** p 
< 0.05 vs. sc. seq., n = 3. B. Degradation of p62, ** p< 0.01, *** p < 0.001 vs. sc. seq., # p < 0.01 vs. cisplatin, 
n = 3. C. LC-3 II protein levels, * p < 0.05 and ** p < 0.01, n = 3. Statistical analysis: ANOVA and Bonferroni 
correction. All results expressed as mean ± SEM, representative blots. Sc. seq. = scrambled siRNA 
sequence/control, AU = arbitrary units. 
 
siRNA 
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Silencing of mTOR in Ect cells was confirmed through Western blotting (0.66 ± 0.02 
vs. sc. seq., p < 0.01, Fig. 6.2.10.A). p62 significantly decreased in Ect1/E6E7 cells 
treated with cisplatin, silenced for the mTOR protein, as well as in the combination 
group in comparison to the control/scrambled sequence (0.62 ± 0.01, 0.25 ± 0.01 and 
0.32 ± 0.12 vs. sc. seq., ** p < 0.01 and *** p < 0.001). Additionally, Ect1/E6E7 cells 
in which mTOR was silenced had a significantly lower intracellular p62 level than 
those cells treated with cisplatin (0.25 ± 0.01 vs. cisplatin, # p < 0.01, Fig. 6.2.10. B). 
LC-3 II signal significantly increased in the cisplatin, silenced and combination groups 
in comparison to the control/scrambled sequence (2.07 ± 0.19, 2.33 ± 0.31 and 2.27 
± 0.14 vs. sc. seq., * p < 0.05, ** p < 0.01, Fig 6.2.10.C). 
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b. The effect of mTOR silencing on autophagy in HeLa cells. 
  
Figure 6.2.11. mTOR silencing in HeLa cells and the effect on autophagy. A. Silencing of mTOR * p < 
0.05 vs. sc. seq., n = 3. B. p62 degradation, ** p < 0.01, ***p < 0.001 vs. sc. seq., # p< 0.01 vs. cisplatin, n = 
3. C. LC-3 II protein levels, n = 3. Statistical analysis: ANOVA and Bonferroni correction. All results 
expressed as mean ± SEM, representative blots Sc. seq. = scrambled siRNA sequence/control, AU = 
arbitrary units.
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mTOR silencing in HeLa cells was confirmed through Western blotting (0.56 ± 0.13  
vs. sc. seq.* p < 0.05, Fig. 6.2.11. A). p62 protein levels were significantly decreased 
in the cisplatin group, the mTOR siRNA group, as well as in the combination group 
when compared to the control (cisplatin: 0.71 ± 0.05, mTOR: 0.18 ± 0.08 ** p < 0.01 
and 0.12 ± 0.04 *** p < 0.001 vs. sc. seq.; mTOR and mTOR siRNA + cisplatin: # p< 
0.001 vs. cisplatin, Fig. 6.2.11. B.). LC-3 II expression levels did not increase 
significantly in any of the treatment groups (Fig. 6.2.11. C). 
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c. The effect of mTOR silencing on autophagy in CaSki cells. 
  
Figure 6.2.12. mTOR silencing in CaSki cells and the effect on autophagy. A. Silencing of mTOR *** p < 
0.001 vs. sc. seq., n = 3. B. p62 degradation, * p< 0.05, **p< 0.01 vs. sc. seq., n = 3. C. LC-3 II protein levels 
* p < 0.01 vs. sc. seq. and # p < 0.01 vs. cisplatin, n = 3 (Representative blot). Statistical analysis: ANOVA 
and Bonferroni correction. All results expressed as mean ± SEM, representative blots. Sc. seq. = scrambled 
siRNA sequence/control, AU = arbitrary units. 
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Efficient silencing of mTOR was confirmed through Western blotting (0.48 ± 0.08 vs. 
sc. seq., *** p < 0.001, Fig. 6.2.12. A). Levels of p62 decreased significantly in 
comparison to the control in CaSki cells treated with cisplatin, and in the silenced 
group (0.75 ± 0.05 * p < 0.01 and 0.45 ± 0.18 * p < 0.01 vs. sc. seq., Fig. 6.2.12. B). 
In Lastly, a significant increase in LC-3 II protein expression was observed in CaSki 
cells treated with cisplatin, silenced for mTOR and the combination of the two 
(cisplatin: 0.54 ± 0.05, mTOR: 0.91 ± 0.04 vs. sc. seq. 0.63 ± 0.12, * p < 0.05, ** p < 
0.01 vs. sc. seq. and mTOR siRNA vs. cisplatin # p < 0.01, Fig. 6.2.12. C.). 
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d. The effect of mTOR silencing with cisplatin treatment on apoptosis in 
Ect1/E6E7 cells. 
 
  
Figure 6.2.13. Effect of the silencing of mTOR on apoptosis in Ect1/E6E7 cells. A. Cell viability (MTT), * 
p < 0.05 and ** p < 0.01 vs. control, n = 3 B. Caspase -3/-7 activity * p < 0.05 vs. sc. seq., # p < 0.05 vs. 
mTOR, n = 3. C. LDH release * p < 0.05 vs. sc.seq., n = 3. Statistical analysis: ANOVA and Bonferroni 
correction. All results expressed as mean ± SEM. Sc. seq. = scrambled siRNA sequence/control, AU = 
arbitrary units. 
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Cell viability (MTT) results reveal significant decreases in the cisplatin and 
combination groups (80.87 ± 6.4%, *p < 0.05 and 76.37 ± 4.35%, ** p < 0.01 vs. sc. 
seq. Fig. 6.2.13. A). Silencing of mTOR and combination treatment with cisplatin 
induced a significant up-regulation in caspase-3/-7 activity in CaSki cells (4.97 ± 1.05 
vs. sc. seq. * p < 0.05 and 4.97 ± 1.05 vs. mTOR siRNA # p < 0.05, Fig. 6.2.13. B). 
LDH release significantly increased in cells treated with cisplatin alone (9.20 ± 2.58% 
vs. sc. seq. * p < 0.05, Fig. 6.2.13. C). 
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e. The effect of mTOR silencing with cisplatin treatment on apoptosis in 
HeLa cells. 
 
 
  
Figure 6.2.14. Effect of the silencing of mTOR with cisplatin treatment on apoptosis in HeLa cells. A. Cell 
viability (MTT), *** p < 0.001 and vs. sc. seq., n = 6 B. Caspase -3/-7 activity, n = 4. C. PARP cleavage, * p < 
0.05 and *** p < 0.001 vs. sc. seq., # p < 0.01 vs. cisplatin and $ p< 0.01 vs. mTOR, n = 3 (corresponding 
representative blot above). D. LDH release, n = 3. Statistical analysis: ANOVA and Bonferroni correction. All 
results expressed as mean ± SEM. Sc. seq. = scrambled siRNA sequence/control, AU = arbitrary units. 
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Cell viability (MTT) was significantly reduced in HeLa cells treated with cisplatin 
(76.78 ± 2.53% vs. sc. seq. * p < 0.001, Fig. 6.2.14. A). No significant changes were 
observed in caspase-3/-7 activity in any of the groups (Fig. 6.2.14. B). Cleaved PARP 
protein levels increased in HeLa cells treated with cisplatin and cisplatin treatment 
with silencing (2.21 ± 0.42 * p< 0.05 and 5.39 ± 0.43 *** p < 0.001 vs. sc. seq; 5.39 ± 
0.43 # p < 0.01 vs. cisplatin; 5.39 ± 0.43 $ p < 0.001 vs. mTOR, Fig. 6.2.14. C). 
Analysis of LDH release did not reveal any significant changes in any of the groups 
(Fig.6.2.14. D). 
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f. The effect of mTOR silencing with cisplatin treatment on apoptosis in 
CaSki cells. 
. 
  
Figure 6.2.15. Effect of the silencing of mTOR on apoptosis in CaSki cells.A. Cell viability (MTT), n = 3 B. 
Caspase -3/-7 activity, n = 4. C. PARP cleavage  *** p < 0.001 vs. sc. seq., # p < 0.001 vs. cisplatin and $ p < 
0.001 vs. mTOR, n = 3 (corresponding representative blot above). D. LDH release * p < 0.05, n = 3. Statistical 
analysis: ANOVA and Bonferroni correction. All results expressed as mean ± SEM. Sc. seq. = scrambled siRNA 
sequence/control, AU = arbitrary units. 
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Cell viability (MTT) of CaSki cells was not altered significantly in any of the treatment 
groups (Fig. 6.2.15. A), similarly, caspase -3/-7 activity did not change significantly 
(Fig. 6.2.15. B). Intracellular levels of cleaved PARP significantly increased in cells 
that were silenced for mTOR and subsequently treated with cisplatin (6.42 ± 0.69 vs. 
sc. seq. *** p < 0.001; 6.42 ± 0.69 vs. cisplatin # p < 0.001; 6.42 ± 0.69 vs. mTOR $ p 
< 0.001, Fig. 6.2.15. C). CaSki cells treated with cisplatin exhibited a significant 
increase in LDH release when compared to the control (18.12 ± 3.12% vs. sc.seq. * p 
< 0.05, Fig. 6.2.15 D). 
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6.2.3. Pharmacological inhibition of autophagy in combination with cisplatin 
treatment: Effects on autophagy and apoptosis. 
a. The effect of bafilomycin (inhibition of autophagy) and cisplatin on 
autophagy in Ect1/E6E7 cells. 
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  Figure 6.2.16. The effect of bafilomycin and cisplatin on autophagy in Ect1/E6E7 cells. A. mTOR 
protein expression, *** p < 0.001 vs. Control, n = 3. B. p62 degradation, * p < 0.05, ** p < 0.01 vs. Control, 
# p < 0.01 vs. cisplatin and $ p< 0.05 vs. bafilomycin, n = 3 (Representative blot). C. LC-3 II protein levels, 
* p < 0.05, *** p < 0.001 vs. Control and # p< 0.05 vs. cisplatin, n = 4. Corresponding densitometry below 
each representative Western blot. E. Lysosomal acidic compartment determined through flow cytometry, * 
p < 0.05, ** p < 0.01 vs. Control and cisplatin # p < 0.01 vs. cisplatin, n = 4. Statistical analysis: ANOVA 
and Bonferroni correction. All results expressed as mean ± SEM. Cont.-control, Cispl.-cisplatin, Baf.- 
Bafilomycin A1, B+C.- Bafilomycin A1 + cisplatin, AU- Arbitrary units. 
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Intracellular levels of mTOR decreased significantly in response to cisplatin treatment 
in Ect1/E6E7 cells when compared to the control (0.80 ± 0.02 vs. control, *** p < 
0.001, Fig. 6.2.16. A). p62 protein levels in Ect1/E6E7 cells decreased significantly 
when treated with cisplatin and the combination of cisplatin and bafilomycin when 
compared to the control (0.62 ± 0.05, ** p < 0.01 and 0.79 ± 0.01, * p < 0.05 vs. 
control, Fig. 6.2.16 B). Additionally, p62 was significantly increased in cells treated 
with bafilomycin when compared to the cisplatin group (1.01± 0.03 vs. cisplatin, # p < 
0.01), as well as between the bafilomycin and combination group (0.79 ± 0.05 vs. 
bafilomycin, $ p < 0.05, Fig. 6.2.16. B). LC-3 II protein levels increased significantly in 
the bafilomycin and combination groups (2.93 ± 0.47, * p < 0.05 and 4.93 ± 1.00 *** p 
< 0.001 vs. control and 4.93 ± 1.00 vs. cisplatin # p < 0.05, Fig. 6.2.16. C.). 
Ect1/E6E7 cells treated with bafilomycin and the combination of bafilomycin + 
cisplatin exhibited significant decreases in mean lysosomal acidic 
compartmentalisation when compared to the control (55.35 ± 8.48, * p < 0.05, 37.5 ± 
2.89, ** p < 0.01 vs. control and 55.35 ± 8.48, * p< 0.05, 37.5 ± 2.89 vs. cisplatin # p< 
0.01, n = 4, Fig. 6.2.16. D.). 
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b. The effect of bafilomycin and cisplatin on autophagy in HeLa cells. 
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Figure 6.2.17. The effect of bafilomycin and cisplatin on autophagy in HeLa cells. A. mTOR protein 
expression, *** p < 0.001 vs. Control, n = 3. B. p62 degradation, * p < 0.05 vs. Control, n = 3. C. LC-3 II 
expression levels, * p < 0.05, *** p < 0.001 vs. Control and # p < 0.01 vs. cisplatin, n = 5. Corresponding 
densitometry below each representative Western blot. D. Lysosomal acidic compartmentalisation determined 
through flow cytometry, *** p < 0.01 vs. Control and cisplatin # p < 0.001 vs. cisplatin, $ p < 0.05 vs. 
bafilomycin. n = 5. Statistical analysis: ANOVA and Bonferroni correction. All results expressed as mean ± 
SEM. Cont.-control, Cispl.-cisplatin, Baf.- Bafilomycin A1, B+C.- Bafilomycin A1 + cisplatin, AU- Arbitrary 
units. 
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Intracellular protein levels of mTOR exhibited a significant decrease in HeLa cells 
treated with bafilomycin and cisplatin (0.86 ± 0.03 vs. control, *** p < 0.001, Fig. 
6.2.17. A). p62 protein levels decreased in a similar fashion, however HeLa cells 
treated with cisplatin also exhibited a significant decrease in p62 when compared to 
the control ( cisplatin: 0.47 ± 0.14 vs. control, * p < 0.05 and bafilomycin + cisplatin: 
0.67 ± 0.1 vs. control * p < 0.05, Fig. 6.2.17. B). LC-3 II signal increased significantly 
in response to bafilomycin as well as the combination of bafilomycin + cisplatin (2.15 
± 0.49 vs. control * p < 0.05, 3.73 ± 0.80 vs. control ** p < 0.01 and 3.73 ± 0.80 vs. 
cisplatin # p < 0.01, Fig. 6.2.17. C). HeLa cells treated with cisplatin exhibited a 
significant increase mean fluorescence intensity of the lysosomal acidic compartment 
in comparison to the control (163.8 ± 15.67%, *** p < 0.001 vs. cisplatin) and cells 
treated with bafilomycin and the combination of bafilomycin + cisplatin exhibited a 
significant decreasein mean fluorescence intensity (58.82 ± 5.30% and 77.70 ± 
4.20%, *** p < 0.001 vs. control; 58.82 ± 5.30% and 77.70 ± 4.20% vs. cisplatin # p < 
0.001 and 77.70 ± 4.20%, $ p < 0.05, n = 4, Fig. 6.2.17. D). 
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c. The effect of bafilomycin and cisplatin on autophagy in CaSki cells. 
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Figure 6.2.18. The effect of bafilomycin and cisplatin on autophagy in CaSki cells. A. mTOR protein 
expression, * p < 0.05 and *** p < 0.001 vs. control, # p < 0.05 vs. cisplatin and $ p < 0.05 vs. bafilomycin, n 
= 3. B. p62 degradation, ** p < 0.01 vs. control, n = 3. C. LC-3 II expression levels * p < 0.05, *** p < 0.001 
vs. control, n = 4. Corresponding densitometry below each representative Western blot. D. Lysosomal acidic 
compartmentalisation determined through flow cytometry, *** p < 0.001 vs. Control and cisplatin  # p < 0.001 
vs. cisplatin, n = 6. . Statistical analysis: ANOVA and Bonferroni correction. All results expressed as mean ± 
SEM. Cont.-control, Cispl.-cisplatin, Bafi.- Bafilomycin A1, B+C.- Bafilomycin A1 + cisplatin, AU- Arbitrary 
units. 
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Intracellular levels of mTOR decreased significantly in response to cisplatin, 
bafilomycin and the combination treatment in CaSki cells when compared to the 
control (0.58 ± 0.13, 0.48 ± 0.11 and 0.13 ± 0.05 vs. control, * p < 0.05, *** p < 0.001, 
Fig. 6.2.18. A.). The combination group also exhibited a significant decrease in 
mTOR protein expression when compared to the cisplatin (0.13 ± 0.05 vs. cisplatin, # 
p < 0.05) and bafilomycin groups (0.13 ± 0.05 vs. bafilomycin, $ p < 0.05.). p62 
protein levels in CaSki cells decreased significantly only when treated with the 
combination of cisplatin and bafilomycin in comparison to the control (0.29 ± 0.1, ** p 
< 0.01 vs. control, Fig. 6.2.18. B.). LC-3 II protein levels increased significantly in the 
cisplatin, bafilomycin and combination groups (0.74 ± 0.05, 1.16 ± 0.46 and 2.12 ± 
0.55 * p < 0.05 vs. control, Fig. 6.2.18. C.). CaSki cells treated with bafilomycin and 
the combination of bafilomycin + cisplatin exhibited a significant decrease in mean 
fluorescence intensity indicating the lysosomal acidic compartment when compared 
to the control (41.88 ± 8.00% and 45.92 ± 10.19%, *** p < 0.001 vs. control and 
41.88 ± 8.00% and 45.92 ± 10.19% vs. cisplatin # p < 0.001, n = 6 (Fig. 6.2.18. D). 
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d. The effects of bafilomycin and cisplatin on apoptosis in Ect1/E6E7 cells.   
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Figure 6.2.19. Effect of the inhibition of autophagy on apoptosis in Ect1/E6E7 cells. A. Cell viability (MTT), n = 
5. B. Caspase -3 and -7 activity, * p < 0.05 vs. control and # p < 0.05 vs. cisplatin, n = 3. C. PARP cleavage, *** p < 
0.001 vs. control, # p < 0.001 vs. cisplatin, and $ p < 0.001 vs. rapamycin, n = 3. D. LDH release, n = 5. E. Propidium 
iodide inclusion (flow cytometry), PI positive: quadrant A, PI negative: quadrant B, * p < 0.05 vs. control and # p < 
0.05 vs. cisplatin, n = 3. Statistical analysis: ANOVA and Bonferroni correction. All results expressed as mean ± SEM. 
Cont.-control.Cont.-control, Cispl.-cisplatin, Baf..- bafilomycin A1, R+C.- Bafilomycin A1 + cisplatin, AU- Arbitrary 
units. 
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Ect1/E6E7 cells did not display any significant differences in the MTT reductive 
capacity in any of the treatment groups (Fig. 6.2.19.A.). Caspase -3 and -7 activity 
was significantly increased in the cisplatin and combination groups (1.28 ± 0.04 and 
4.49 ± 0.09 vs. control * p < 0.05; 4.49 ± 0.09 vs. cisplatin, # p < 0.05, Fig. 6.2.19.B). 
Cleaved PARP protein levels in Ect1/E6E7 cells increased in cells treated with 
cisplatin, bafilomycin and the combination of bafilomycin and cisplatin (1.10 ± 0.01, 
1.48 ± 0.02 and 2.35 ± 0.21 vs. control, ** p < 0.01, 1.48 ± 0.02 and 2.35 ± 0.21 vs. 
cisplatin, # p < 0.01 and 2.35 ± 0.21 vs. bafilomycin, $ p < 0.05, Fig. 6.2.19.C). A 
significant increase in LDH release was observed in Ect1/E6E7 cells treated with 
bafilomycin + cisplatin (31.40 ± 9.05% vs. control, ** p < 0.01, 31.40 ± 9.05% vs. 
cisplatin # p < 0.05 and 31.40 ± 9.05% vs. bafilomycin, $ p < 0.05, Fig. 6.2.19.D). A 
significant increase in PI positive cells was observed in the bafilomycin and 
combination groups (12.55 ± 1.75% and 16.92 ± 3.76% vs. control, * p < 0.05; 16.92 
± 3.76% vs. cisplatin, # p < 0.05, Fig. 6.2.19.E).  
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e. The effects of bafilomycin and cisplatin on apoptosis in HeLa cells. 
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Figure 6.2.20. Effect of the inhibition of autophagy on apoptosis in HeLa cells. A. Cell viability (MTT) *p<0.05 
vs. bafilomycin, n = 8. B. Caspase -3 and -7 activity, n = 3. C. PARP cleavage, *** p < 0.001 vs. control, #p < 0.001 
vs. cisplatin and $  p< 0.01 vs. bafilomycin, n = 4. D. LDH release, * p < 0.05 vs. control and # p < 0.05 vs. 
cisplatin, n = 5. E. . Propidium iodide inclusion (flow cytometry), PI positive: quadrant A, PI negative: quadrant B, * 
p< 0.05 vs. control, # p< 0.05 vs. cisplatin and $ p < 0.05 vs. bafilomycin, n = 4. Statistical analysis: ANOVA and 
Bonferroni correction. All results expressed as mean ± SEM. Cont.-control, Cispl.-cisplatin, Rapa.- Bafilomycin A1, 
B+C.- Bafilomycin A1 + cisplatin, AU- Arbitrary units. 
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Cell viability (MTT) was significantly decreased in the combination treatment group 
when compared to the bafilomycin group (86.54 ± 8.15% vs. bafilomycin, * p < 0.05, 
Fig. 6.2.20 A). The analysis of the presence of active caspase -3 and -7 did not 
reveal any significant changes in their activity in any of the treatment groups (Fig. 
6.2.20. B). Cleaved PARP levels increased significantly in HeLa cells treated with the 
combination of bafilomycin and cisplatin (3.23 ± 0.23 vs. control, ***p<0.001, 3.23 ± 
0.23 # p < 0.001 vs. cisplatin and 3.23 ± 0.23, $ p < 0.01 vs. bafilomycin, 
Fig.6.2.20.D). HeLa cells treated with bafilomycin + cisplatin exhibited a significant 
increase in LDH release (39.20 ± 11.78%, vs. control, ** p < 0.05 and 39.20% ± 
11.78 vs. cisplatin, # p < 0.05, Fig. 6.2.20.E). A significant increase in the percentage 
of PI positive cells was observed in the combination treatment group (20.00 ± 3.81% 
vs. control, * p < 0.05; 20.00 ± 3.81% vs. cisplatin, # p < 0.05 and 20.00 ± 3.81% vs. 
bafilomycin, $ p < 0.05).   
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f. The effects of bafilomycin and cisplatin on apoptosis in CaSki cells. 
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Figure 6.2.21. Effect of the inhibition of autophagy on apoptosis in CaSki cells. A. Cell viability (MTT), 
***p<0.05 vs. control, * p < 0.05 vs. cisplatin and $ p < 0.001 vs. bafilomycin, n = 8. B. Caspase -3 and -7 activity, 
** p < 0.01 vs. control and  # p < 0.05 vs. cisplatin, n = 3. C. Cleaved caspase-3, *** p < 0.001 vs. control, 
#p<0.001 vs. cisplatin and $ p < 0.001 vs. bafilomycin, n = 4. D. Cleaved PARP, *** p < 0.001 vs. control, #p<0.001 
vs. cisplatin and $ p < 0.001 vs. bafilomycin, n = 4. E. LDH release, * p < 0.05, ** p < 0.01 vs. control and # p <0.05 
vs. bafilomycin, n = 5. F. Propidium iodide inclusion (flow cytometry), PI positive: quadrant A, PI negative: quadrant 
B, * p < 0.05 vs. control, # p < 0.05 vs. cisplatin and $ p < 0.05 vs. bafilomycin, n = 4. Statistical analysis: ANOVA 
and Bonferroni correction. All results expressed as mean ± SEM. Cont.-control, Cispl.-cisplatin, Baf.- bafilomycin 
A1, B+C.- Bafilomycin A1 + cisplatin, AU- Arbitrary units. 
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Cell viabilty (MTT) significantly decreased in the combination treatment group in 
comparison to the control group (51.07 ± 9.36% vs. control, ***p < 0.001), cisplatin 
group (51.07 ± 9.36% vs. cisplatin, # p < 0.05) and the bafilomycin group (51.04 ± 
9.36% vs. bafilomycin, *** p < 0.001, Fig. 6.2.21.A). Active caspase -3 and -7 
revealed a significant increase in activity in the bafilomycin (3.27 ± 0.46 vs. control, ** 
p < 0.01 and 3.27 ± 0.46 vs. cisplatin, # p < 0.05) and combination group (5.36 ± 1.12 
vs. control, ** p < 0.01 and 5.36 ± 0.46 vs. cisplatin, # p < 0.05, Fig. 6.2.21.B). 
Western blot analysis of cleaved caspase-3 indicated significantly increased levels in 
CaSki cells treated with combination of bafilomycin and cisplatin when compared to 
the control (24.97 ± 0.99 vs. control, *** p < 0.001), cisplatin (24.97 ± 0.99 vs. 
cisplatin, # p < 0.001) and bafilomycin groups (24.97 ± 0.99 vs. bafilomycin, $ p < 
0.001, Fig. 6.2.21.C). Cleaved PARP levels increased significantly in HeLa cells 
treated with the combination of bafilomycin and cisplatin (17.42 ± 1.31 vs. control, *** 
p < 0.001, 17.42 ± 1.31 # p < 0.001 vs. cisplatin and 17.42 ± 1.31, $ p < 0.001 vs. 
bafilomycin, Fig. 6.2.21.D.). LDH release in CaSki cells significantly increased in 
comparison to the control (11.08 ± 4.18% * p < 0.05 and 4.53 ± 0.76% p < 0.01 vs. 
control), additionally, cells treated with bafilomycin + cisplatinalso exhibited a 
significant increase in LDH released in comparison to the control (35.58 ± 10.87%, ** 
p < 0.001 vs. control) and bafilomycin treatment groups (35.58 ± 10.87% vs. 
bafilomycin, # p < 0.05, Fig. 6.2.21.E). A significant increase in the percentage of PI 
positive cells was only observed in the combination treatment group (31.83 ± 8.40 vs. 
control, * p < 0.05; 31.83 ± 8.40% vs. cisplatin, # p < 0.05 and 31.83 ± 8.40% vs. 
bafilomycin, $ p < 0.05). 
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g. Analysis of cell cycle progression modulated by bafilomycin and 
cisplatin treatment in Ect1/E6E7 cells.  
Cell cycle analysis of Ect1/E6E7 cells did not reveal any significant changes in the 
percentage of cells in the various stages of the cell cycle.  
Figure 6.2.22. Modulation of cell cycle progression by bafilomycin and cisplatin in Ect1/E6E7 
cells. Cells were either treated with bafilomycin (10 nM) or cisplatin  (15 µM) or the combination of the 
two for 24 h, n = 3. Statistical analysis: ANOVA and Bonferroni correction. All results expressed as 
mean ± SEM. Baf.. + cispl. = bafilomycin + cisplatin. 
. baf. + cispl. = bafilomycin + cisplatin. 
Debris
Apoptosis
Dip G1
Dip G2
Dip S
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h. Analysis of cell cycle progression modulated by bafilomycin and 
cisplatin treatment in HeLa cells. 
 
 
 
Figure 6.2.23. Modulation of cell cycle progression by bafilomycin and cisplatin in HeLa cells. Cells 
were either treated with bafilomycin (10 nM) or cisplatin  (15 µM) or the combination of the two for 24 h, * p 
< 0.05 vs. control G1/G0 and S, # p < 0.05 vs. cisplatin G1, n = 3. Statistical analysis: ANOVA and 
Bonferroni correction. All results expressed as mean ± SEM  baf. + cispl. = bafilomycin + cisplatin. 
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Significant alterations in cell cycle phases were observed with cisplatin treatment in 
comparison to the control (34.79 ± 8.80% vs. control G1, * p < 0.05) and cisplatin 
treatment in comparison to HeLa cells treated with bafilomycin (69.31 ± 6.50% vs. 
cisplatin G1, # p < 0.05). Cisplatin treated cells also exhibited a shift in the 
percentage of cells into the S-phase (63.14 ± 8.25% vs. control S, * p < 0.05, Fig. 
6.2.23.). 
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i. Analysis of cell cycle progression modulated by bafilomycin and 
cisplatin treatment in CaSki cells. 
 
  
Figure 6.2.24. Modulation of cell cycle progression by bafilomycin and cisplatin in CaSki cells. Cells 
were either treated with bafilomycin (10 nM) or cisplatin (15 µM) or the combination of the two for 24 h, ** p < 
0.01 vs. control S, ** p < 0.01 vs. control G2/M, n = 3. Statistical analysis: ANOVA and Bonferroni correction. 
All results expressed as mean ± SEM, baf. + cispl. = bafilomycin + cisplatin. 
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CaSki cells treated with cisplatin exhibited a significant increase in the S-phase 
(40.66 ± 1.70% vs. control S, ** p < 0.01) with a concomitant decrease in the G2/M 
phase (0.16 ± 0.16% vs. control, p < 0.01). Similarly, CaSki cells treated with 
bafilomycin as well as the combination of bafilomycin and cisplatin both exhibited a 
significant decrease in the percentage of cells in the G2/M phase (0.00 ± 0.00% and 
0.11 ± 0.11% vs. control G2/M, ** p < 0.01, Fig. 6.2.24.).  
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6.2.4. Biological inhibition of autophagy in combination with cisplatin 
treatment: Effects on autophagy and apoptosis. 
a. The effect of ATG5 silencing on autophagy in Ect1/E6E7 cells.  
Figure 6.2.25. Atg5 silencing and the effect on autophagy in Ect1/E6E7 cells. A. Silencing of ATG 5 
confirmed through Western blotting ** p < 0.01 vs. sc. seq., n = 3. B. p62 degradation, * p < 0.05 vs. sc. seq., 
** p < 0.01 vs. sc. seq. and # p < 0.05 vs. cisplatin, n = 3. C. LC-3 II protein levels, * p < 0.05 vs. sc. seq., # p 
< 0.05 vs. cisplatin, n = 3. Statistical analysis: ANOVA and Bonferroni correction. All results expressed as 
mean ± SEM Sc. seq. = scrambled siRNA sequence/control, cispl. = cisplatin, AU = arbitrary units.
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Efficient silencing of ATG was confirmed through Western blotting (0.57 ± 0.07 vs. sc. 
seq., ** p < 0.01, Fig. 6.2.25.A.). Intracellular protein levels of p62 were significantly 
decreased in cells treated with cisplatin when compared to the control (0.75 ± 0.05 
vs. control, * p < 0.05) and increased in cells where ATG 5 was silenced (1.14 ± 0.01 
vs. control, ** p < 0.01 and # p< 0.05 vs. cisplatin, Fig. 6.2.25.B.). LC-3 II protein 
levels increased significantly in cells treated with cisplatin (1.17 ± 0.05 vs. control, * p 
< 0.05) and the combination of silencing with cisplatin treatment (0.68 ± 0.03 vs. 
control, * p < 0.05). Additionally, in both groups where ATG 5 was silenced, LC-3 II 
protein expression was significantly lower when compared to the cisplatin treated 
group (0.68 ± 0.12 and 0.68 ± 0.03 vs. cisplatin, # p < 0.05, Fig. 6.2.25.C.). 
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b. The effect of ATG5 silencing on autophagy in HeLa cells. 
  
 
 
 
Figure 6.2.26. Atg5 silencing and the effect on autophagy in HeLa cells. A. Silencing of ATG 5 confirmed 
through Western blotting *** p < 0.001 vs. sc. seq., n = 3. B. p62 degradation, * p < 0.05 vs. sc. seq., # p< 0.05 vs. 
cisplatin, n = 3. C. LC-3 II protein levels, ** p < 0.01 vs. control, # p < 0.05 vs. cisplatin and $ p< 0.05 vs. ATG 5 
siRNA, n = 3. Statistical analysis: ANOVA and Bonferroni correction. All results expressed as mean ± SEM Sc. 
seq. = scrambled siRNA sequence/control, cispl. = cisplatin, AU = arbitrary units. 
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Efficient silencing of the ATG 5 protein was confirmed through the Western blotting 
procedure (0.32 ± 0.06 vs. sc. seq. *** p < 0.001, Fig. 6.2.26.A). Assessment of 
markers of autophagy revealed a significant decrease in p62 intracelluar protein 
levels after treatment with cisplatin (0.51 ± 0.14 vs. sc. seq., * p < 0.05) in 
comparison to the control cells. Additionally, in comparison to the cisplatin treated 
HeLa cells, a significant increase in p62 was observed in silenced cells (1.52 ± 0.26 
vs. cisplatin, # p< 0.05) and within the combination group (1.35 ± 0.24 vs. cisplatin, # 
p< 0.05, Fig. 6.2.26.B). Cisplatin treatment in CaSki cells induced a significant 
increase in LC-3 II protein expression when compared to the control (0.78 ± 0.02 vs. 
control, * p< 0.01, Fig. 6.2.26.C). Additionally, silencing of ATG5 combined with 
cisplatin treatment induced a significant increase in LC-3 II protein levels when 
compared to the control (1.27 ± 0.13 vs. control, ** p < 0.01), cisplatin (1.27 ± 0.13 
vs. cisplatin, # p < 0.05) and ATG 5 (1.27 ± 0.13 vs. ATG 5 siRNA, $ p < 0.05, Fig. 
6.2.26.C). 
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c. The effect of ATG5 silencing on autophagy in CaSki cells. 
 
  
Figure 6.2.27. Atg5 silencing and the effect on autophagy in CaSki cells. A. Silencing of ATG 5 confirmed 
through Western blotting *** p < 0.001 vs. sc. seq., n = 3. p62 degradation, *** p < 0.001 vs. sc. seq., * p < 0.05 
vs. control and # p< 0.05 vs. cisplatin, n = 3. C. LC-3 II protein levels, n = 3. Statistical analysis: ANOVA and 
Bonferroni correction. All results expressed as mean ± SEM. Sc. seq. = scrambled siRNA sequence/control, 
cispl. = cisplatin, AU = arbitrary units. 
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Efficient silencing of the ATG 5 protein was confirmed through Western blotting (0.40 
± 0.04 vs. sc. seq. p < 0.001, Fig. 6.2.27.A). Assessment of markers of autophagy 
revealed a significant decrease in p62 intracelluar protein levels after treatment with 
cisplatin (0.35 ± 0.02 vs. sc. seq., *** p < 0.001) and a significant increase in p62 
after silencing of ATG 5 (2.56 ± 0.42 vs. control, * p < 0.05), in comparison to the 
control cells (Fig. 6.2.27.B). Additionally, in comparison to the cisplatin treated CaSki 
cells, a significant increase in p62 was observed where ATG 5 was silenced (2.56 ± 
0.42 vs. cisplatin, # p < 0.01, Fig. 6.2.27.B.). No statistically significant changes in 
LC-3 II protein expression were observed in any of the treatment groups (Fig. 
6.2.27.C.).  
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d. The effect of ATG5 silencing on apoptosis in Ect1/E6E7 cells. 
 
 
Figure 6.2.28.. Effect of the silencing of ATG 5 on apoptosis in Ect1/E6E7 cells. A. Cell viability (MTT), 
* p < 0.05 vs. sc. seq. and # p < 0.05 vs. cisplatin, n = 4 B. Caspase-3 and -7 activity, n = 4. C. LDH 
release, * p < 0.05 vs. sc.seq., # p < 0.05 vs. cisplatin and $ p < 0.05 vs. ATG5 siRNA, n = 3. Statistical 
analysis: ANOVA and Bonferroni correction. All results expressed as mean ± SEM. Sc. seq. = scrambled 
siRNA sequence/control, AU = arbitrary units. 
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Analysis of apoptotic markers after silencing of ATG 5 in combination with cisplatin 
revealed a significant decrease in MTT reductive capacity of Ect1/E6E7 in the 
cisplatin and combination groups (80.87 ± 6.40%, 68.40 ± 1.34% vs. sc.seq., * p < 
0.05 and 68.40 ± 1.39% vs. ATG 5 siRNA, # p < 0.05, Fig. 6.2.28.A.). Caspase -3 
and -7 activity did not change significantly in any of the treatment groups (Fig. 
6.2.28.B.). LDH release increased significantly in the cisplatin and combination 
groups in comparison to the control/scrambled sequence (9.20 ± 2.58% and 10.47 ± 
2.34% vs. sc. seq., * p < 0.05). Additionally, silencing resulted in a significant 
decrease in LDH release in comparison to cells treated with cisplatin (0.01 ± 0.00% 
vs. cisplatin, # p < 0.05, Fig. 6.2.28.C).  
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e. The effect of ATG5 silencing on apoptosis in HeLa cells . 
 
  
Figure 6.2.29. Effect of ATG5 silencing on apoptosis in HeLa cells. A. Cell viability (MTT), ** p < 0.01 vs. sc. 
seq. and # p < 0.05 vs. cisplatin, n = 4 B. Caspase-3 and -7 activity, * p < 0.05 vs. control, # p < 0.05 vs. cisplatin 
and $ p < 0.05 vs. ATG5 siRNA, n = 4. C. PARP cleavage, * p < 0.05 and ** p < 0.01 vs. sc. seq., # p < 0.01 vs. 
cisplatin and $ p < 0.05 vs. ATG 5 siRNA, n = 3 (corresponding representative blot above). D. LDH release, n = 3. 
Statistical analysis: ANOVA and Bonferroni correction. All results expressed as mean ± SEM. Sc. seq. = 
scrambled siRNA sequence/control, AU = arbitrary units. 
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Silencing of ATG 5 was utilised in order to confirm previous findings which indicated 
that the inhibition of autophagy combined with cisplatin treatment induces cell death. 
A significant decrease in cell viability of HeLa cells treated with cisplatin was 
observed (78.18 ± 2.73% vs. scr. seq, ** p < 0.01, Fig. 6.2.29.A). Additionally, HeLa 
cells that were silenced for ATG 5 and treated with cisplatin thereafter displayed a 
significant reduction in viability when compared to the control cells (44.53 ± 13.54% 
vs. scr. seq., ** p < 0.01) and cells silenced for ATG 5 alone (44.53 ± 13.54% vs. 
ATG 5 siRNA, # p < 0.05, Fig. 6.2.29.A.). Caspase activity remained unchanged in all 
groups except in the combination group where ATG 5 was silenced with subsequent 
treatment with cisplatin (2.26 ± 0.38 vs. control, * p < 0.05, 2.26 ± 0.38 vs. cisplatin, # 
p < 0.05, and 2.26 ± 0.38 vs. ATG 5 siRNA, $ p< 0.05, Fig. 6.2.29.B.). Cleavage of 
PARP, which is indicative of apoptotic induction, was significantly increased in the 
silenced and combination group in comparison to the control (1.75 ± 0.1 and 4.85 ± 
0.36 vs. sc.seq., * p < 0.05, ** p < 0.01). Furthermore, PARP cleavage in the 
combination group was significantly increased in comparison to the cisplatin (4.85 ± 
0.36 vs. cisplatin, # p< 0.01) and the ATG5 siRNA group (4.85 ± 0.36 vs. ATG 5 
siRNA., $ p< 0.05, Fig. 6.2.29.C.). No significant changes in LDH release were 
observed in either of the treatment groups (Fig. 6.2.29.D.).  
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f. The effect of ATG5 silencing on apoptosis in CaSki cells 
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Figure 6.2.30. Effect of the silencing of ATG 5 on apoptosis in CaSki cells. A. Cell viability (MTT), * p < 0.05 
vs. sc. seq., n = 3. B. Caspase-3 and -7 activity, * p < 0.05 vs. sc. seq., n = 4. C. Caspase-3 cleavage, * p < 0.05 
and *** p < 0.001 vs. sc. seq., # p < 0.05 and $ p < 0.001 vs. cisplatin and δ p < 0.01 vs. ATG 5 siRNA, n = 3. D. 
PARP cleavage, * p < 0.05 vs. sc. seq. and # p < 0.05 vs. cisplatin, n = 3. E.  LDH release, * p < 0.05, *** p < 0.001 
vs. sc. seq., # p < 0.001 vs. cisplatin and $ p < 0.001 vs. ATG 5 siRNA, n = 3. Statistical analysis: ANOVA and 
Bonferroni correction. All results expressed as mean ± SEM. Sc. seq. = scrambled siRNA sequence/control, AU = 
arbitrary units. 
Stellenbosch University  http://scholar.sun.ac.za
139 
 
Cell viability (MTT) decreased significantly in the combination group in comparison to 
the control (74.23 ± 5.07% vs. sc. seq., * p < 0.05, Fig. 6.2.30.A). Caspase activity 
was observed to increase significantly only in the combination group (10.28 ± 4.07 
vs. sc. seq. * p < 0.05, Fig. 6.2.30.B). Furthermore, Western blot analysis of caspase-
3 cleavage indicated significantly higher intracellular levels in the silenced and 
combination treatment groups in comparison to the control (7.99 ± 1.28 and 17.63 ± 
0.97 vs. sc. seq. * p < 0.05, *** p < 0.001) and cisplatin (7.99 ± 1.28 and 17.63 ± 0.97 
vs. cisplatin, # p < 0.05, $ p < 0.001, Fig. 6.2.30.C). A significant difference in 
caspase-3 cleavage was observed between the silenced and combination group 
(17.63 ± 0.97 vs. ATG 5 siRNA, # p < 0.01, Fig. 6.2.30.C.). Similarly, cleaved PARP 
levels were increased, however only in the combination group in comparison to the 
control (20.43 ± 4.44 vs. sc. seq., * p < 0.05) and the cisplatin group (20.43 ± 4.44 vs. 
cisplatin, # p < 0.05). LDH release increased significantly in CaSki cells treated with 
cisplatin (18.12 ± 3.12% vs. sc. seq., * p < 0.05), silenced for ATG 5 (9.23 ± 0.66% 
vs. sc. seq., * p < 0.05) as well as silenced for ATG 5 with cisplatin treatment (60.77 
± 5.28% vs. sc. seq., *** p < 0.001; 60.77 ± 5.28% vs. cisplatin, # p < 0.001 and 
60.77 ± 5.28% vs. ATG 5 siRNA, $ p < 0.001, Fig. 6.2.30.D). 
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g. Summary of results. 
 
  
Cisplatin
mTOR 
siRNA
mTOR 
siRNA 
+ cispl. Cisplatin
mTOR 
siRNA
mTOR 
siRNA 
+ cispl. Cisplatin
mTOR 
siRNA
mTOR 
siRNA 
+ cispl.
AUTOPHAGY
p62 ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ─
LC-3 II ↑ ↑ ↑ − ↑ ↑ ↑ ↑ ↑
MTT ↓ ─ ↓ ↓ ─ ─ ─ ─ ─
CELL DEATH
Caspase-Glo ─ ─ ↑ ─ ─ ─ ─ ─ ─
PARP cleavage ─ ─ ─ ↑ ─ ↑ ─ ─ ↑
LDH Release ↑ ─ ─ ─ ─ ─ ↑ ─ ─
Ect1/E6E7 HeLa CaSki
mTOR siRNA
Table 3.a.  Summary of results: The effect of rapamycin and cisplatin on autophagy and apoptosis 
in three cervical cell lines. 
Table 3b.  Summary of results: The effect of mTOR silencing and cisplatin on autophagy  and 
apoptosis in three cervical cell lines. 
Cisplatin Rapamycin R+C Cisplatin Rapamycin R+C Cisplatin Rapamycin R+C
AUTOPHAGY
mTOR ↓ ↓ ↓ ↓ ↓ ↓ ─ ↓ ↓
p62 ↓ ─ ↓ ─ ↓ ↓ ↓ ↓ ↓
LC-3 II ↑ ↓ ↓ ─ ─ ─ ↑ ─ ↓
Lysosomes ─ ─ ↑ ↑ ↑ ↑ ─ ─ ─
MTT ─ ─ ─ ─ ↓ ↓ ↓ ↓ ↓
CELL DEATH
Caspase-Glo ─ ↓ ↓ ─ ─ ─ ─ ↑ ↑
PARP cleavage ─ ─ ↑ ─ ─ ↓ ─ ↓ ─
PI inclusion ─ ↑ ↑ ─ ─ ↑ ─ ─ ─
LDH Release ─ ─ ─ ─ ─ ↑ ─ ─ ─
CELL CYCLE ─ ↓ G1,↑S ↓ G1,↑S ↓ G1,↑S ─ ─ ↑S ─ ─
Ect1/E6E7 HeLa CaSki
RAPAMYCIN
↑ - significant increase, ↓ significant decrease, ─ not significant  
↑ - significant increase, ↓ significant decrease, ─ not significant  
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Cisplatin
ATG5 
siRNA
ATG5 siRNA 
+ cispl. Cisplatin
ATG5 
siRNA
ATG5 siRNA 
+ cispl. Cisplatin
ATG5 
siRNA
ATG5 siRNA 
+ cispl.
AUTOPHAGY
p62 ↓ ↑ ─ ↓ ↑ ↑ ↓ ↑ ─
LC-3 II ↑ − ↑ ↑ ─ ↑ ─ ─ ─
MTT ↓ ─ ↓ ↓ ─ ↓ ─ ─ ↓
CELL DEATH
Caspase-Glo ─ ─ ─ ─ ─ ↑ ─ ─ ↑
PARP cleavage ─ ─ ─ ↑ ─ ↑ ─ ─ ↑
Caspase-3 cleavage x x x x x x x ↑ ↑
LDH Release ↑ ─ ─ − − − ↑ ↑ ↑
ATG5 siRNA
Ect1/E6E7 HeLa CaSki
Table 4 b.  Summary of results: The effect of ATG5 silencing and cisplatin on autophagy and apoptosis 
in three cervical cell lines. 
Cisplatin Bafilomycin A1 B+C Cisplatin Bafilomycin A1 B+C Cisplatin Bafilomycin A1 B+C
AUTOPHAGY
mTOR ↓ ─ ─ ↓ ─ ↓ ↓ ↓ ↓
p62 ↓ ─ ↓ ↓ ─ ↓ ─ ─ ↓
LC-3 II ↑ ↑ ↑ ─ ↑ ↑ ↑ ↑ ↑
Lysosomes ─ ↓ ↓ ↑ ↓ ↓ ─ ↓ ↓
MTT ─ ─ ─ ─ ─ ─ ─ ─ ↓
CELL DEATH
Caspase-Glo ↑ ─ ↑ ─ ─ ─ ─ ↑ ↑
PARP cleavage ↑ ↑ ↑ ─ ─ ↑ ─ ─ ↑
Caspase-3 cleavage x x x x x x x x ↑
PI inclusion ─ ↑ ↑ ─ ─ ↑ ─ ─ ↑
LDH Release ─ ─ ↑ ─ ─ ↑ ─ ─ ↑
CELL CYCLE ─ ─ ─ ↓ G2/M,↑S ─ ─ ↑S ↓ G2/M ↓ G2/M
BAFILOMYCIN A1
Ect1/E6E7 HeLa CaSki
Table 4 a.  Summary of results: The effect of bafilomycin and cisplatin on autophagy  and 
apoptosis in three cervical cell lines. 
↑ - significant increase, ↓ significant decrease, ─ not significant, x not detected.  
↑ - significant increase, ↓ significant decrease, ─ not significant, x not detected.  
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6.3. Discussion 
The previous observation that a low, non-toxic concentration of cisplatin induces 
autophagy brought forth the possibility that this response may be exploited in order to 
improve cisplatin-induced apoptosis with the hope of eliminating the need for the high 
concentrations that are currently in clinical use. If such a lower cisplatin concentration 
with autophagy induction/inhibition enhances cell death, this could decrease the 
severity of the side-effects considerably, and as a result of this, chemotherapy 
treatment regimens may be prolonged. It has been shown in literature that both the 
induction and inhibition of autophagy can improve the sensitivity of various cancer 
cell types to chemotherapy treatment (Levy and Thorburn, 2011, Notte et al., 2011). 
This part of the study therefore aimed to determine whether the induction or inhibition 
of autophagy may contribute to the improvement of cisplatin-induced apoptosis in two 
cancerous cell lines (HeLa and CaSki).  
 
6.3.1. The effect of the combination of rapamycin and cisplatin treatment on 
autophagy in three cervical cell lines. 
Firstly, autophagy was induced with the use of an established pharmacological agent 
known as rapamycin. It specifically inhibits mTOR, an upstream autophagic 
modulator, thereby inducing autophagy. Since cisplatin induces autophagy on its 
own, two things should be considered:  Firstly, will the induction of autophagy drive 
the cells into metabolic failure? And secondly, will induction of autophagy above the 
cisplatin-induced levels function as an additional resistance mechanism against 
cisplatin treatment? The effect of the combination treatment (rapamycin and cisplatin) 
on autophagy was initially assessed, and the effects on apoptosis induction was 
evaluated. 
Ect1/E6E7 
Treatment with rapamycin alone and in combination with cisplatin induced a 
significant decrease in the intracellular levels of mTOR when compared to the control 
cells (Fig. 6.2.1. A). Since cisplatin treatment alone induced a decrease in mTOR 
protein levels, it might have been expected that mTOR protein levels would be lower 
in the combination group than in the other two treatment groups, however this was 
not the case. A possible explanation for this could be that since autophagy has been 
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up-regulated by pre-treatment with rapamycin, a negative feedback mechanism could 
be responsible for preventing further up-regulation upon treatment with cisplatin. This 
phenomenon has been observed in oncogene-induced senescence where autophagy 
was activated. This correlated with negative feedback in the mTOR pathway in 
human diploid fibroblasts (Young et al., 2009).  
An equally important marker of autophagy, p62, was analysed and although 
rapamycin treatment alone did not induce significant degradation through autophagy 
induction, the combination of cisplatin and rapamycin did (Fig.6.2.1.B.). Intracellular 
levels of p62 in this group were similar to those seen in cells treated with cisplatin 
alone, thus the combination treatment did not prove to be more effective in inducing 
autophagy and this result may in effect be attributed to cisplatin treatment alone. 
Although p62 plays a role in a myriad of other important cellular processes, during 
the dynamics of autophagy its degradation is indicative of autophagy up-regulation 
(Mizushima et al., 2010). In the context of non-cancerous cells, rapamycin was 
observed to decrease protein levels of p62 in human embryonic kidney cells by a 
minimal 32% (Tung et al., 2010), which agrees with the observations obtained in this 
study where rapamycin did not decrease p62 protein levels in the non-cancerous 
Ect1/E6E7 cells. This may therefore suggest that essentially, the effect of rapamycin 
on p62 protein levels may be negligible in these cells since its effects were minor in 
comparison to the other untreated (control) and treated groups. 
Lastly, the presence of LC-3 II protein (and therefore autophagosomes) was 
assessed (Fig. 6.2.1.C.). Both rapamycin treated groups had significantly higher 
levels of LC-3 II protein in comparison to the control group. The combination 
treatment of rapamycin and cisplatin induced a significant decrease in p62 protein 
levels in comparison to the control and rapamycin groups and exhibited a 
concomitant increase in LC-3 II protein levels. Interestingly, since p62 and LC-3 II 
function at the same level of the autophagic signalling cascade i.e. the 
autophagosome, the relative protein levels of each should in theory correlate with 
one another such that a decrease in p62 is indicative of an increase in autophagy 
(LC-3 II) (Mizushima et al., 2010) . This increase in LC-3 II in a non-cancerous cell 
line in response to rapamycin treatment is supported by a study in which a primary 
culture of rodent pancreatic islets was observed to initiate a similar response 
(Tanemura et al., 2009). The Western blotting data suggest that even though the 
upstream autophagy molecules do not exhibit pronounced changes in their 
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expression in response to the combination of rapamycin and cisplatin, downstream at 
the level of the autophagosome, the effect is more pronounced (although an additive 
effect is not necessarily observed).  
In order to build upon the Western blotting data obtained (Fig. 6.2.1. A, B and C), 
analysis of the lysosomal acidic compartment as an indication for autophagic activity 
was assessed through the use of flow cytometry (Fig. 6.2.1. D.). The results suggest 
that Ect1/E6E7 cells treated with a combination of rapamycin and cisplatin were the 
only group that had significantly increased levels of the acidic lysosomal 
compartment. The completion of the autophagic process requires that 
autophagosomes fuse with lysosomes to form autophagolysosomes with the 
eventual purpose of degrading the intracellular components so that they may be 
utilised by the cell’s metabolism (Klionsky and Deter, 2008). Therefore their presence 
may be used as a marker for the up-regulation of autophagy. Since lysosomal 
biogenesis is in effect one of the final stages of the autophagic pathway, an increase 
in the presence of lysosomes is likely to correlate with a decrease in p62 and 
increase in LC-3 II protein levels. This was indeed the case since the combination 
group exhibited significant changes in both of these markers. An additive effect with 
rapamycin and cisplatin treatment in Ect1/E6E7 cells was not observed upon 
analysis of lysosomal biogenesis. 
The capacity of the Ect1/E6E7 cells to induce autophagy was determined to be 
relatively high upon stimulation with the combination of rapamycin and bafilomycin 
(Fig. 4.6.). The positive results observed here i.e. significant molecular and lysosomal 
changes in response to rapamycin and cisplatin treatment, may be as a result of this 
increased autophagic capacity. The true significance of this will be determined after 
the analysis of the responses of the two cancerous cell lines to this treatment regime. 
HeLa 
As with the Ect1/E6E7 cells, the combination of rapamycin and cisplatin treatment on 
autophagy was assessed through the analysis of three autophagy markers: mTOR, 
p62 and LC-3 II. Analysis of mTOR revealed significantly lowered expression in all 
groups (Fig. 6.2.2. A), additionally, no additive effect in further decreasing mTOR 
expression was observed in cells treated with the combination of rapamycin and 
cisplatin. Since rapamycin is an mTOR inhibitor, a decrease in its expression was 
expected. Interestingly, the response of the HeLa cells to rapamycin treatment 
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suggests a certain degree of sensitivity when compared to results obtained with 
Ect1/E6E7 cells, i.e. the same concentration of rapamycin had a more pronounced 
effect in inhibiting mTOR (Fig.6.2.1. A.). Furthermore, cisplatin treatment alone was 
able to significantly decrease mTOR expression, which agrees with a study 
conducted by Faried and colleagues who observed that a concentration of cisplatin 
that inhibited 20% of HeLa and CaSki cell proliferation (i.e. a low concentration, 6.28 
μM) was able to effectively down-regulate mTOR (Faried et al., 2008b). The analysis 
of mTOR under these treatment conditions suggests that both rapamycin and 
cisplatin are able to effectively reduce expression of mTOR in HeLa cells and that the 
combination of rapamycin and cisplatin treatment does not prompt additional 
inhibition of mTOR. 
The analysis of p62, a late stage autophagic marker, revealed significant decreases 
in intracellular protein levels in the rapamycin and combination treatment groups. 
Treatment with rapamycin induced p62 degradation in the HeLa cells which is in 
agreement with a study performed by Bjorkoy and colleagues (Bjorkoy et al., 2005). 
The presence of p62 in the combination group is markedly lower than both the 
rapamycin and cisplatin control groups, which points towards a possible additive 
effect induced by the two pharmacological agents. 
Since p62 protein levels in the combination treatment group (Fig. 6.2.2. B) were 
particularly reduced; LC-3 II protein levels should be consequently high. This was not 
the case for both rapamycin treated groups (Fig. 6.2.2.C). A study conducted by 
Chang and colleagues did not observe an enhancement of LC-3 II after rapamycin 
treatment in hepatomblastoma cell lines (Chang et al., 2011). Similarly, treatment 
with rapamycin did not induce pronounced up-regulation of LC-3 II in lung cancer 
cells (Kim et al., 2009). It is noteworthy to mention that although LC-3 II protein levels 
did not appear to be up-regulated, this does not infer that autophagy is not activated. 
This is established by the fact that during the late stages of autophagy, LC3-II is also 
degraded along with other cytoplasmic constituents, therefore generating a ‘negative 
result’ as such (Kabeya et al., 2000, Tanida et al., 2005, Mizushima et al., 2010). 
Therefore the data obtained from Western blotting suggests an up-regulation of 
autophagy in HeLa cells treated with rapamycin and cisplatin in combination, 
however cisplatin treatment had no effect on rapamycin-induced autophagy. 
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Analysis of lysosomal acidity revealed significant increases in all treatment groups, 
which combined with the Western blotting data suggest that firstly, rapamycin does 
induce autophagy in HeLa cells, secondly that these cells are in the late stages of 
autophagy and finally that cisplatin has no effect on rapamycin-induced autophagy. If 
it is recalled from chapter 3, HeLa cells demonstrated insignificant flux through the 
autophagic pathway, but were able to respond efficiently to the combination 
treatment in inducing autophagy, therefore the significance of this lowered flux may 
be observed after analysis of apoptosis. 
CaSki 
Lastly, analysis of the aggressive CaSki cells on rapamycin and cisplatin induced 
autophagy revealed the following: mTOR expression was significantly reduced in 
cells treated with rapamycin and the combination of rapamycin and cisplatin in 
comparison to the control (Fig.6.2.3. A.).  
Intracellular p62 protein levels decreased significantly in the combination group and 
this result implies that autophagy has been activated (Mizushima et al., 2010). Here it 
is evident that the addition of cisplatin after pre-treatment with rapamycin has an 
additive effect in reducing p62 protein expression when compared to cells treated 
with cisplatin alone (Fig. 6.2.3.B.). Thus far, these results are indicative of an up-
regulation in autophagy in response to the combination treatment with rapamycin and 
cisplatin. 
LC-3 II protein levels in the cisplatin group were significantly increased (Fig. 6.2.3. 
C),  and the addition of cisplatin after pre-treatment with rapamycin significantly 
decreased LC-3 II protein levels in comparison to the rapamycin treated group. As 
with the HeLa cells, CaSki cells treated with a combination of rapamycin and cisplatin 
may have very low/undetectable levels of LC-3 II due to its high rate of fusion of 
autophagosomes with lysosomes (Scheffner et al., 1991). From the analysis of these 
three autophagic markers, it may be concluded that autophagy is likely to be 
occurring in CaSki cells after treatment with rapamycin and cisplatin in combination. 
In order to support the above results, changes in the lysosomal acidic compartment 
with the use of Lysotracker™ were assessed (Fig. 6.2.3. D). Surprisingly, the results 
obtained were contradictory to the Western blot data (Fig. 6.2.3. A-C); no significant 
changes were observed in the rapamycin and even the combination treated group. A 
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study conducted by Safaei and colleagues may provide a possible explanation for 
this finding: the presence of lysosomes in cisplatin-sensitive and cisplatin-resistant 
ovarian carcinoma cell lines were detected with the use of Lysotracker™. It was 
observed that the cisplatin-resistant cell type had markedly fewer lysosomes than the 
cisplatin-sensitive counterparts (Safaei et al., 2005b). Since it was concluded that the 
CaSki cells had the greatest tolerance and therefore resistance to cisplatin treatment 
(Chapter 2), this may be a possible explanation for the results described (Figure 
6.2.3. C).  
From this section, the following conclusions may be drawn: The non-cancerous 
Ect1/E6E7 cells significantly induced autophagy after exposure to the combination 
treatment (Fig. 5.3.1). The HeLa and CaSki cells exhibited decreased LC-3 II at the 
end of the treatment period which indicates late-stage autophagy due to LC-3 II 
degradation. Autophagic flux measurements in the CaSki cell line (Chapter 4.2.) 
indicate that they have sufficient capacity to induce autophagy and thus we can 
attribute this to the results obtained here. To determine whether the combination 
treatment sensitised cervical cancer cells to cisplatin treatment, apoptosis was hence 
analysed. 
 
6.3.2. The effect of the combination of rapamycin and cisplatin treatment on 
apoptotic induction in three cervical cell lines. 
Analysis of apoptosis and membrane integrity was assessed by the analysis of cell 
viability (MTT), caspase-3/-7 activity, PARP cleavage, LDH release and PI inclusion. 
Ect1/E6E7 
Firstly, cell viability of Ect1/E6E7 cells was assessed through the MTT assay which 
revealed no significant changes in the combination treatment group (Fig. 6.2.4. A). 
This result is desirable considering that the goal of this study is to maintain the 
integrity of the non-cancerous cells. Analysis of caspase-3 and -7 activity revealed 
significant decreases in their activity in the combination group in comparison to the 
control and cisplatin treated group (Fig. 6.2.4. B). A explanation for this may be that 
once caspase-3 is activated, XIAP specifically reduces the level of active caspase-3 
through binding with the caspase and degrading it via its E3 ubiquitin protein ligase 
(Suzuki et al., 2001). Therefore caspase-3 and -7 were both likely to be activated at 
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an earlier stage, and at the end of the treatment period had been degraded by this 
ubiquitin system, creating the above mentioned result (Fig. 6.2.4. B). 
A more direct biochemical marker of apoptosis is the cleavage of PARP (Berger and 
Petzold, 1985) which revealed that only treatment with the combination of rapamycin 
and cisplatin induced significant cleavage (Fig. 6.2.4. C). Furthermore, the 
combination treatment group was positive for propidium iodide (PI) inclusion, as 
observed in figure 6.2.4. E. A lack of LDH release with an increase in PI inclusion 
seems conflicting since a positive result for both tests is dependent on the 
permeabilisation of the plasma membrane. Keilhoff and Wolf observed that LDH 
release occurred only in response to cellular stress and as cell death progressed, 
LDH activity in the medium decreased significantly (Keilhoff and Wolf, 1993). This 
supports the results obtained in Figures 6.2.4. D. and E, which suggest that these 
cells are in the late stages of apoptosis. It is noteworthy to mention that only about 
25% of the total Ect1/E6E7 cell population exhibited apoptotic characteristics in 
response to rapamycin and cisplatin treatment (Fig. 6.2.4. E) which is favourable 
since damage to non-cancerous cells is central to inducing the side-effects 
commonly observed by chemotherapy treatment. 
HeLa 
Cell viability (MTT) decreased significantly, although only by about 25% in cells 
treated with the combination of rapamycin and cisplatin. Additionally, the addition of 
cisplatin after pre-treatment with rapamycin has no effect on rapamycin-induced MTT 
reductive capacity. What can be inferred however is that treatment with rapamycin 
may affect mitochondrial functioning since this assay is based on the reductive 
function of these metabolic organelles. Data to support this was demonstrated by 
Scheike and colleagues who observed that treatment with rapamycin lowered 
mitochondrial oxygen consumption and decreased oxidative capacity in Jurkat cells 
(Schieke et al., 2006). 
Analysis of activity of the effector caspsae -3 and -7 did not reveal significant 
increases in any of the treatment groups (Fig. 6.2.5. B.), and this correlated with a 
lack of PARP cleavage (Fig. 6.2.5. C). The HeLa cells may not be undergoing 
apoptosis at this point in the treatment protocol, however an increase in the 
incubation time with cisplatin may elicit an apoptotic response since its effects are 
known to be time-dependent (Choi et al., 2004, Cheng et al., 2010).  
Stellenbosch University  http://scholar.sun.ac.za
149 
 
Possibly the most striking result observed is that the combination of rapamycin and 
cisplatin treatment decreased PARP cleavage in HeLa cells (Fig. 6.2.5. C). Although 
not significant, the level of PARP cleavage in cells treated with rapamycin and 
cisplatin appear to be considerably lower (P = 0.053), this may point to the ability of 
rapamycin to assist in HeLa cell survival in the face of cisplatin treatment. It has 
previously been established that cisplatin increases autophagy (Chapter 5) and this 
is a likely mechanism of resistance/survival, thus pre-treatment with an autophagy 
inducer, such as rapamycin, may be protective against the damaging effects of 
cisplatin. Equally important is the finding that rapamycin inhibits the protective 
functioning of PARP, thereby preventing the poly(ADP-ribosyl)ation of DNA and 
preventing DNA repair (Fahrer et al., 2009). 
Evaluation of LDH release in HeLa cells revealed an increase after treatment with the 
combination of rapamycin and cisplatin (Fig.6.2.5. D) which may be indicative of a 
stress response (Keilhoff and Wolf, 1993) due to the metabolic/mitochondrial 
disruptions induced by treatment with rapamycin (Schieke et al., 2006).The 
percentage of PI positive cells in the rapamycin and cisplatin treated group were 
significantly higher than the other treatment groups (Fig. 6.2.5. E), but only by about 
4% (mean = 9.83%). It can therefore be concluded that the combination treatment 
possibly induces minor mitochondrial dysfunction and membrane permeabilisation in 
a small percentage of HeLa cells after the treatment period, however the results do 
not suggest that this is an effective method in inducing apoptosis in adenocarcinoma 
cells. 
The rationale behind inducing autophagy with a pharmacological agent such as 
rapamycin, and subsequently attempting to increase autophagic levels with a 
substance also known to induce autophagy, such as cislpatin, is that massive 
autophagic up-regulation (above a defined threshold) could result in large parts of the 
cytosol being degraded, leading to irreversible cellular atrophy (Gozuacik and Kimchi, 
2007). Referring back to the autophagic flux analysis of the HeLa cells, it was clear 
that their capacity to induce autophagy upon stimulation was partial, therefore it may 
have been predicted that this method of attempting to induce cell death with 
autophagy (Kroemer and Levine, 2008) may not have been successful. 
CaSki 
Stellenbosch University  http://scholar.sun.ac.za
150 
 
The MTT results revealed that the combination of rapamycin and cisplatin treatment 
decreased MTT reductive capacity by roughly 48% (Fig. 6.2.6. A) and when 
compared to the rapamycin treated group, the addition of cisplatin caused a further 
decrease of 22.43%. This result infers that under these conditions, mitochondrial 
activity is likely to be compromised (Slater et al., 1963) and that cisplatin worsens this 
rapamycin-induced state. Under these conditions one may expect an increase in 
cleavage of caspases -3 and -7 (due to cytochrome-c release from the mitochondrial 
membrane). This was indeed the case and both groups treated with rapamycin 
exhibited increases in caspase activity (Fig. 6.2.6. B.).  
PARP cleavage, one of the biochemical characteristics of apoptosis was absent in 
CaSki cells treated with the combination of rapamycin and cisplatin (Fig. 6.2.6. C). 
This is similar to the results observed in the HeLa cells (Fig. 6.2.5. C), however the 
absence of PARP in the rapamycin group appears to be more pronounced and may 
once again be attributed to the rapamycin itself (Fahrer et al., 2009). Even though 
there is an absence of cleaved PARP, apoptosis is not dependant its cleavage and is 
able to occur independently (Wang et al., 1997). 
Analysis of the membrane integrity did not reveal any significant changes in any of 
the treatment groups (Fig. 6.2.6. D. and E.). Since the early markers of apoptosis 
were suggestive of apoptotic induction, it is likely that an increase in incubation time 
with cisplatin will produce positive results. 
Referring back to the characterisation of autophagic flux (Fig. 4.6.), these cells had 
an increased capacity to induce autophagy upon stimulation, as well as a high basal 
level of autophagic activity, therefore a method such as this whereby autophagy was 
induced with rapamycin and then stimulated again with cisplatin, in addition to the 
already elevated basal autophagic levels is promising. The importance of autophagic 
flux evaluation before treatment intervention such as this is necessary, since it 
proved to be ineffective in inducing apoptosis in the HeLa cells with a low autophagic 
flux, but was able to induce apoptosis in the CaSki cell lines with relatively higher 
autophagic flux. 
Collectively, the results suggest apoptosis induction. Sensitisation of CaSki cells to 
cisplatin treatment through mTOR inhibition with the use of rapamycin has proven to 
be successful (Faried et al., 2008b), however the dose of cisplatin utilised in that 
study was 116.6 µM (in comparison to 15 µM used in this study). It has been 
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demonstrated here that with the use of a concentration almost eight-fold lower, that 
apoptotic cell death was achieved in the aggressive CaSki cell line. 
 
6.3.3. The effect of rapamycin and cisplatin treatment on the modulation of cell 
cycle progression. 
The importance of the cell cycle and its role as an indication for sensitivity in 
combination chemotherapy has been realised (Shah and Schwartz, 2001). Cell-cycle 
mediated drug resistance occurs when treatment with one agent impacts the cell-
cycle such that the subsequent chemotherapy agent administered immediately 
afterward is less effective (Shah and Schwartz, 2001). It is therefore necessary to 
conduct cell cycle analysis to determine whether the chemotherapy agents of choice 
act on cell cycle progression. 
Ect1/E6E6 
Treatment with cisplatin did not induce any significant alterations in the distribution of 
cells in the various stages of the cell cycle, however treatment with rapamycin 
significantly decreased the percentage of cells in the G1/G0 phase with a 
concomitant increase in the percentage of cells in the S phase (Fig. 6.2.7.). This is 
contrary to other studies which observed that rapamycin induces G1 phase cell cycle 
arrest in yeast and non-cancerous mammalian cells (Heitman et al., 1991, Morris, 
1991, Dumont et al., 1990, Powell et al., 1999). Literature suggests that a shift into 
the S phase generally occurs in response to DNA strand breaks (Kastan et al., 2000), 
and since there have been no particular roles for p53 and p21 in controlling the 
progression of the S phase, the delay may be beneficial for the cells (in order to 
repair strand breaks) without inducing permanent arrest (Bartek and Lukas, 2001). It 
was established that Ect1/E6E7 cells exhibit inclusion of PI (Fig.6.2.4.E), which 
includes DNA degradation, in response to both rapamycin and the combination 
treatment. As previously mentioned, rapamycin inhibits PARP activity (Fahrer et al., 
2009), thus resulting in its reduced activity to aid in the DNA repair process (Hamid 
Boulares et al., 1999). Due to the inactivity of PARP, a shift into the S phase may be 
the result. Cisplatin does not appear to play a role in prompting this S phase shift. 
HeLa 
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A significant increase in the percentage of cells that entered the S phase after 
cisplatin treatment was observed (Fig. 6.2.8). In cancer cells, this is a typical 
observation (Qin and Ng, 2002, Sorenson and Eastman, 1988a, Sorenson and 
Eastman, 1988b, Eastman, 2009, Shah and Schwartz, 2001). Surprisingly, entry into 
the S phase resulted in a 2-fold decrease in sensitivity of cancer cells to cisplatin and 
may confer protection to cisplatin induced apoptosis (Mueller et al., 2006), thus a 
shift into this phase does not signify cell death in this model. This can be supported 
by the results obtained in Chapter 4.1 where it was demonstrated that 15 µM cisplatin 
does not induce apoptosis. Treatment with rapamycin indicated a similar profile to 
that of the cisplatin treated groups. Interestingly, the addition of cisplatin seemed to 
revert the cell cycle profile back to a state that resembles the control group. 
CaSki 
As observed with the HeLa cells, the more aggressive CaSki cells exhibit an increase 
in the percentage of cells in S phase, however a decrease in the percentage of cells 
in the G1 phase was not observed (Fig. 6.2.9). The combination treatment did induce 
an increase in the percentage of cells in S phase, but only by 14.81%. The fact that 
these cells do exhibit any obvious shifts or arrests may prove to be promising due to 
the fact that cells that do undergo growth arrest may be protected from apoptosis and 
be resistant to the particular drug (Shah and Schwartz, 2001). 
6.3.4. The effect of mTOR silencing combined with cisplatin treatment on 
autophagy in three cervical cell lines. 
In order to control for any off target effects that rapamycin may have, it was 
necessary to biologically inhibit mTOR through RNA interference. This technique has 
been widely used and accepted to assess gene function (Sharp, 2001). 
Ect1/E6E7 
The silencing of mTOR efficiently induced the degradation of p62 with and without 
the addition of cisplatin (Fig. 6.2.10. B). Additionally, the presence of cisplatin had no 
additive effect on improving p62 degradation through the silencing of mTOR. 
Analysis of LC-3 II confirmed that silencing of mTOR in combination with cisplatin 
treatment increases autophagy (Fig. 6.2.10. C), which agrees with results obtained 
using rapamycin and cisplatin and the effect of this combination on autophagy (Fig. 
6.2.1.C.). Cisplatin does not exhibit any additive effect on LC-3 II expression levels 
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when added to culture after the silencing period. The results obtained above which 
suggest that the silencing of mTOR induces autophagy in non-cancerous cell lines 
agree with other studies (Bohensky et al., 2010, Sakiyama et al., 2009). Furthermore, 
rapamycin proves to be an acceptable pharmacological inducer of autophagy in a 
non-cancerous cervical cell line. 
HeLa 
Efficient inhibition of mTOR was observed after silencing HeLa cells (Fig. 6.2.11. A). 
The results obtained with regards to autophagic induction mirror those obtained with 
rapamycin treatment (Fig. 6.2.2.), however the effects of mTOR silencing on p62 
were more pronounced (Fig. 6.2.11. B).  
Intracellular levels of LC-3 II did not exhibit any significant increases in response to 
the silencing of mTOR (Fig. 6.2.11. C). Corresponding p62 protein levels suggest its 
degradation (6.2.11. B.), and its lowered expression correlates with autophagic 
induction (Mizushima et al., 2010). Furthermore, during the late stages of autophagy, 
LC-3 II itself becomes degraded along with other cytoplasmic constituents, thus 
rendering the protein levels as insignificant (Kabeya, Mizushima et al. 2000; Tanida, 
Minematsu-Ikeguchi et al. 2005; Mizushima, Yoshimori et al. 2010). In conclusion, 
the inhibition of mTOR through pharmacological and biological methods prove to be 
sufficient in inducing autophagy in HeLa cells, but no additive effect was observed 
with cisplatin treatment in silenced cells. 
CaSki 
The silencing of mTOR in CaSki cells produced similar results to those obtained with 
the use of rapamycin treatment (Fig. 6.2.3.), however p62 protein levels were 
significantly reduced after treatment with rapamycin and cisplatin in combination, 
whereas biological inhibition of mTOR in combination with cisplatin did not produce 
such an effect (Fig. 6.2.12. B). Silencing of mTOR without cisplatin treatment 
decreased p62 protein levels, which is indicative of autophagy induction, however, 
this was lost after cisplatin treatment. P62 has been implicated in cisplatin resistance 
in ovarian cancer cells by clearing ubiquinated proteins and preventing endoplasmic 
reticulum stress (Yu et al., 2011b). Additionally, it was observed that p62 protein 
levels were increased in cisplatin treated cells that were still viable (Moretti et al., 
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2009). Taken together, it may be speculated that the addition of cisplatin returns p62 
levels to that of the viable control cells thus conferring survival. 
Silencing of mTOR alone increased LC-3 II protein expression, more so than the 
control and the cisplatin treated group, however, this effect was lost after cisplatin 
treatment. It could be due to a down-regulation of autophagy, or simply a loss in LC-3 
II due to its degradation with other cytoplasmic constituents during the autophagic 
process. p62 protein levels point to the former however, unless autophagy is able to 
proceed without p62 degradation. 
Taken together, these results suggest that the inhibition of mTOR in CaSki cells 
through silencing induces autophagy, however the addition of cisplatin leads to a 
decrease in this response, as indicated by the p62 and LC-3 II protein levels. The 
return of p62 levels back to a control state may be indicative for cell survival. 
 
6.3.5.  The effect of the combination of mTOR silencing and cisplatin treatment 
on apoptotic induction in three cervical cell lines. 
It was necessary to determine whether the apoptotic effects induced through 
treatment with rapamycin were a result of the inhibition of mTOR, and not as a result 
of potential off-target molecular effects. Thus silencing was employed to inhibit the 
translation of mTOR mRNA into the protein. Some markers and methods of 
apoptosis measurement (that were used to assess the effects of rapamycin and 
cisplatin) were not used in this section, as silencing in this context is utilised purely as 
a proof of concept. 
Ect1/E6E7 
Treatment with rapamycin in combination with cisplatin at the end of the treatment 
period displayed characteristics of membrane permeabilization, indicating late-stage 
apoptosis (Fig.6.2.4. D and E). Conversely, the silencing of mTOR combined with 
cisplatin did not exhibit such characteristics, instead, a significant decrease in cell 
viability was observed (Fig. 6.2.13. A) and caspase-3 and -7 activity was increased 
(Fig. 6.2.13. B). Cisplatin alone did not increase caspase-3 and -7 activity 
significantly; this points to the fact that the addition of cisplatin after silencing induced 
caspase -3 and -7 cleavage effectively, however, protein levels of cleaved caspase -
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3 were not detectable by Western blot, indicating that the percentage of cells 
undergoing apoptosis was likely to be minor. Similarly, PARP cleavage was also 
undetectable through Western blotting.  
In conclusion, above data suggest that treatment with the combination of rapamycin 
and cisplatin induced apoptosis at an earlier time point, thus causing the Ect1/E6E7 
cells to undergo plasma membrane permeabilisation at the end of the treatment 
period. Conversely, the silencing of mTOR with cisplatin treatment induced a slower 
onset of apoptosis. This may be attributed to the fact that rapamycin, apart from 
inhibiting mTOR, also induces derangements in mitochondrial function (Schieke et 
al., 2006), therefore this may have contributed to an earlier onset of apoptosis in the 
Ect1/E6E7 cells. Nevertheless, the effect of mTOR inhibition combined with low-dose 
cisplatin treatment is mildly cytotoxic to these non-cancerous cells, thus this avenue 
of treatment proves to be promising, provided that it is successful in inducing cell 
death in the cancerous cell lines. 
HeLa 
Analysis of apoptotic markers in HeLa cells treated with the combination of 
rapamycin and cisplatin revealed a slight decrease in cell viability (MTT) and LDH 
release, however no evidence of apoptosis was observed (Fig. 6.2.5.). Inhibition of 
mTOR through silencing yielded somewhat different results (Fig. 6.2.14.): Cleaved 
PARP protein levels were higher in comparison to the other two treatment groups 
(and control), which is contrast to the levels of cleaved PARP observed after 
treatment with rapamycin and cisplatin (Fig. 6.2.5. D.). Rapamycin was observed to 
inhibit PARP (Fahrer et al., 2009), which accounted for the lack of cleavage 
observed. It was proposed that since no definite signs of autophagy were present, 
rapamycin treatment may play a protective role and aid in HeLa cell survival. This 
notion has now partially been discarded since PARP cleavage was detected.  
Above results are in contrast to other studies which found that the inhibition of mTOR 
in conjunction with cisplatin treatment induces apoptosis in leukemia cells (Shi et al., 
1995), ovarian cancer cells (Bae‐Jump et al., 2009, Peng et al., 2010), basal-like 
breast cancer cells (Wong et al., 2011), laryngeal cancer cells (Lei et al., 2009) and 
in oesophageal squamous cell carcinoma in nude mice (Hou et al., 2010a). 
Interestingly, very few studies address this method of inducing apoptosis in cervical 
cancer cells, as well as the effect it may have on non-cancerous cells. In a study 
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conducted by Faried and colleagues, mTOR inhibition with rapamycin and 
subsequent treatment with cisplatin induced apoptosis in both HeLa and CaSki cells 
(Faried et al., 2008b), however, the reason for this may be attributed to the fact that 
the concentrations of cisplatin used were based on the IC50 values, i.e. HeLa = 15.7 
µM and CaSki = 116.6 µM. Another study conducted by Ji and Zheng found that the 
inhibition of mTOR with rapamycin and siRNAs sensitised HeLa cells to cisplatin 
treatment at concentrations ranging from 0.1 – 100 µM (Ji and Zheng, 2010). 
Sensitising cervical cancer cells to cisplatin treatment will likely induce apoptosis 
when the concentration of cisplatin is already high. The challenge therefore lies in 
being able to induce a similar magnitude of apoptosis with a lower concentration of 
cisplatin, thus eliminating the need for high concentrations and the debilitating side-
effects which accompany it. Due to this reason alone, the combination of rapamycin 
and cisplatin treatment is not effective in inducing apoptosis in HeLa cells, but the 
possibility that an increase in exposure time to cisplatin, thereby improving the 
chance for apoptotic induction should not be excluded. 
CaSki 
Silencing of mTOR in combination with cisplatin resulted PARP cleavage but no 
other markers of apoptosis were affected (Fig. 6.2.15). This finding confirms the fact 
that PARP cleavage should not be utilized as the only marker of apoptosis, as 
rapamycin has clearly inhibited its expression in both the HeLa and CaSki cells (Fig. 
6.2.5.D. and 6.2.6. D.). Therefore other biochemical markers such as cleaved 
caspase-3 and -7 should be used in addition. The more pronounced effect on 
apoptosis in CaSki cells treated with rapamycin could be attributed to the fact that 
silencing offers only partial inhibition of mTOR (48% in this case), whereas 
rapamycin was able to reduce mTOR expression by 68%. 
The use of rapamycin as a means of sensitisation to chemotherapy treatment in 
CaSki cells was demonstrated by (Faried et al, 2006), where it was observed that 
rapamycin treatment sensitises CaSki cells to treatment with paclitaxel (Faried et al., 
2006). Thus this is a treatment option; however it seems to be dependent on high 
doses of chemotherapy treatment. Nevertheless, rapamycin, and not silencing as 
means of inhibiting mTOR is more efficient in inducing apoptosis in CaSki cells, and 
this result may be improved by increasing the exposure time to cisplatin treatment.  
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It can be concluded that the use of rapamycin as a means of sensitising CaSki cells 
to cisplatin treatment reveals promising results. This is supported by the fact that only 
minor induction of autophagy in non-cancerous cells is observed. Therefore, 
rapamycin as a pre-treatment followed by low-dose cisplatin is an encouraging future 
prospect for the treatment of squamous cell carcinoma of the cervix.  
 
6.3.6. The effect of autophagy inhibition with bafilomycin in combination with 
cisplatin treatment on autophagy in three cervical cell lines.  
Bafilomycin A1 is a macrolide antibiotic isolated from Streptomyces griseus, which is 
able to inhibit V-type H+ -ATPases (vacuolar proton pump) at concentrations as low 
as 10 nM (Bowman et al., 1988) and is able to inhibit cell growth at high 
concentrations (> 10 µM) (Ohkuma et al., 1993). Since this study is based on 
inhibiting autophagy through the impedance of autophagosome-lysosome fusion, a 
non-toxic dose of 10 nM was chosen.  
Ect1/E6E7 
Treatment with bafilomycin did not appear to alter mTOR expression levels in 
Ect1/E6E7 cells (Fig. 6.2.16. A). It may be speculated that the lack of degradation of 
damaged cytoplasmic constituents would result in a positive feedback signal as 
means of further activating mTOR in an attempt to clear these constituents. A study 
conducted by Wang and Miller observed this in fibroblasts after treatment with 
bafilomycin (Wang and Miller, 2012). In the present study, mTOR levels remained 
similar to that of the control. A possible explanation for this is explained in study 
conducted by Ohsaki and colleagues who demonstrated that inactivated mTOR is 
present in the lysosomes, and are subsequently recruited to the 
autophagolysosomes to be degraded, a process that is inhibited by bafilomycin A1 
(Ohsaki et al., 2010). This may explain the reason for the unchanging intracellular 
protein level: lysosomal production is lowered due to bafilomcin A1 treatment, thus 
mTOR cannot be recruited to lysosomes to eventually be degraded through the 
process of autophagy, and therefore accumulates in the cytosol. 
Further downstream, the analysis of p62 protein levels in the bafilomycin A1 treated 
group were similar to that of the control, however in the combination group, p62 
protein levels were decreased in comparison to both the control and bafilomycin 
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group. Since bafilomycin prevents lysosomal biogenesis (Bowman et al., 1988), 
cytoplasmic constituents sequestered by autophagosomes may not be degraded. 
p62 is one such protein that is recruited to the autophagosome (Bjorkoy et al., 2005, 
Pankiv et al., 2007, Bjorkoy et al., 2009), therefore increasing its presence in the 
cytosolic fraction. It is important to keep in mind that bafilomycin A1 does not afford 
complete inhibition of lysosomal production (Fig.6.2.16. D.), therefore the addition of 
cisplatin may promote the utilisation of the available lysosomes, thereby minimally 
degrading p62. 
LC-3 II levels increased significantly in response to treatment with bafilomycin with 
and without cisplatin treatment (Fig. 6.2.16.C). The accumulation of LC-3 II proteins 
was expected after treatment with bafilomycin (Klionsky et al., 2008) and has been 
observed in non-cancerous cells elsewhere (Kawakami et al., 2009, Ding et al., 2010, 
Kimura et al., 2012). Finally, the analysis of lysosomal presence was conducted with 
the use of a Lysotracker ™ through flow cytometry. Both bafilomycin A1 treated 
groups had significantly decreased lysosomal acidity which confirmed vacuolar 
ATPase disruption. 
HeLa 
A significant decrease in mTOR protein expression was observed in the combination 
treatment group (Fig. 6.2.17. A). This may have had a substantial effect on 
autophagic induction since p62 protein levels in the combination group were also 
significantly lower when compared to that of the control (Fig. 6.2.17. B). The addition 
of bafilomycin under control conditions is indicative of the basal autophagic flux and 
indicative for the requirement of autophagy in quality control purposes. But once the 
cell encounters a stressor (i.e. cisplatin), the specific up-regulation in autophagy and 
lysosome production is required. Bafilomycin A1 does not completely inhibit the 
vacuolar ATPase pump (Fig.5.3.17. E.), therefore the degradation of p62 is still able 
to occur. 
If the focus is shifted toward LC-3 II expression (Fig. 5.3.17. D.), it is clear that the 
addition of cisplatin markedly increases both LC-3 I and II expression in the 
combination treatment group. A large and possible lethal accumulation of 
autophagosomes with ‘yet- to- be- degraded’ components are taking up some much 
needed space in the cytosol. Whether this accumulation proves to be lethal or not will 
have to be addressed. 
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Analysis of lysosomal acidity in HeLa cells treated with bafilomycin revealed 
significant decrease in lysosome acidification (Fig. 6.2.17. D). Furthermore, the up-
regulation of lysosomal biogenesis in the presence of cisplatin in the combination 
treatment group increased 0.7 fold. This is contrast to another study which 
determined that the addition of cisplatin to bafilomycin pre-treated renal tubular 
epithelial cells prevented formation of cisplatin induced autophagic lysosomes (Yang 
et al., 2008). Nevertheless, this correlates with p62 data and suggests that even 
though lysosomal production is partially inhibited, HeLa cells are able to attempt to 
discard any cytoplasmic constituents damaged by cisplatin treatment. It was briefly 
mentioned in chapter 4 that lysosomes are utilised by cancer cells as intermediary 
compartments for the storage of cisplatin (Molenaar et al., 2000, Safaei et al., 2005a) 
in order to distribute it to efflux systems, which include vesicles (Eaton, 2002 Safaei, 
2005).  The increase in lysosomal production may be for this reason, or for their use 
in the formation of autophagolysosomes.  
In conclusion, bafilomycin treatment alone significantly and successfully inhibits 
autophagy in HeLa cells. 
CaSki 
mTOR expression in both bafilomycin treated groups decreased significantly (Fig. 
6.2.18. A). Interestingly, a synergistic effect was observed in the combination group 
which exhibited a further decrease in intracellular mTOR levels, therefore the 
presence of cisplatin was likely to play a role in the activation (inhibition) of mTOR. 
Even though this activation is further upstream, its effects are observed in p62 
protein levels downstream in the combination group (Fig. 6.2.18. B), which is 
indicative of p62 degradation and autophagy. Bafilomycin alone had no effect on p62 
protein levels; however treatment with cisplatin seemed to partially disrupt its anti-
autophagic activity and is suggested by a significant decrease in intracellular protein 
levels.  
LC-3 II levels were significantly increased in both bafilomycin treated groups, 
however a synergistic effect due to the addition of cisplatin was not observed (Fig. 
6.2.18. C). A study conducted by Lui and colleagues observed that the addition of 3-
MA prior to cisplatin treatment decreased the conversion of LC-3 I to LC-3 II in 
oesophageal squamous cell carcinoma (Liu et al., 2011), which is in contrast to this 
study. The concentration of cisplatin utilised in the afore mentioned study was 1.5 
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mg, which is especially high, therefore the decrease in the autophagic response may 
be due to apoptosis induction that bypasses autophagy. The results obtained as 
mentioned above which analyse the effect of bafilomycin with cisplatin treatment on 
mTOR protein levels has not been addressed in the literature, thus there is limited 
information to compare these results with.  
The intracellular lysosomal acidic compartment, as mentioned with the use of flow 
cytometry indicates the effectiveness of bafilomycin in inhibiting lysosomal 
biogenesis in CaSki cells, and this effectiveness is maintained after treatment with 
cisplatin (Fig. 6.2.18. D). Due to this, it cannot be deduced that the increase in p62 
degradation is due to the increased presence of lysosomes. 
It may be concluded that bafilomycin as a single treatment agent inhibits mTOR to 
the same extent as cisplatin, but is able to prevent p62 and LC-3 II degradation 
efficiently in CaSki cells. The addition of cisplatin after pre-treatment with bafilomycin 
appears to abolish its anti-autophagy effects. Its subsequent effects on cell death 
induction will be addressed in the following section.  
 
6.3.7. The effect of autophagy inhibition with bafilomycin in combination with 
cisplatin treatment on cell death induction in three cervical cell lines. 
Ect1/E6E7 
The inhibition of autophagy with and without cisplatin had no effect on the MTT 
reductive capacity of Ect1/E6E7 cells (Fig. 6.2.19. A.), thus bafilomycin A1 as a 
single treatment agent does not disturb mitochondrial functioning, and the presence 
of cisplatin equally has no effect. It has been speculated that bafilomycin A1  may 
have an alternative function besides that of inhibiting vacuolar ATPase. In neuronal 
cells it was observed to maintain mitochondrial integrity under autophagic stress 
(Shacka et al., 2006). This may explain the efficient MTT reductive capacity (cell 
viability) observed in these cells in both bafilomycin A1 treated groups. 
Caspase-3 and -7 activity increased 4.49 fold in comparison to the control which is 
indicative of their cleavage and apoptosis induction (Fig. 6.2.19.B). Here, bafilomycin 
A1 pre-treatment enhanced cisplatin-induced caspase activity. This is the first 
indication that Ect1/E6E7 cells induce autophagy as a potential survival mechanism 
Stellenbosch University  http://scholar.sun.ac.za
161 
 
in the face of cisplatin treatment. These results are in agreement with recent studies 
conducted on renal proximal tubule cells (Periyasamy-Thandavan et al., 2008, 
Kaushal et al., 2008, Inoue et al., 2010, Pallet and Anglicheau, 2009, Takahashi et 
al., 2012). 
PARP cleavage levels correspond to caspase activity observed in Figure 6.2.16. B. 
due to the fact that caspase-3 was found to be responsible for the cleavage of PARP  
(Nicholson, Tewari et al., 1995).  Bafilomycin and cisplatin act synergistically to 
produce a 2.35 fold increase in PARP cleavage when compared to the control (Fig. 
6.2.19. C). LDH release increased significantly to about 31% (Fig. 6.2.19. D.), which 
indicates a significant stress response (Keilhoff and Wolf, 1993) in these cells. 
Permeabilisation of the plasma membrane, thus allowing for the inclusion of PI was 
occuring in only 16.92% of the non-cancerous Ect1/E6E7 cells treated with the 
combination of cisplatin and bafilomycin (Fig. 6.2.19.E). 
Minor levels of cell death was observed in these non-cancerous cells which approves 
this method of inducing cell death as appropriate, especially for the purposes of this 
study.  
HeLa 
At the end of the treatment period, HeLa cells were observed to have a slight but 
significant decrease in MTT reductive capacity when treated with the combination of 
bafilomycin A1 and cisplatin, suggesting minor mitochondrial dysfunction (Fig. 6.2.20. 
A). A study conducted by Shingu and colleagues observed that bafilomycin treatment 
alone decreased mitochondrial membrane potential by an insignificant 3.43% 
(Shingu et al., 2009), which suggests that its effects on mitochondria are negligible. 
This result is supported by a study which observed that bafilomycin alone did not 
affect the MTT reductive capacity in glioma and fibrosarcoma cell lines, however the 
combination of bafilomycin and cisplatin reduced this capacity to below 40% of the 
control (Harhaji-Trajkovic et al., 2009). The concentration of cisplatin that was used 
was 50 µM, which as a single agent, reduced the MTT reductive capacity to 50% of 
the control. 
The first indication that HeLa cells require autophagy in order to survive cisplatin 
treatment was observed in Figure 6.2.20.C. Here pre-treatment with bafilomycin and 
subsequent treatment with cisplatin increased PARP cleavage significantly in 
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comparison to the control and the other treatment groups. Bafilomycin improved the 
cytotoxicity of low-dose cisplatin in HeLa cells. There is very little, to no information 
regarding the effects of bafilomycin A1 treatment in particular, and cisplatin treatment 
in inducing PARP cleavage in HeLa cells, thus there these results cannot be 
contextualized with others. However, this is observed with other autophagy inhibtors 
such as 3-MA and chloroquine (discussed below).  
The percentage of LDH release increased by almost 40% in the combination 
treatment group (Fig. 6.2.20.D). In a study conducted by Harhaji-Trajkovic and 
colleagues, bafilomycin treatment alone increased LDH release in mouse 
fibrocarcoma, rat glioma and human glioma cell lines; however the concentration 
used was 10 times higher than the concentration used in this study (Harhaji-Trajkovic 
et al., 2009). This provides further evidence that bafilomycin A1 treatment in this 
study induces low levels of cytotoxicity. More importantly is the percentage of cells 
positive for PI inclusion where bafilomycin A1 and cisplatin acted in a synergistic 
manner to induce cell death (Fig. 6.2.20.E). 
It can be concluded that HeLa cells likely require autophagy in order to survive 
cisplatin treatment and that the up-regulation of autophagy functions as a resistance 
mechanism in these cells. Pre-treatment with bafilomycin, and therefore the inhibition 
of autophagy, sensitises cervical adenocarcinoma cells (HeLa) efficiently to cisplatin 
treatment. The literature agrees with this finding; however the use of bafilomycin 
does not feature prominently in a setting such as this. Instead, autophagy inhibition 
through the use of 3-MA and chloriquine is better documented. A recent study 
observed that the combination of cisplatin (6 μg/ml) with 3-MA or chloriquine 
enhanced cisplatin cytotoxicity in HeLa cells (Xu et al., 2012b). Similarly, efficient cell 
death was observed in metastatic skin carcinoma when autophagy was inhibited with 
3-MA and subsequently treated with 20 μg/ml cisplatin (Claerhout et al., 2010). 
Hepatocarcinoma cells underwent efficient cell death in response to combination 
treatment with 3-MA and 8 μg/ml cisplatin (Guo et al., 2012). Indeed, these studies 
have found success in inducing cell death through the inhibition of autophagy, 
however the concentrations of cisplatin used in each study are based on the IC50 and 
are therefore already toxic to the cancer cells. In contrast, it has been demonstrated 
in the present study that the inhibition of autophagy is sufficient to enhance the 
cytotoxicity of a low, non-toxic dose of cisplatin in HeLa cells.  
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CaSki 
The effect of the combination of bafilomycin and cisplatin treatment was effective in 
decreasing CaSki cell viability (Fig. 6.2.21. A). An additive effect was observed which 
decreased cell viability by almost 50%. The success of this result is highlighted by a 
study where bafilomycin pre-treatment with subsequent addition of 50 µM cisplatin 
(IC50) reduced MTT to just below 40% of the control (Harhaji-Trajkovic et al., 2009). 
This concentration is over 3 times that of the concentration used in this study and as 
a single agent induces a decrease of 50% in the MTT reductive capacity. This in turn 
was associated with an increase in caspase -3 and -7 activity and cleavage was 
observed (Fig. 6.2.21. B and C). As with the HeLa cells, this result indicates a 
reliance of the CaSki cells on autophagy as a mechanism of survival in the face of 
cisplatin treatment. 
LDH release increased by 35.58% and the percentage of cells positive for PI 
increased by 31.83%.(Fig. 6.2.21. E. and F).   Taken together, the above results 
suggest strongly that pre-treatment with an autophagy inhibitor effectively sensitises 
the aggressive CaSki cells to a low concentration of cisplatin treatment. 
 
6.3.8. The effect of bafilomycin and cisplatin treatment on modulation of the 
cell cycle. 
Ect1/E6E7 
Ect1/E6E7 cells do not appear to be affected by the combination treatment and 
continue to grow normally (Fig. 6.2.22). 
HeLa 
The response of HeLa cells to cisplatin exhibit the characteristic shift from G1/G0 into 
the S phase that is commonly observed after cisplatin treatment (Qin and Ng, 2002, 
Sorenson and Eastman, 1988b, Shah and Schwartz, 2001). Interestingly, even 
though apoptosis was observed when HeLa cells were treated with the combination 
of bafilomycin and cisplatin, no significant shifts between the cell cycle phases was 
observed (Fig.6.2.23). The distribution of cells between the phases in the 
combination group resemble those in the cisplatin treatment group, thus this is likely 
due to cisplatin treatment alone. This lack of arrest is not beneficial to cancer cells 
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due to the fact that they utilise this mechanism to their advantage in order to repair 
any damage that may have been incurred during treatment (Shah and Schwartz, 
2001). 
CaSki 
Cell cycle analysis of the aggressive CaSki cells did not exhibit any change of the cell 
cycle, even though apoptosis was actively occurring (6.2.24.). This is a promising 
result as arrests, particularly in the S phase result in a 2-fold decrease in sensitivity to 
cisplatin (Donaldson et al., 2006) and may induce resistance against apoptosis 
(Mueller et al., 2006). 
 
6.3.9. The effect of the combination of ATG5 silencing and cisplatin treatment 
on autophagic induction in three cervical cell lines. 
Bafilomycin is known as an inhibitor of autophagy (Yamamoto et al., 1998, Klionsky 
et al., 2008), however it blocks autophagy far downstream and therefore still allows 
for the initial molecular aspects to occur. Biological inhibition of autophagy using 
ATG5 siRNA may therefore be better suited as a method of inhibition as it has a 
specific target and prevents the maturation of autophagosome (Mizushima et al., 
1998). Hence, ATG5 silencing will be adressed in the following chapter.  
Ect1/E6E7 
Silencing of ATG 5 inhibited autophagy in Ect1/E6E7 cells as demonstrated in Figure 
6.2.25. The lack of p62 degradation is observed in both groups where ATG5 was 
silenced, indicating that autophagasome maturation was (partially) disrupted. Similar 
results were observed in primary human keratinocytes, a cell line very similar to 
Ect1/E6E7 cells; however shRNA ATG5 were used instead (Lee et al., 2011). ATG 5 
silencing was also observed to increase p62 protein levels in baby mouse kidney 
cells (Mathew et al., 2009). These results support the afore mentioned findings in the 
Ect1/E6E7 cells and confirm the autophagy inhibitory effect of ATG5 siRNA in non-
cancerous cell lines. LC-3 II expression was as expected: silencing alone did not 
alter LC-3 II expression when compared to that of the control; however, the addition 
of cisplatin induced a slight increase in its expression (Fig. 6.2.25. C). Collectively 
these results confirm the inhibition of autophagy this in vitro model of non-cancerous 
Ect1/E6E7 cells with the use of ATG5 siRNA. 
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HeLa 
The effect of the silencing of ATG 5 on HeLa cells prevented the degradation of p62, 
as observed by the increase in the intracellular protein levels in both silencing groups 
(Fig. 6.2.26.. B). LC-3 II protein levels remained low in the silenced group that had 
not been treated with cisplatin (Fig. 6.2.26.. C). Unexpectedly, the addition of 
cisplatin induced an increase in autophagosome production (Fig. 6.2.26.. C). It is 
important to mention that silencing only partially inhibits the translation of mRNA into 
protein, therefore a small amount of translation is still able to occur. This may explain 
the increase in autophagosomal production in the combination group.  
CaSki 
The inhibition of ATG5 prevented the degradation of p62 significantly and is 
indicative of decreased autophagosome production and function (Fig. 6.2.27.. B).  
 
6.3.10. The effect of ATG5 silencing combined with cisplatin treatment on 
apoptotic induction in three cervical cell lines. 
Ect1/E6E7 
Cell viability (MTT) was reduced in the Ect1/E6E7 cells in the combination group (Fig. 
6.2.28.A). A study on the effect of ATG 5 silencing and cisplatin treatment 
demonstrated a significant increase in caspase -3 activity in renal tubule epithelial 
cells (Yang et al., 2008). This may be comparable to this result on the one hand, but 
on the other hand, the concentration of cisplatin utilised was 50 µM, more than three 
times the concentration that was used in the present study. LDH release was 
significantly elevated in the combination group and it is clear here that the addition of 
cisplatin played a role in this stress induced response (Fig. 6.2.28.C).  
Overall, the results obtained with biological inhibition of autophagy compared to 
those obtained with pharmacological inhibition are relatively similar. More importantly 
however, the effect on cell death in this non-cancerous cell line is very limited. It may 
be argued that the low concentration of cisplatin chosen (15 µM) may have 
contributed to this positive result. A gap in the literature has now been addressed 
since it has been demonstrated here for the first time that this particular treatment 
protocol has very little effect on the integrity of a non-cancerous cell type.  
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HeLa 
The effects of autophagy inhibition with the use of ATG 5 siRNA plus cisplatin 
decreased MTT reductive capacity in HeLa cells by almost 56% (Fig. 6.2.29. A) 
compared to a 14.5% decrease with the use of bafilomycin and cisplatin (Fig. 
6.2.5.A). Interestingly, caspase -3 and -7 activity increased significantly in response 
to biological inhibition of autophagy with cisplatin treatment (Fig. 6.2.29. B). If this 
result is compared to the effect of the pharmacological agent bafilomycin, effector 
caspase activity was comparable to that of the control (Fig. 6.2.5. B).  
The biological inhibition of autophagy with the use of ATG5 markedly improved 
cisplatin cytotoxicity in HeLa cells and underlines the importance of the caution one 
should be reminded of when using chemical agents. The effect observed with the use 
of these agents should be verified with the appropriate siRNA or shRNA.  
CaSki 
The converse was observed in CaSki cells after the analysis of cell viability (MTT): 
only a 26% decrease in reductive capacity was observed with the use of biological 
autophagy inhibition in conjunction with cisplatin treatment, compared to 49% 
decrease in MTT reductive capacity with the use of bafilomycin as an autophagy 
inhibitor (Fig. 6.2.30. A).  
Caspase activity increased and was detectable through Western blotting, which 
indicates the effectiveness of this method in inducing apoptosis. Additionally, 
silencing of ATG5 alone induced a significant increase in caspase-3 cleavage. PARP 
cleavage was equally high (Fig. 6.2.30. D) in the combination group LDH release 
increased to 61% in comparison to 35% after treatment with bafilomycin and 
cisplatin. 
It may therefore be concluded that autophagy is utilised by these cervical cancer 
cells as a survival mechanism after treatment with a low concentration of cisplatin 
and efficient apoptotic cell death is induced in both cancerous cell lines whether 
autophagy is inhibited pharmacologicaly or biologically. Furthermore, the effects of 
cell death on the non-cancerous cell line is minimal, and therefore proves to be an 
effective method for the treatment of cervical cancer 
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7  
The Role of Bcl-2 in Cisplatin Treatment in Cervical Cancer Cells. 
7.1. Introduction and Aims 
The interaction between Beclin-1 and Bcl-2 proteins is an important point of 
convergence between the autophagic and apoptotic pathways respectively. Due to 
the functional interaction between Bcl-2 and Beclin-1 and its role in the regulation 
autophagy, ratio analysis of Beclin-1 to Bcl-2 as means of detecting the role of 
autophagy within the cell under homeostatic and treatment/stress conditions is 
recommended (Pattingre and Levine, 2006a). Additionally, Bcl-2 has a prominent role 
in the malignant cell and has been found to confer resistance in a variety of 
cancerous cell lines (Campos et al., 1993, Cho et al., 2006, Michaud et al., 2009, 
Miyashita and Reed, 1993). The response of Bcl-2 to a low concentration of cisplatin 
and its effect on preventing apoptosis in cervical cancer cells has not yet been 
assessed.  
Therefore, the aims of this chapter are i) to evaluate the basal levels of Bcl-2 and 
Beclin-1 in HeLa and CaSki cell lines, ii) to determine the relationship (ratio) between 
Beclin-1 and Bcl-2 under control conditions and in response to cisplatin treatment to 
determine whether their interaction may indicate cellular resistance, and finally iii) to 
silence Bcl-2 to further define its role during cisplatin treatment.  
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7.2. Results 
7.2.1. The Beclin-1 and Bcl-2 expression levels under basal (NT) as well as 
cisplatin treated (T) conditions in HeLa and CaSki cells. 
  
Figure 7.2.1. Densitometric analysis of Beclin-1 and Bcl-2 protein levels in non- treated (NT) and 
treated (T) HeLa and CaSki cells as obtained through densitometric analysis of Western blots. Bcl-2 
and Beclin-1 protein levels in HeLa and CaSki cells were analysed for changes in expression after the 
addition of 15 μM cisplatin for a period of 24 h. Analysis within each cell line: *p<0.05 vs. Beclin-1 T (HeLa), ** 
p < 0.01 vs. Beclin-1 NT (CaSki), # p < 0.001 vs. Beclin-1 T (CaSki), $ p < 0.001 vs. Bcl-2 NT (CaSki) and δ p 
< 0.05 vs. Beclin-1 NT (CaSki), analysis between cell lines: * p < 0.05, *** p < 0.001, n = 3. 
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Bcl-2 and Beclin-1 protein expression levels were analysed before (NT) and after (T) 
treatment with cisplatin for a period of 24 h (Fig. 7.2.1. A). After treatment with 
cisplatin, Bcl-2 protein levels increased significantly in HeLa cells (7648 ± 183.40 * p 
< 0.05 vs. Beclin-1 T (HeLa). At basal levels, Bcl-2 protein expression was 
significantly lower than Beclin-1 protein levels in CaSki cells (2314 ± 122.80 ** p < 
0.01 vs. Beclin-1 NT (CaSki). The addition of cisplatin (T) induced a significant 
increase in Beclin-1 and Bcl-2 protein levels in CaSki cells (7656 ± 353.80 vs. Beclin-
1 NT (CaSki), δ p < 0.05, 13673 ± 590.1, # p < 0.001 vs.Bcl-2 NT (CaSki) and $ p < 
0.001 vs. Beclin-1 T (CaSki). 
Comparisons between the two cervical cancer cell lines revealed that Bcl-2 and 
Beclin-1 protein expression in CaSki cells significantly increased in response to 
cisplatin treatment when compared to the treated HeLa cells (7656 ± 353.80 vs. 
Beclin-1 T (HeLa), * p < 0.05 and 13673 ± 590.10 vs. Bcl-2 (T) HeLa, *** p < 0.001). 
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7.2.2. The Beclin-1/Bcl-2 ratio in the response to cisplatin treatment in HeLa 
and CaSki cells.  
 
  
A. 
Stellenbosch University  http://scholar.sun.ac.za
171 
 
 
 
 
 
 
  
Figure 7.2.2. Analysis of Beclin-1 and Bcl-2 protein levels under basal conditions as well as in response to 
cisplatin treatment (15 µM; 24 h). A. Analysis of the Beclin-1/Bcl-2 ratio in HeLa and CaSki cells not treated (NT) 
or treated (T) with 15 µM cisplatin for 24 h, * p < 0.05 and *** p < 0.001 vs. HeLa NT, # p < 0.01 vs. NT (CaSki), n = 
4. B. Representative immunofluorescent images of HeLa and CaSki cells depicting expression of Bcl-2 and Beclin-
1 under basal conditions (NT) and in response to cisplatin treatment (T). Blue- Hoechst 33342, green- Bcl-2 and 
red- Beclin-1. Scale bar = 20 µm, n = 3. 
B. 
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Analysis of the Beclin-1/Bcl-2 ratio reveals that HeLa cells treated with cisplatin 
display a significant decrease in the Beclin-1/Bcl-2 ratio in comparison to the HeLa 
control cells (NT) (0.59 ± 0.05 vs. HeLa (NT), *** p < 0.001, Fig. 7.2.2. A.). CaSki 
cells exhibit a significantly higher ratio at basal levels in comparison to the HeLa cells 
(3.4 ± 0.80 vs. HeLa NT, * p < 0.05) After treatment, the ratio decreases significantly 
in comparison to the CaSki control cells (NT) 0.53 ± 0.05 vs. CaSki NT. # p < 0.01). 
The presence of Beclin-1 and Bcl-2 proteins was analysed with the use of 
immunofluorescence with and without the addition of cisplatin (Fig. 7.2.2. B.). Images 
represent Beclin-1 and Bcl-2 expression determined through Western blotting in 
Figure 7.2.2. A. Both figures indicate an increase in Beclin-1 and Bcl-2 protein 
expression increases in response to cisplatin treatment. 
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7.2.3. The effect of Bcl-2 silencing in HeLa and CaSki cells on intracellular 
Beclin-1 protein levels.  
 
  
A. 
Figure 7.2.3. Silencing of Bcl-2 in HeLa and CaSki cells and resulting expression levels of Beclin-1. A. 
and B. Silencing of Bcl-2 confirmed through Western blotting, *** p < 0.001, n = 3. C. Beclin-1 protein 
expression in HeLa cells, ** p < 0.01, *** p < 0.001 vs. Sc. seq. (control), # p < 0.01 and $ p < 0.001 vs. 
cisplatin and δ p < 0.05 vs. Bcl-2 siRNA, n=3. D. Beclin-1 protein expression in CaSki cells, * p < 0.05, ** p < 
0.01 vs. Sc. seq. (control) and # p < 0.05 vs. cisplatin, n=3. 
B. 
C. D. 
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Silencing of Bcl-2 was confirmed through the Western blotting technique in both 
HeLa (0.22 ± 0.09 vs. sc. seq., *** p < 0.001) and CaSki cells (0.17 ± 0.02 vs. sc. 
seq., p < 0.001, Fig. 7.2.3. A. and B.).  Due to the important relationship between 
Beclin-1 and Bcl-2, it was necessary to assess Beclin-1 protein levels in response to 
Bcl-2 silencing with and without cisplatin treatment (Fig. 7.2.3. C. and D.). Beclin-1 
protein levels increased significantly in both treatment groups where Bcl-2 was 
silenced in HeLa cells (5.72 ± 0.12 vs. control, * p < 0.01 and cisplatin # p < 0.01; 
7.86 ± 0.52 vs. control, *** p < 0.001, # p < 0.01 vs. cisplatin and δ p < 0.05 vs. Bcl-2 
siRNA). A similar observation was made with the CaSki cells, however cisplatin 
treatment alone increased Beclin-1 expression significantly (1.58 ± 0.11 vs. control, * 
p < 0.05). A significant increase was also observed in both groups where Bcl-2 was 
silenced (2.39 ± 0.14 vs. control, * p < 0.05 and # p < 0.05 vs. cisplatin; 2.44 ± 0.20 
vs. control, p < 0.01).  
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7.2.4. The Beclin-1/Bcl-2 ratio in HeLa and CaSki cell lines after Bcl-2 silencing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2.4. The Bcl-2/Beclin-1 ratio increases in HeLa and CaSki cells after the 
silencing of Bcl-2. Ratios were determined according to densitometric analysis of Beclin-1 
and Bcl-2. * p < 0.05 and ** p < 0.01 vs. sc. Seq. HeLa; α p < 0.05 and $ p < 0.001 vs. sc. 
Seq. CaSki; δ p < 0.05 vs. Bcl-2 siRNA CaSki; # p < 0.01 vs. Bcl-2 + cisplatin HeLa, n = 3. Sc. 
Seq. = scrambled sequence (control), AU = arbitrary units. 
α 
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The Beclin-1/Bcl-2 ratio was assessed after silencing of Bcl-2 in HeLa and CaSki 
cells (Fig.7.2.4.). The ratio increased significantly in both silencing groups in HeLa 
cells (6.23 ± 0.64 and 6.97 ± 1.27 vs. sc. seq. HeLa, * p < 0.05 and ** p < 0.01). The 
silencing of Bcl-2 in CaSki cells increased the Beclin-1/Bcl-2 ratio significantly in 
comparison the scrambled sequence (7.00 ± 0.80 vs. sc. seq. CaSki, α p < 0.05). 
The addition of cisplatin in this group increased the ratio significantly in comparison 
to the scrambled sequence (13.25 ± 1.15 vs. sc. seq. CaSki, $ p < 0.001), Bcl-2 
siRNA (13.25 ± 1.15 vs. Bcl-2 siRNA CaSki, δ p < 0.05) and in comparison to Bcl-2 
siRNA + cisplatin ratio in HeLa cells (13.25 ± 1.15 vs. Bcl-2 siRNA + cisplatin HeLa,  
# p < 0.01).  
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7.2.5. The effect of Bcl-2 silencing on apoptosis during cisplatin treatment in 
cervical cancer cells. 
  
Figure 7.2.5. The effect of Bcl-2 silencing on apoptosis during cisplatin treatment in cervical cancer 
cells. A. Caspase -3/-7 activity, ** p < 0.01 vs. sc. seq. # p < 0.01 vs. cisplatin and $ p < 0.01 vs. Bcl-2 siRNA, 
n = 4. B. PARP cleavage levels, ** p < 0.01 vs. sc. seq., # p < 0.001 vs. cisplatin and $ p < 0.01 vs. Bcl-2 
siRNA, n = 3. C. Caspase -3/-7, * p < 0.05 vs. sc.seq. and # p < 0.05 vs. cisplatin, n = 3. D. PARP cleavage, ** 
p < 0.01 vs. sc.seq., # p < 0.01 vs. cisplatin and $ p < 0.01 vs. Bcl-2 siRNA, n = 3. Sc. seq. – scrambled 
sequence (control), AU – arbitrary units. 
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Effector caspase activity was analysed as a marker of apoptosis which revealed that 
the silencing of Bcl-2 significantly increased cisplatin-induced caspase activation in 
HeLa cells (2.24 ± 0.13 vs. sc. seq., ** p < 0.01, vs. cisplatin, # p < 0.01, vs. Bcl-2 
siRNA, $ p < 0.01, Fig. 7.2.5. A). Equally, the silencing of Bcl-2 significantly 
increased cisplatin-induced PARP cleavage in HeLa cells (3.11 ± 0.17 vs. sc. seq., ** 
p < 0.01, vs. cisplatin # p < 0.001, vs. Bcl-2 siRNA, $ p < 0.01, Fig. 7.2.5. B).  
CaSki cells exhibited a similar response to Bcl-2 silencing with cisplatin treatment: 
Effector caspase activity increased significantly after Bcl-2 was silenced and cells 
were treated with cisplatin (8.17 ± 2.17 vs. sc. seq., * p < 0.05, vs. cisplatin, # p < 
0.05, Fig, 7.2.5. C.). PARP cleavage increased concomitantly in this groups in 
addition to caspase activation (5.75 ± 0.55 vs. sc. seq., ** p < 0.01 vs. sc.seq., vs. 
cisplatin, # p < 0.01, vs. Bcl-2 siRNA, $ p < 0.01. 
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7.2.6. Comparison of caspase-3/-7 activity and PARP cleavage between HeLa 
and CaSki cells in response to Bcl-2 silencing with cisplatin treatment. 
 
CaSki cells exhibit significantly higher effector caspase activity in comparison to 
HeLa cells after the combination of Bcl-2 silencing and cisplatin treatment (9.95 ± 
2.15, * p < 0.05 vs. HeLa). The comparison of PARP cleavage between the two cell 
lines reveal significantly increased protein levels in CaSki cells (5.75 ± 0.55, * p < 
0.05 vs. HeLa). 
 
  
Figure 7.2.6. Comparison of caspase-3/-7 activity and PARP cleavage between HeLa and 
CaSki cells after Bcl-2 silencing with cisplatin treatment (15 µM, 24 h). A. Caspase activity, 
*p<0.05 vs. HeLa. B. PARP cleavage, * p < 0.05 vs. HeLa. AU- arbitrary units. 
A. B. 
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7.3. Discussion 
The role of Bcl-2 in response to a low concentration of cisplatin treatment in cervical 
cancer cells remains poorly understood, and since its effects on inducing cisplatin 
resistance may be involved, it is necessary to dissect the role of the anti-apoptotic 
protein, Bcl-2 in cisplatin resistance in HeLa and CaSki cells. It was demonstrated in 
previous chapters that at this particular dose and time point (15 μM; 24 h), no 
significant cell death occurred (Chapter 4.1), however, an autophagic response was 
induced (Chapter 4.2). Furthermore it was established that this autophagic response 
promoted the survival of cervical cancer cells during cisplatin treatment (Chapter 5). 
Even though the response to cisplatin-induced autophagy is Beclin-1 dependant (I.e. 
an increase is Beclin-1 was observed), intracellular protein levels of Bcl-2 were also 
observed to increase. This seems paradoxical considering the current understanding 
of the interaction between Beclin-1 and Bcl-2 (Pattingre et al., 2005). This suggests 
that an increased expression of Bcl-2, along with increased autophagy may play a 
role in conferring these cervical cancer cells resistant to cisplatin treatment. 
Bcl-2 and Beclin-1 protein expression levels were analysed under control conditions, 
as well as after a 24 h treatment period with 15 μM cisplatin (Fig. 7.1.). In HeLa cells 
the protein expression levels of Bcl-2 and Beclin-1 were found to be similar at basal 
levels, however after cisplatin treatment, Bcl-2 protein levels increased significantly, 
and Beclin-1 levels remained unchanged. In CaSki cells a significant decrease in Bcl-
2 protein levels was observed before treatment, which increased significantly after 
treatment with cisplatin. Basal levels of Bcl-2 have previously been demonstrated to 
serve as an indicator of resistance to chemotherapy: higher basal Bcl-2 levels in 
colon cancer cells have been shown to be indicative of increased resistance to 5-
flouracil (Violette et al., 2002). This is not the case between HeLa and CaSki cell 
lines since the basal Bcl-2 levels tend toward a decrease in CaSki cells at the 
homeostatic state in comparison to the HeLa cells (P = 0.07), however they are more 
resistant to cisplatin treatment. The increased response of Bcl-2 to cisplatin treatment 
in both cell lines is in contrast to a study which demonstrated that over time, Bcl-2 
protein levels decrease in HeLa cells in response to 40 μM of cisplatin (Maldonado et 
al., 1997). A possible explanation for decreased Bcl-2 protein levels in their study 
may be attributed to the fact that such a high concentration of cisplatin might directly 
induce apoptosis and counteract any form a resistance which is normally employed 
to attempt cellular survival. The use of a concentration similar to the one used in the 
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present study (4.5 μg/ml or 15 μM) revealed that after 24 h of treatment with 10 μM 
cisplatin, Bcl-2 expression levels did not change, however its over-expression with a 
vector containing full-length Bcl-2 was able to suppress cisplatin-induced apoptosis in 
rat neuroblastoma cells (Park et al., 2001). In bladder cancer cells however, a slight 
increase in Bcl-2 was observed after treatment with 10 μg/ml of cisplatin for a 24 h 
time period (Cho et al., 2006) which agrees with our results (Figure 7.1.). Moreover, a 
study demonstrated that intracellular glutathione levels are regulated partly by Bcl-2 
and confer resistance of MCF-7 breast cancer cells to cisplatin treatment. 
Additionally it was observed that at low concentrations, Bcl-2 was able to induce 
resistance even in the presence of BSO which is an inhibitor of the rate-limiting 
enzyme responsible for glutathione synthesis (Rudin et al., 2003). These studies 
point to a probable role for Bcl-2 as a mechanism of resistance to cisplatin in HeLa 
and CaSki cells at low-concentrations of cisplatin. To our knowledge, the increased 
expression of Bcl-2 in CaSki cells after treatment with a low-concentration of cisplatin 
has not been documented before. Our data strongly suggest that at this 
concentration, cervical cancer cells up-regulate Bcl-2 as a mechanism by which the 
cells survive cisplatin treatment. Referring back to chapter 4 where both HeLa and 
CaSki cells induced autophagy in response to cisplatin treatment, and considering 
the relationship between Beclin-1 and Bcl-2 on autophagy (Pattingre et al., 2005), it 
may indicate that Beclin-1 and Bcl-2 are acting independently of another: Beclin-1 as 
a pro-autophagy protein, and Bcl-2 as an anti-apoptotic protein. It is likely that when 
forming a complex, the above mentioned functions are still maintained. In support of 
this notion, it was observed that Bcl-2 was still able to exert its anti-apoptotic function 
even while being bound to Beclin-1 (Ciechomska et al., 2009). Co-
immunoprecipitation is required for future studies in order to validate this claim. 
Due to the importance of the functional interaction between Bcl-2 and Beclin-1 and its 
role in the regulation autophagy, ratio analysis of Beclin-1 to Bcl-2 as means of 
detecting the role of autophagy within the cell under homeostatic and 
treatment/stress conditions is recommended (Pattingre and Levine, 2006a). Our data 
indicate that the Beclin-1/Bcl-2 ratio is significantly higher in the CaSki cells when 
compared to the HeLa cells at basal levels (Fig. 7.2.2. A.). This is indicative of an 
increased basal autophagic activity (Pattingre et al., 2005), which agrees with results 
obtained in Chapter 4.2., where basal levels of CaSki cells exhibited increased LC-3 
II protein levels (Fig. 4.6.). After cisplatin treatment, this ratio decreased significantly 
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in both cervical cancer cell lines, which may indicate a decrease in autophagic 
activity. This is contrast to other autophagic markers that were analysed which 
demonstrated that cisplatin treatment alone is sufficient to induce autophagy (chapter 
4). Both Beclin-1 and Bcl-2 protein levels increased (Fig.7.2.1.). Bcl-2 may therefore 
play an alternative role at this particular cisplatin concentration in cervical cancer 
cells, one which is independent of Beclin-1 interaction, and therefore autophagic 
control.  
Qualitative images depicting Bcl-2 and Beclin-1 expression levels in non-treated (NT) 
and treated (T) cells confirm data generated through western blot analyses of the 
expression levels of the individual proteins, however, treatment with cisplatin was 
observed to induce the accumulation of Bcl-2 in the nuclei of both HeLa and CaSki 
cells (Fig.7.2.2. B). This may be indicative of apoptosis, since its nuclear 
translocation may prevent it from exerting its anti-apoptotic effects, i.e. complexing 
with bax at the mitochondrial membrane. A similar response was observed in 
neuronal nuclei of cells that were damaged through hypoxia-ischaemia (Zhu et al., 
2010), which suggests that nuclear translocation occurs in cells which are 
undergoing cell death. This reiterates the notion that in this in vitro model, Bcl-2 and 
Beclin-1 work independently. 
In order to further elucidate this potential independent role of Bcl-2, silencing was 
performed. Bcl-2 was efficiently silenced in both HeLa and CaSki cells (Fig. 7.2.3. A. 
and B.), after which Beclin-1 expression was assessed. In HeLa cells, Beclin-1 
expression was significantly elevated in both silencing groups, and the addition of 
cisplatin synergistically elevated this expression when compared to the silencing of 
Bcl-2 alone (Fig. 7.2.3. C.). A similar result was observed in the CaSki cells where 
silencing of Bcl-2 induced an up-regulation in Beclin-1 expression, however in this 
case, the addition of cisplatin after Bcl-2 silencing had no additional effect on 
increasing Beclin-1 protein levels (Fig. 7.2.3. D.). These results infer that Bcl-2 does 
control Beclin-1 expression to a certain extent (i.e. bound to Beclin-1), particularly in 
response to cisplatin treatment in HeLa cells, i.e. cisplatin treatment alone did not 
substantially increase Beclin-1 as observed when Bcl-2 was silenced. Nevertheless, 
silencing of Bcl-2 up-regulated Beclin-1 expression in both cervical cancer cell lines 
which agrees with a study that Bcl-2 silenced  MCF-7 breast cancer cells increased 
Beclin-1 expression, and after 72 h resulted in autophagic cell death (Akar et al., 
2008). 
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The above results prompted the re-analysis of the Beclin-1/Bcl-2 ratio in the context 
of Bcl-2 silencing (Fig. 7.2.4.). The ratio increased significantly in both cell lines with 
and without the treatment of cisplatin. However in CaSki cells, the addition of 
cisplatin exhibited a synergistic effect in increasing this ratio. In order to interpret the 
above results to make a distinction between autophagy acting as a survival 
mechanism and autophagy as a mechanism of cell death, Beclin-1 expression is 
required to be elevated for the latter to occur (Shimizu et al., 2004). This observation 
is similar to our findings where a significant increase in Beclin-1 protein levels, as 
well as Beclin-1/Bcl-2 ratios were observed in HeLa and CaSki cells after silencing of 
Bcl-2 with and without additional treatment with cisplatin.  
Analysis of apoptotic death markers suggests a role of Bcl-2 as a mechanism which 
delays the onset of apoptosis, thereby conferring resistance to cisplatin treatment. 
Both HeLa and CaSki cells displayed increased caspase -3/-7 activity in response to 
the combination of Bcl-2 silencing and cisplatin treatment (Fig. 7.2.3. A and C.). 
Equally indicative of cell death induction was a significant increase in PARP cleavage 
in both cell lines (Fig. 7.2.3. B. and D.). Since the up-regulation of Bcl-2 in response 
to cisplatin was significantly higher than that of the HeLa cells (Fig. 7.1.), it may be 
argued that their ability to resist the intracellular effects of cisplatin is particularly 
dependent on the up-regulation of Bcl-2. Figure 7.2.6. demonstrates that the 
silencing of Bcl-2 sensitises CaSki cells to cisplatin-induced apoptosis to a much 
greater extent than in the HeLa cells.  
Taken together, the results obtained on the Beclin-1/Bcl-2 ratio after silencing, as 
well as PARP cleavage and caspase activity, cell death with autophagy (Galluzzi et 
al., 2009, Levine and Yuan, 2005) may be occurring in this in vitro model, as the 
presence of apoptosis is evident. Silencing of Bcl-2 improved sensitivity to cisplatin 
treatment in bladder cancer cells (Cho et al., 2006), melanoma cells (Wacheck et al., 
2003), ovarian cancer cells (Wang et al., 2009), non-small lung cancer cells (Losert 
et al., 2007) and lung adenocarcinoma cells (Huang et al., 2007), however its effect 
on cervical cancer cells using a low concentration of cisplatin has not been 
addressed in the literature. 
In summary, we demonstrate that in cervical cancer cells, Bcl-2 is up-regulated as a 
potential means of providing partial resistance against a low concentration of cisplatin 
treatment. Silencing of Bcl-2 is able to greatly improve cisplatin sensitivity in both cell 
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lines, particularly in the aggressive CaSki cells. Furthermore, we have demonstrated 
that the exaggerated up-regulation of Bcl-2 by CaSki cells in response to cisplatin 
treatment is likely to contribute to (in combination with autophagy) the aggressive, 
metastatic nature of this cell type. Therefore, our results confirm another ‘side-effect’ 
of cisplatin treatment, i.e. dependence on Bcl-2 expression for cellular survival. This 
method, in combination with autophagy inhibition as pre-treatments is a promising 
method to greatly improve the chemotherapeutic value of a low concentration of 
cisplatin in a cervical cancer setting in vitro, and is recommended as a future study. 
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8  
The Expression Profile of Bcl-2, mTOR and LC-3 in the Various Stages of 
Cervical Cancer Development.  
8.1. Introduction and Aims 
Due to the fact that cervical cancer is characterised by a well-defined pre-malignant 
phase (Ambros and Kurman, 1990) without an immediate onset that commonly 
occurs with other cancers, it offers an opportunity for the assessment of molecular 
changes that may occur during the transformation phase.  
Due to the role of autophagy and apoptosis in cancer, the aim of this chapter is to 
assess the expression profiles of mTOR and LC-3 and one anti-apoptotic marker 
(Bcl-2) during the various stages of tissue transformation as this has not been 
addressed in the literature. 
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8.2. Results 
8.2.1. The mTOR expression profile in normal, low-grade and high-grade 
squamous intraepithelial lesion tissue and cancerous cervical tissue. 
 
 
 
 
 
 
 
 
Figure 8.2.1.A. The mTOR expression profile in normal, low-grade and high-grade squamous 
intraepithelial lesions and cervical carcinoma tissue in cervix. Representative Western blot, 
***p<0.001, ** p < 0.01 vs. normal, # p < 0.001 vs. LSIL, $ p < 0.001 vs. HSIL. Statistical analysis: 
ANOVA and Bonferroni correction. All results expressed as mean ± SEM, Normal: n=10, LSIL: n=29, 
HSIL: n=33, CA: n=13. LSIL: low-grade squamous intraepithelial lesion, HSIL: high-grade squamous 
intraepithelial lesion, CA: carcinoma. 
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B. 
Figure 8.2.1.B. Immunohistochemistry of mTOR (red) in normal, LSIL, HSIL and CA. 
Representative images of mTOR expression profiles in normal (n=4), LSIL (n=6), HSIL (n=8) and 
cervical carcinogenesis (n=5), scale bar: 20 µm. LSIL – low-grade squamous cervical carcinoma, HSIL 
– high-grade squamous cervical carcinoma, CA- carcinoma. 
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mTOR protein expression was significantly increased in low-grade squamous 
intraepithelial lesions (LSIL) in comparison to the normal cervical tissue (3.52 ± 0.71 
vs. normal, *** p < 0.001). In cervical carcinoma tissue. mTOR expression was 
significantly increased in comparison to the normal cervical tissue (2.39 ± 0.29 vs. 
normal, ** p < 0.01 vs. normal) and high-grade squamous intraepithelial lesion (HSIL) 
tissue (2.39 ± 0.29 vs. HSIL, $ p < 0.001). HSIL cervical tissue had significantly 
decreased expression levels of mTOR in comparison to the LSIL cervical tissue (0.81 
± 0.24 vs. LSIL, # p < 0.001, Fig. 8.2.1. A). 
The expression of mTOR was assessed with the use of immunohistochemistry on 
tissue sections that are representative of each stage the progression towards cervical 
cancer development. Fluorescent images suggest an increase in mTOR expression 
in LSIL (Fig. 8.2.1. B). 
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8.2.2. The Bcl-2 expression profile in normal, low-grade and high-grade 
squamous intraepithelial lesion tissue and cancerous cervical tissue. 
 
  
Figure 8.2.2.A. The Bcl-2 expression profile in normal, low-grade and high-grade squamous 
intraepithelial lesions and cervical carcinoma tissue in cervix. Representative Western blot, * p < 
0.05 vs. normal, # p < 0.001 vs. LSIL, $ p < 0.05 vs. HSIL. Statistical analysis: ANOVA and Bonferroni 
correction. All results expressed as mean ± SEM, normal (n=4), LSIL (n=6), HSIL (n=8) and cervical 
carcinogenesis (n=5). LSIL: low-grade squamous intraepithelial lesion, HSIL: high-grade squamous 
intraepithelial lesion, CA: carcinoma. 
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Figure 8.2.2. B. Immunohistochemistry of Bcl-2 (green) in normal, LSIL, HSIL and CA. 
Representative images of  Bcl-2 expression profiles in normal, LSIL, HSIL and cervical carcinogenesis, 
scale bar: 20 µm. LSIL – low-grade squamous cervical carcinoma, HSIL – high-grade squamous 
cervical carcinoma, CA- carcinoma. 
B. 
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Bcl-2 expression was significantly increased in cervical carcinoma tissue in 
comparison to normal tissue (1.62 ± 0.16 vs. normal, * p < 0.05), LSIL tissue (1.62 ± 
0.16 vs. LSIL, # p < 0.001) and HSIL tissue (1.62 ± 0.16 vs. HSIL, $ p < 0.01, Fig. 
8.2.2. A). 
Immunohistochemistry revealed that cervical carcinoma tissue had increased Bcl-2 
protein expression (Fig. 8.2.2. B).  
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8.2.3. The LC-3 expression profile in normal, low-grade and high-grade 
squamous intraepithelial lesion tissue and cancerous cervical tissue. 
 
 
  
Figure 8.2.3.A. The LC-3 II expression profile in normal, low-grade and high-grade squamous 
intraepithelial lesions and cervical carcinoma tissue in cervix. Representative Western blot, *** p < 
0.001, ** p < 0.01 vs. normal, # p < 0.001 vs. LSIL, $ p < 0.05 vs. LSIL. Statistical analysis: ANOVA and 
Bonferroni correction. All results expressed as mean ± SEM, Normal: n=10, LSIL: n=29, HSIL: n=33, CA: 
n=13. LSIL: low-grade squamous intraepithelial lesion, HSIL: high-grade squamous intraepithelial lesion, 
CA: carcinoma. 
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B. 
Figure 8.2.3.B. Immunohistochemistry of LC-3 (green) in normal, LSIL, HSIL and CA. Representative 
images of LC-3 expression profiles in normal (n=4), LSIL (n=6), HSIL (n=8) and cervical carcinogenesis 
(n=5), scale bar: 20 µm. LSIL – low-grade squamous cervical carcinoma, HSIL – high-grade squamous 
cervical carcinoma, CA- carcinoma. 
Hoechst FITC (LC3) Merge 
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Western blot analysis revealed an increase in LC-3 II protein levels in HSIL tissue in 
comparison to normal cervical tissue (2.01 ± 0.31 vs. normal, ***p < 0.001) and LSIL 
tissue (2.01 ± 0.31 vs. LSIL, # p < 0.001). Cervical carcinoma tissue also has 
significantly increased LC-3 II protein levels in comparison to normal cervical tissue 
(1.37 ± 0.14 vs. normal, ** p < 0.01) and LSIL tissue (1.37 ± 0.14 vs. normal, $ p < 
0.05, Fig. 8.2.3. A). 
Immunohistochemistry of reveal that LC-3 expression is increased in HSIL and 
cervical carcinoma tissue sections (Fig. 8.2.3. B). 
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8.3. Discussion 
Cervical cancer is characterised by a well-defined pre-malignant phase (Ambros and 
Kurman, 1990) which is attributed to infection with the human papilloma virus (HPV). 
These pre-malignant phases are characterised by low- and high-grade squamous 
intraepithelial lesion (LSIL and HSIL) development after infection with the virus 
(Nobbenhuis et al., 1999). The lesions that develop become a platform for the 
pathological expansion of the cancer and compromise the control of proliferation and 
differentiation of the tumour cells (Green and Evan, 2002). Central to the proliferation 
of the tumour cells is the aberrant alteration of survival pathways and changes in the 
apoptotic threshold of these cells.  
The importance of autophagy in cervical cancer cells has been demonstrated in 
previous chapters. Additionally, basal autophagic levels as well as flux capacities 
proved to differ considerably between normal and cancerous cervical cell types, 
which enabled to point out each cancer cell type as likely being either resistant or 
sensitive to undergo cell death upon autophagic modulation. It is therefore of interest 
to examine clinical specimens for the presence of autophagy at various pathological 
stages and possibly utilise the results obtained from the in vitro data as a means of 
determining whether adjuvant treatment in combination with a low-dose of cisplatin 
would be effective in a clinical setting of cervical cancer treatment. 
Little is known regarding the role of autophagy and apoptosis in the development of 
cervical cancer through the analysis of clinical specimens, therefore the aim of this 
chapter was to assess the role of autophagy through mTOR and LC-3 II protein 
expression as well as apoptosis through Bcl-2 expression in the progression from 
normal to cancerous cervical tissue. 
8.3.1. mTOR 
The molecular link between mTOR and cancer was discovered when it was observed 
that the TSC complex (mutations of which cause the hamartomatous syndrome) 
upstream of mTOR negatively regulates its activity (Inoki et al., 2002). Additionally, it 
had been observed that the mTOR pathway is constitutively activated in a variety of 
cancers (West et al., 2002), which subsequently results in the inhibition of mTOR and 
the induction of a variety of processes, including autophagy (Loewith et al., 2002). 
The analysis of mTOR protein expression in normal, LSIL, HSIL and cancerous 
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cervical tissue revealed that both the LSIL and cancerous cervical tissue had 
increased mTOR protein expression levels in comparison to the normal cervical 
tissue (Fig. 8.2.1.A) whereas HSIL cervical tissue had significantly lower mTOR 
expression levels in comparison to both LSIL and cancerous cervical tissue, and was 
comparable to the control. To support this observation, activated mTOR (lowered 
total mTOR) was observed to be present in HSILs (Feng et al., 2009), however, its 
activation was also observed in squamous cell carcinoma (Feng et al., 2009), 
advanced squamous cell carcinoma (Faried et al., 2008a) and adenocarcinoma of 
the cervix (Faried et al., 2008a). Since mTOR inhibition results in the activation of 
autophagy, it may be argued that this process is activated in normal and HSIL tissue, 
more so than in LSIL and cancerous cervical tissue. The observation that mTOR 
levels are significantly increased in the cancerous tissue when compared to the 
normal tissue may suggest that autophagy has an important role in normal cellular 
homeostasis. This notion is supported by the fact that under normal conditions, 
autophagy is activated in order to prevent genomic instability and other oncogenic 
events from taking place (Abedin et al., 2007, Katayama et al., 2007). In cancer, 
protein synthesis is required to outweigh protein degradation in order for tumour 
growth (Otsuka and Moskowitz, 1978), and the expression of mTOR is therefore 
required to increase cell size and mass (Fingar et al., 2002). Additionally, during the 
early stages of tumourigenesis, autophagic degradation and proteolysis were 
observed to be lower when compared to their non-cancerous counterparts (Gunn et 
al., 1977, Kisen et al., 1993, Kirkegaard et al., 2004). In order to support this 
statement however, a more direct marker of autophagy, such as LC-3 II is required to 
be assessed. 
8.2.2. Bcl-2 
Analysis of cervical pre-malignant and malignant tissue revealed that Bcl-2 protein 
expression was significantly increased in cervical carcinoma tissue samples (Fig. 
8.2.2. A) and suggests that the malignant state requires such an alteration in order to 
maintain the malignant phenotype. The importance of proliferation in cancer, and 
therefore a decreased ability to undergo apoptosis underlines the characteristic 
nature of cancer. Bcl-2, an anti-apoptotic protein, is thus a crucial regulator of 
apoptosis inhibition in this diseased state.  
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A systematic survey and meta-analysis of the transcriptional profiles of a variety of 
cancers indicated that the dysregulation of Bcl-2 is a key distinguishing factor 
between normal and cancer cells (Slavov and Dawson, 2009), moreover, its 
increased expression has been correlated with increased resistance of a variety of 
cancers to chemotherapy drugs, including cisplatin (Carson and Ribeiro, 1993, 
Campos et al., 1993). As mentioned previously, evidence documenting the 
expression of Bcl-2 in cervical cancers is confounding. An increase in Bcl-2 protein 
expression demonstrated in this study agrees with a study conducted by Dimitrakakis 
and colleagues which demonstrated that Bcl-2 protein expression is directly related 
to the grade of cervical intraepithelial neoplasia (Dimitrakakis et al., 2000), however it 
is in contrast to another study which demonstrated that Bcl-2 protein expression in 
neoplastic cervical tissue in significantly decreased in comparison to the normal 
cervical tissue (Tjalma et al., 1998). A possible approach by which to define this role 
more clearly would be to evaluate the corresponding beclin-1 protein levels, since the 
interaction between these two molecules acts as a rheostat in determining the 
decision between autophagy and apoptosis initiation (Pattingre et al., 2005). A 
different, more recent study demonstrated that beclin-1 protein expression levels in 
cervical carcinoma was significantly lower than when compared to the normal 
squamous epithelial tissue (Zhu et al., 2012). This finding supports this study, as well 
as the study conducted by Dimitrakakis and colleagues which both suggest 
increased Bcl-2 protein expression levels in cervical carcinoma. 
Previous in vitro work (Chapter 7) revealed that basal levels of Bcl-2 differ 
significantly between the cancerous HeLa and CaSki cells (Fig. 7.2.1.), however 
whether this expression is elevated compared to the normal Ect1/E6E7 cells, as 
observed in the tissue, remains to be determined. Following treatment with cisplatin 
however, Bcl-2 expression increased, and after silencing apoptosis was observed, 
which indicates that cervical cancer cells are dependent on Bcl-2 expression as a 
means of preventing apoptosis. Therefore, the in vitro, as well as the ex vivo data 
strongly suggest that Bcl-2 is a promising therapeutic target for the treatment of 
cervical cancer. Future studies may focus on silencing of Bcl-2 prior to a low-
concentration of cisplatin treatment to further improve cell death in vitro, which may 
serve as an additional method for the treatment of cervical cancer. 
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8.2.3. LC-3 II 
Western blot analysis suggests that both HSIL and cervical carcinoma tissue had 
increased LC-3 II protein levels in comparison to the control and LSIL tissue samples 
(Fig. 8.2.3. A). Due to the fact that LC-3 II is a reliable, direct marker of autophagy 
(Mizushima, 2004), these results suggest the up-regulation of autophagy under both 
these pre-malignant and malignant circumstances. These results are supported by 
the down-regulation of mTOR protein expression HSIL tissue (Fig. 8.2.1.) as 
previously discussed; however this result is not as conclusive when mTOR 
expression in the cancerous cervical tissue is analysed. 
The result obtained in Figure 8.2.3. is in contrast to a study which observed that 
cancerous cervical tissue had significantly lowered LC-3 protein levels in comparison 
to normal cervical tissue (Zhu et al., 2012), its expression in pre-malignant tissue was 
not assessed, and to our knowledge has not been evaluated before. In order to 
provide a possible explanation as to why autophagy may be up-regulated in pre-
malignant HSILs could be due to the presence of the HPV virus: In addition to the 
role of autophagy as a survival mechanism, it has also been implicated as an anti-
viral mechanism by which a cell rids itself of intracellular pathogens through 
sequestration of the viral counterparts within autophagosomes for degradation 
through fusion with lysosomes (Kirkegaard et al., 2004, Lee and Iwasaki, 2008, 
Hussey et al., 2009). Conversely, it can also be utilized and exploited by the invading 
virus as a method of replication or as an exit strategy, and in this case functions as a 
pro-viral mechanism (de Bruin and Medema, 2008). This has not been proven 
directly in HPV, however a study revealed that the transfection of cervical cells with 
HPV E6 and E7 proteins induced an ‘autophagic-like response’, and thus this may 
serve as a possible explanation for the increased autophagy levels. An additional 
reason may be that high-grade lesions develop rapidly and corresponds to 
morphological features of the basal cells, including a minimal amount of cytoplasm 
and thus a high nucleus to cytoplasm ratio (Wright, 2006). Therefore autophagy may 
be required to sustain this rapid growth by continuously supplying substrates for 
anabolic reactions.  
Generally, once the cervix presents with HSILs, surgical methods are put in place for 
its removal, which leads to post-operative effects and discomfort (Zivadinovic et al., 
2012). The fact that HSILs have increased levels of autophagy in comparison to the 
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control tissue (Fig. 8.2.3.) suggests that its progression toward malignancy may be 
controlled through the pharmacological inhibition of autophagy. Hydroxychloriquine, 
an anti-malarial agent and autophagy inhibitor (Rubinsztein et al., 2007) may be a 
possible candidate. This is however dependent on acquiring conclusive evidence that 
autophagy is indeed increased in HSILs. Future studies are required to determine the 
role of autophagy in HPV infection, as this may provide an additional avenue for the 
treatment of pre-malignant lesions induced by HPV infection. 
The In vitro work conducted in Chapter 6 suggests that in cervical cancer, autophagy 
inhibition in conjunction with a low-concentration of cisplatin treatment is effective in 
inducing efficient cell death. Due to the fact that autophagy is significantly increased 
in cancerous cervical tissue (Fig. 8.2.3.), this method indeed indicates a promising 
approach for treatment of patients with cervical cancer. 
In conclusion, HSIL cervical tissue exhibited increased autophagic activity when 
compared to the normal and LSIL cervical tissue counterparts which, to our 
knowledge, has been demonstrated for the first time. Additionally, cervical carcinoma 
tissue expresses increased Bcl-2 protein levels, as well as LC-3 II protein levels, 
which is indicative of suppressed apoptosis and increased autophagy respectively. 
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9 
Summary and Conclusion 
 
Due to the severity of the side-effects which often accompany cisplatin-based 
chemotherapeutic regimes, alternative treatment strategies are required. These 
should make use of a lower dose of cisplatin which, with the use of an adjuvant 
treatment, improves the chemotherapeutic value of such a dose, with minimal 
cytotoxic effects on non-cancerous cells. An in vitro model of cervical cancer was 
employed which made use of three human cervical cell lines: a non-cancerous 
ectocervical cell line (Ect1/E6E7), an adenocarcinoma cell line (HeLa) and a 
metastatic squamous epithelial cell line (CaSki). 
Cisplatin dose-response curves revealed that 15 μM (4.5 μg/ml cisplatin) had no 
significant effects on cell death induction in the non-cancerous cells, and was 
therefore selected to be used throughout the remainder of the study. This 
concentration had no significant effects on cell death induction in both cancerous cell 
lines. 
In organs that have a high-metabolic demand, the level of autophagic activity is 
equally high (Mizushima et al., 2004). In cancer cells, metabolism is altered in order 
to favour anabolic reactions as a mechanism of sustaining increased growth rates, 
thus basal autophagic levels and flux capacities may reveal valuable information as 
to the aggressiveness of various cancers, as well as their reliance on autophagy. Our 
data demonstrate that each cervical cell line had a differential capacity to induce 
autophagy upon stimulation, with the HeLa cells having the lowest capacity. This 
data strengthens previous findings that autophagic induction is cell type dependent. 
Moreover, we have demonstrated that there are also differences in the same cell 
type between normal and transformed cells. 
It was then required that the role of autophagy be evaluated in response to the 
chosen concentration of cisplatin, and it was observed that autophagy was induced in 
all three cell lines in response to 15 μM cisplatin for a 24 h treatment period. We then 
determined the significance of this response through inhibiting as well as inducing 
autophagy prior to cisplatin treatment, and subsequently analysing a variety of cell 
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death markers. We have demonstrated here for the first time that the inhibition of 
autophagy with bafilomycin A1 or ATG5 siRNA in combination with a non-toxic 
concentration of cisplatin induced efficient apoptotic cell death in both cervical cancer 
cell lines, with minimal cell death induced in the normal, non-cancerous cells. We 
therefore confirm that autophagy inhibition prior to a low-concentration of cisplatin 
treatment significanlty improves the cytotoxicity of cisplatin in cervical cancer cells, 
and that cisplatin-induced apoptosis may be exploited as a means of improving the 
clinical efficacy of the drug. 
The prominent role of Bcl-2 in cisplatin resistance in other cancer cell lines prompted 
the analysis of the response of this anti-apoptotic protein to a low-concentration of 
cisplatin treatment. Bcl-2 was up-regulated significantly in both cancerous cell lines 
24 h after cisplatin treatment. Here we demonstrate the requirement of Bcl-2 up-
regulation in cervical cancer cells through silencing of Bcl-2 prior to cisplatin 
treatment. Significant increases in cisplatin-induced apoptosis in both cell lines were 
observed, however the CaSki cells were affected to a larger extent. Additionally, the 
Beclin-1 Bcl-2 ratio increased significantly in both cell lines which indicates that cell 
death is occurring with autophagy. Our data strongly suggest that both cervical cell 
lines, particularly the aggressive CaSki cells are dependent on the up-regulation of 
Bcl-2 in response to cisplatin treatment, and that this is a distinct intracellular 
characteristic which may be exploited in order to improve cisplatin-induced apoptosis. 
Future studies are required to assess whether the effects on cell death are improved 
if Bcl-2 silencing together with autophagy inhibition is used prior to a low-
concentration of cisplatin treatment. 
In order to determine the value of the above findings, clinical specimens were 
collected to assess the expression profile of autophagic (mTOR and LC-3) and anti-
apoptotic (Bcl-2) markers in normal, pre-malignant (LSIL and HSIL) and cancerous 
cervical tissue. mTOR and LC-3 II expression in the various stages of cervical cancer 
development suggest that autophagy is significantly up-regulated in HSILs and 
carcinoma of the cervix and that Bcl-2 expression, which is in agreement with other 
studies, is increased exclusively in cancerous cervical tissue. These data underline 
the relevance of the results obtained in the in vitro study: basal autophagic levels are 
increased in cervical carcinoma, which is likely to respond well to pre-treatment with 
an autophagic inhibitor with a low-dose of cisplatin treatment. This response may be 
further improved with the inhibition of Bcl-2 as an additional pre-treatment. 
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The value of this treatment method, if moved into the clinic, is that a low-dose of 
cisplatin could be used with a pre-treatment such as autophagy and/or Bcl-2 
inhibition, which may then allow prolonged exposure to cisplatin chemotherapy and 
therefore longer treatment regimes, with minimal amount of side-effects.  
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